

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
26 January 2006 (26.01.2006)

PCT

(10) International Publication Number
WO 2006/008508 A1

- (51) International Patent Classification: **C11B 3/00**, (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (21) International Application Number: PCT/GB2005/002823
- (22) International Filing Date: 18 July 2005 (18.07.2005)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
0416035.4 16 July 2004 (16.07.2004) GB
60/591,185 26 July 2004 (26.07.2004) US
0513859.9 7 July 2005 (07.07.2005) GB
- (71) Applicant (for all designated States except US): DANISCO A/S [DK/DK]; Langebrogade 1, PO Box 17, DK-1001 Copenhagen K (DK).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): SOE, Jorn, Borch [DK/DK]; Orøvænget 11, DK-8381 Tilst (DK). TURNER, Mark [GB/DK]; Gøgevang 49, DK-2970 Hørsholm (DK).
- (74) Agents: WILLIAMS, Aylsa et al.; D Young & Co, 120 Holborn, London EC1N 2DY (GB).
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— with international search report
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

BEST AVAILABLE COPY



WO 2006/008508 A1

(54) Title: ENZYMATIC OIL-DEGUMMING METHOD

(57) Abstract: A process of enzymatic degumming edible oils, comprising treating the edible oil with a lipid acyltransferase so as to transfer an acyl group from a major part of the phospholipid to one or more acyl acceptors, wherein the acyl acceptor may be any compound comprising a hydroxy group. In one embodiment preferably the acyl acceptor is water and in another embodiment preferably the acyl acceptor is one or more sterols and/or stanols. When the acyl acceptor is a stanol and/or sterol, one or more sterol esters and/or stanol esters are produced. The lipid acyltransferase for use in the process of the present invention may comprises one or more of the following amino acid sequences: SEQ ID No. 1, SEQ ID No. 3, SEQ ID No. 4, SEQ ID No. 5, SEQ ID No. 6, SEQ ID No. 7, SEQ ID No. 8, SEQ ID No. 9, SEQ ID No. 10, SEQ ID No. 11, SEQ ID No. 12, SEQ ID No. 13, SEQ ID No. 14, or SEQ ID No. 15, SEQ ID No. 16, SEQ ID No. 17, SEQ ID No. 18, SEQ ID No. 36, SEQ ID No. 38, SEQ ID No. 40, SEQ ID No. 41, SEQ ID No. 45, SEQ ID No. 47, SEQ ID No. 50 or an amino acid sequence which has 75% or more identity thereto. A novel lipid acyltransferase comprising the amino acid sequence shown as SEQ ID No. 16 is also taught.

16541

ENZYMATIC OIL-DEGUMMING METHOD

REFERENCE TO RELATED APPLICATIONS

Reference is made to the following related applications: United States Application
5 Serial Number 09/750,990 filed on 20 July 1999, United States Application Serial
Number 10/409,391, WO2004/064537, WO2004/064987, PCT/IB2004/004378 and
PCT/IB2004/004374. Each of these applications and each of the documents cited in
each of these applications ("application cited documents"), and each document
referenced or cited in the application cited documents, either in the text or during the
10 prosecution of those applications, as well as all arguments in support of patentability
advanced during such prosecution, are hereby incorporated herein by reference.
Various documents are also cited in this text ("herein cited documents"). Each of the
herein cited documents, and each document cited or referenced in the herein cited
documents, is hereby incorporated herein by reference.

15

FIELD OF INVENTION

The present invention relates to a method for enzymatically degumming edible oils
using a lipid acyltransferase.

20

The present invention further relates to one or more lipid acyltransferases.

The present invention yet further relates to the use of a lipid acyltransferase to the
degumming of edible oils.

25

TECHNICAL BACKGROUND

Traditionally two processes have been used for degumming of oil which are the
physical degumming and the chemical degumming processes. Back in the 1990's the
30 enzymatic degumming process was developed based on the use of pancreatic
phospholipase. Because this enzyme was non-kosher the phospholipase was eventually

substituted by a microbial phospholipase A1 (Lecitase Ultra™ - Novozymes, Denmark). The enzymatic process has several advantages over the chemical or the physical degumming processes including cost savings, higher yield and a more environmentally friendly process.

5

SUMMARY ASPECTS OF THE PRESENT INVENTION

In one aspect, the present invention provides a method for the enzymatic degumming of vegetable oils or edible oils using a lipid acyltransferase as defined herein.

10

The present invention also provides a process of enzymatic degumming of vegetable or edible oils, comprising treating the edible or vegetable oil with a lipid acyl transferase according to the present invention so as to remove a major part of the phospholipid.

15

The present invention also provides a process of enzymatic degumming of vegetable or edible oils, comprising treating the edible or vegetable oil with a lipid acyl transferase according to the present invention so as to transfer an acyl group from a major part of the phospholipid to one or more acyl acceptors, for example to one or more sterols and/or stanols.

20

In another aspect, the present invention provides one or more lipid acyltransferases.

In one aspect, the present invention provides a lipid acyltransferase comprising the amino acid sequence shown as SEQ ID No. 16.

25

In another aspect, the present invention provides a lipid acyltransferase comprising the amino acid sequence shown as SEQ ID No. 16, or an amino acid sequence which has 75% or more, preferably 85% or more, more preferably 90% or more, even more preferably 95% or more, even more preferably 98% or more, or even more preferably 99% or more identity to SEQ ID No. 16.

30

In a yet further aspect, the present invention provides the use of a lipid acyltransferase in the degumming of edible oils (i) to remove phospholipids (such as phosphatidylcholine) and/or (ii) to increase the formation of sterol esters and/or stanol esters in the oil and/or (iii) to remove phospholipids (such as phosphatidylcholine) and/or to increase the formation of sterol esters and/or stanol esters in the oil without significantly increasing free fatty acids in the oil.

PREFERABLE ASPECTS

10 The lipid acyltransferase for use in the present invention may be a natural lipid acyltransferase or may be a variant lipid acyltransferase.

For instance, the lipid acyltransferase for use in the method and uses of the present invention may be one as described in WO2004/064537 or WO2004/064987, or
15 PCT/IB2004/004378 or GB0513859.9, for example.

The term "lipid acyltransferase" as used herein means an enzyme that has acyltransferase activity (generally classified as E.C. 2.3.1.x), whereby the enzyme is capable of transferring an acyl group from a lipid to one or more acceptor substrates,
20 such as one or more of the following: a sterol; a stanol; a carbohydrate; a protein; a protein subunit; glycerol – preferably a sterol and/or a stanol.

Preferably, the lipid acyltransferase according to the present invention or for use in the methods and/or uses of the present invention is capable of transferring an acyl group
25 from a lipid (as defined herein) to one or more of the following acyl acceptor substrates: a sterol or a stanol, preferably a sterol.

For some aspects the "acyl acceptor" according to the present invention may be any compound comprising a hydroxy group (-OH), such as for example, polyvalent
30 alcohols, including glycerol; sterols; stanols; carbohydrates; hydroxy acids including fruit acids, citric acid, tartaric acid, lactic acid and ascorbic acid; proteins or a sub-unit thereof, such as amino acids, protein hydrolysates and peptides (partly hydrolysed

protein) for example; and mixtures and derivatives thereof. Preferably, the “acyl acceptor” according to the present invention is not water.

The acyl acceptor is preferably not a monoglyceride.

5

In one aspect, the lipid acyltransferase according to the present invention or for use in the methods and/or uses of the present invention may, as well as being able to transfer an acyl group from a lipid to a sterol and/or a stanol, additionally be able to transfer the acyl group from a lipid to one or more of the following: a carbohydrate, a protein, a protein subunit, glycerol.

10

Preferably, the lipid substrate upon which the lipid acyltransferase according to the present invention acts is one or more of the following lipids: a phospholipid, such as a lecithin, e.g. phosphatidylcholine.

15

This lipid substrate may be referred to herein as the “lipid acyl donor”. The term lecithin as used herein encompasses phosphatidylcholine, phosphatidylethanolamine, phosphatidylinositol, phosphatidylserine and phosphatidylglycerol.

For some aspects, preferably the lipid substrate upon which the lipid acyltransferase according to the present invention or for use in the method and/or uses of the present invention acts as a phospholipid, such as lecithin, for example phosphatidylcholine.

20

For some aspects, preferably the lipid acyltransferase according to the present invention or for use in the method and/or uses of the present invention is incapable, or substantially incapable, of acting on a triglyceride and/or a 1-monoglyceride and/or 2-monoglyceride.

25

Suitably, the lipid acyltransferase according to the present invention or for use in the method and/or uses of the present invention may exhibit one or more of the following phospholipase activities: phospholipase A2 activity (E.C. 3.1.1.4) or phospholipase A1 activity (E.C. 3.1.1.32).

30

Suitably, for some aspects the lipid acyltransferase according to the present invention or for use in the method and/or uses of the present invention may be capable of transferring an acyl group from a phospholipid to a sterol and/or a stanol.

5

For some aspects, preferably the lipid acyltransferase according to the present invention or for use in methods and/or uses of the present invention is capable of transferring an acyl group from a phospholipid to a sterol and/or a stanol to form at least a sterol ester and/or a stanol ester.

10

For some aspects, preferably the lipid acyltransferase according to the present invention or for use in the method and/or uses of the present invention does not exhibit triacylglycerol lipase activity (E.C. 3.1.1.3) or does not exhibit significant triacylglycerol lipase activity (E.C. 3.1.1.3).

15

The lipid acyltransferase according to the present invention or for use in the method and/or uses of the present invention may be capable of transferring an acyl group from a lipid to a sterol and/or a stanol. Thus, in one embodiment the "acyl acceptor" according to the present invention may be either a sterol or a stanol or a combination of both a sterol and a stanol.

20

Preferably, the lipid acyltransferase enzyme according to the present invention or for use in methods and uses of the present invention may be characterised using the following criteria:

25

(i) the enzyme possesses acyl transferase activity which may be defined as ester transfer activity whereby the acyl part of an original ester bond of a lipid acyl donor is transferred to an acyl acceptor to form a new ester; and

30

(ii) the enzyme comprises the amino acid sequence motif GDSX, wherein X is one or more of the following amino acid residues L, A, V, I, F, Y, H, Q, T, N, M or S.

Preferably, X of the GDSX motif is L or Y. More preferably, X of the GDSX motif is L. Thus, preferably the enzyme according to the present invention comprises the amino acid sequence motif GDSL.

5 The GDSX motif is comprised of four conserved amino acids. Preferably, the serine within the motif is a catalytic serine of the lipid acyltransferase enzyme. Suitably, the serine of the GDSX motif may be in a position corresponding to Ser-16 in *Aeromonas hydrophila* lipolytic enzyme taught in Brumlik & Buckley (Journal of Bacteriology Apr. 1996, Vol. 178, No. 7, p 2060-2064).

10

To determine if a protein has the GDSX motif according to the present invention, the sequence is preferably compared with the hidden markov model profiles (HMM profiles) of the pfam database in accordance with the procedures taught in WO2004/064537 or WO2004/064987.

15

Pfam is a database of protein domain families. Pfam contains curated multiple sequence alignments for each family as well as profile hidden Markov models (profile HMMs) for identifying these domains in new sequences. An introduction to Pfam can be found in Bateman A *et al.* (2002) Nucleic Acids Res. 30; 276-280. Hidden Markov models are used in a number of databases that aim at classifying proteins, for review see Bateman A and Haft DH (2002) Brief Bioinform 3; 236-245.

20

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12230032&dopt=Abstract

25

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11752314&dopt=Abstract

For a detailed explanation of hidden Markov models and how they are applied in the Pfam database see Durbin R, Eddy S, and Krogh A (1998) Biological sequence analysis; probabilistic models of proteins and nucleic acids. Cambridge University Press, ISBN 0-521-62041-4. The Hammer software package can be obtained from Washington University, St Louis, USA.

30

Alternatively, the GDSX motif can be identified using the Hammer software package, the instructions are provided in Durbin R, Eddy S, and Krogh A (1998) Biological sequence analysis; probabilistic models of proteins and nucleic acids. Cambridge University Press, ISBN 0-521-62041-4 and the references therein, and the HMMER2 profile provided within this specification.

The PFAM database can be accessed, for example, through several servers which are currently located at the following websites.

10 <http://www.sanger.ac.uk/Software/Pfam/index.shtml>
<http://pfam.wustl.edu/>
<http://pfam.jouy.inra.fr/>
<http://pfam.cgb.ki.se/>

15 The database offers a search facility where one can enter a protein sequence. Using the default parameters of the database the protein sequence will then be analysed for the presence of Pfam domains. The GDSX domain is an established domain in the database and as such its presence in any query sequence will be recognised. The database will return the alignment of the Pfam00657 consensus sequence to the query
20 sequence.

Preferably the lipid acyltransferase enzyme for use in methods and uses of the invention can be aligned using the Pfam00657 consensus sequence (for a full explanation see WO2004/064537 or WO2004/064987).

25

Preferably, a positive match with the hidden markov model profile (HMM profile) of the pfam00657 domain family indicates the presence of the GDSL or GDSX domain according to the present invention.

30 Preferably when aligned with the Pfam00657 consensus sequence the lipid acyltransferase for use in the methods or uses of the invention may have at least one, preferably more than one, preferably more than two, of the following, a GDSx block, a

GANDY block, a HPT block. Suitably, the lipid acyltransferase may have a GDSx block and a GANDY block. Alternatively, the enzyme may have a GDSx block and a HPT block. Preferably the enzyme comprises at least a GDSx block.

- 5 Preferably, residues of the GANDY motif are selected from GANDY, GGNDA, GGNDL, most preferably GANDY.

Preferably, when aligned with the Pfam00657 consensus sequence the enzyme for use in the methods or uses of the invention have at least one, preferably more than one, preferably more than two, preferably more than three, preferably more than four, preferably more than five, preferably more than six, preferably more than seven, preferably more than eight, preferably more than nine, preferably more than ten, preferably more than eleven, preferably more than twelve, preferably more than thirteen, preferably more than fourteen, of the following amino acid residues when compared to the reference *A. hydrophilia* polypeptide sequence, namely SEQ ID No. 1: 28hid, 29hid, 30hid, 31hid, 32gly, 33Asp, 34Ser, 35hid, 130hid, 131Gly, 132Hid, 133Asn, 134Asp, 135hid, 309His.

20 The pfam00657 GDSX domain is a unique identifier which distinguishes proteins possessing this domain from other enzymes.

The pfam00657 consensus sequence is presented in Figure 12 as SEQ ID No. 2. This is derived from the identification of the pfam family 00657, database version 6, which may also be referred to as pfam00657.6 herein.

25

The consensus sequence may be updated by using further releases of the pfam database (for example see WO2004/064537 or WO2004/064987).

30 The presence of the GDSx, GANDY and HPT blocks are found in the pfam family 00657 from both releases of the database. Future releases of the pfam database can be used to identify the pfam family 00657.

In one embodiment, the lipid acyltransferase enzyme for use in methods and uses of the present invention may be characterised using the following criteria:

- (i) the enzyme possesses acyl transferase activity which may be defined as ester transfer activity whereby the acyl part of an original ester bond of a lipid acyl donor is transferred to acyl acceptor to form a new ester;
- (ii) the enzyme comprises the amino acid sequence motif GDSX, wherein X is one or more of the following amino acid residues L, A, V, I, F, Y, H, Q, T, N, M or S.;
- (iii) the enzyme comprises His-309 or comprises a histidine residue at a position corresponding to His-309 in the *Aeromonas hydrophila* lipid acyltransferase enzyme shown in Figures 11 and 13 (SEQ ID No. 1 or SEQ ID No. 3).

Preferably, the amino acid residue of the GDSX motif is L.

In SEQ ID No. 3 or SEQ ID No. 1 the first 18 amino acid residues form a signal sequence. His-309 of the full length sequence, that is the protein including the signal sequence, equates to His-291 of the mature part of the protein, i.e. the sequence without the signal sequence.

In one embodiment, the lipid acyltransferase enzyme for use in methods and uses of the present invention comprises the following catalytic triad: Ser-34, Asp-134 and His-309 or comprises a serine residue, an aspartic acid residue and a histidine residue, respectively, at positions corresponding to Ser-34, Asp-134 and His-309 in the *Aeromonas hydrophila* lipid acyltransferase enzyme shown in Figure 13 (SEQ ID No. 3) or Figure 11 (SEQ ID No. 1). As stated above, in the sequence shown in SEQ ID No. 3 or SEQ ID No. 1 the first 18 amino acid residues form a signal sequence. Ser-34, Asp-134 and His-309 of the full length sequence, that is the protein including the signal sequence, equate to Ser-16, Asp-116 and His-291 of the mature part of the protein, i.e. the sequence without the signal sequence. In the pfam00657 consensus sequence, as given in Figure 12 (SEQ ID No. 2) the active site residues correspond to Ser-7, Asp-157 and His-348.

In one embodiment, the lipid acyltransferase enzyme for use in methods and uses of the present invention may be characterised using the following criteria:

- 5
- (i) the enzyme possesses acyl transferase activity which may be defined as ester transfer activity whereby the acyl part of an original ester bond of a first lipid acyl donor is transferred to an acyl acceptor to form a new ester; and
 - (ii) the enzyme comprises at least Gly-32, Asp-33, Ser-34, Asp-134 and His-309 or comprises glycine, aspartic acid, serine, aspartic acid and histidine residues at positions corresponding to Gly-32, Asp-33, Ser-34, Asp-134 and His-309, respectively, in the *Aeromonas hydrophila* lipid acyltransferase enzyme shown in Figure 13 (SEQ ID No. 3) or Figure 11 (SEQ ID No. 1).
- 10

15 Suitably, the lipid acyltransferase enzyme for use in methods and uses of present invention comprises one or more of the following amino acid sequences:

- (i) the amino acid sequence shown as SEQ ID No. 3 (see Figure 13)
- (ii) the amino acid sequence shown as SEQ ID No. 4 (see Figure 14)
- (iii) the amino acid sequence shown as SEQ ID No. 5 (see Figure 15)
- 20 (iv) the amino acid sequence shown as SEQ ID No. 6 (see Figure 16)
- (v) the amino acid sequence shown as SEQ ID No. 7 (see Figure 17)
- (vi) the amino acid sequence shown as SEQ ID No. 8 (see Figure 18)
- (vii) the amino acid sequence shown as SEQ ID No. 9 (Figure 19)
- (viii) the amino acid sequence shown as SEQ ID No. 10 (Figure 20)
- 25 (ix) the amino acid sequence shown as SEQ ID No. 11 (Figure 21)
- (x) the amino acid sequence shown as SEQ ID No. 12 (Figure 22)
- (xi) the amino acid sequence shown as SEQ ID No. 13 (Figure 23)
- (xii) the amino acid sequence shown as SEQ ID No. 14 (Figure 24)
- (xiii) the amino acid sequence shown as SEQ ID No. 1 (Figure 11)
- 30 (xiv) the amino acid sequence shown as SEQ ID No. 15 (Figure 25) or an amino acid sequence which has 75% or more identity with any one of the sequences shown as SEQ ID No. 1, SEQ ID No. 3, SEQ ID No. 4, SEQ ID No. 5, SEQ ID No. 6,

SEQ ID No. 7, SEQ ID No. 8, SEQ ID No. 9, SEQ ID No. 10, SEQ ID No. 11, SEQ ID No. 12, SEQ ID No. 13, SEQ ID No. 14, or SEQ ID No. 15.

Suitably, the lipid acyltransferase enzyme for use in methods and uses of the present invention comprises either the amino acid sequence shown as SEQ ID No. 3 or as SEQ ID No. 4 or SEQ ID No. 1 or SEQ ID No. 15 or comprises an amino acid sequence which has 75% or more, preferably 80% or more, preferably 85% or more, preferably 90% or more, preferably 95% or more, identity with the amino acid sequence shown as SEQ ID No. 3 or the amino acid sequence shown as SEQ ID No. 4 or the amino acid sequence shown as SEQ ID No. 1 or the amino acid sequence shown as SEQ ID No. 15.

Suitably the lipid acyltransferase enzyme for use in methods and uses of the present invention comprises an amino acid sequence which has 80% or more, preferably 85% or more, more preferably 90% or more and even more preferably 95% or more identity with any one of the sequences shown as SEQ ID No. 3, SEQ ID No. 4, SEQ ID No. 5, SEQ ID No. 6, SEQ ID No. 7, SEQ ID No. 8, SEQ ID No. 9, SEQ ID No. 10, SEQ ID No. 11, SEQ ID No. 12, SEQ ID No. 13, SEQ ID No. 14, SEQ ID No. 1, or SEQ ID No. 15.

Suitably, the lipid acyltransferase enzyme for use in methods and uses of the present invention comprises one or more of the following amino acid sequences:

- (a) an amino acid sequence shown as amino acid residues 1-100 of SEQ ID No. 3 or SEQ ID No. 1;
- (b) an amino acid sequence shown as amino acids residues 101-200 of SEQ ID No. 3 or SEQ ID No. 1;
- (c) an amino acid sequence shown as amino acid residues 201-300 of SEQ ID No. 3 or SEQ ID No. 1; or
- (d) an amino acid sequence which has 75% or more, preferably 85% or more, more preferably 90% or more, even more preferably 95% or more identity to any one of the amino acid sequences defined in (a)-(c) above.

Suitably, the lipid acyltransferase enzyme for use in methods and uses of the present invention comprises one or more of the following amino acid sequences:

- (a) an amino acid sequence shown as amino acid residues 28-39 of SEQ ID No. 3 or SEQ ID No. 1;
- 5 (b) an amino acid sequence shown as amino acids residues 77-88 of SEQ ID No. 3 or SEQ ID No. 1;
- (c) an amino acid sequence shown as amino acid residues 126-136 of SEQ ID No. 3 or SEQ ID No. 1;
- 10 (d) an amino acid sequence shown as amino acid residues 163-175 of SEQ ID No. 3 or SEQ ID No. 1;
- (e) an amino acid sequence shown as amino acid residues 304-311 of SEQ ID No. 3 or SEQ ID No. 1; or
- 15 (f) an amino acid sequence which has 75% or more, preferably 85% or more, more preferably 90% or more, even more preferably 95% or more identity to any one of the amino acid sequences defined in (a)-(e) above.

In one aspect, the lipid acyltransferase for use in the method and uses of the present invention may be the lipid acyl transferase from *Candida parapsilosis* as taught in EP 1 275 711. Thus in one aspect the lipid acyltransferase for use in the method and uses
20 of the present invention may be a lipid acyltransferase comprising one of the amino acid sequences taught in SEQ ID No. 17 (Figure 28) or SEQ ID No. 18 (Figure 29).

Much by preference, the lipid acyltransferase for use in the method and uses of the present invention may be a lipid acyltransferase comprising the amino acid sequence
25 shown as SEQ ID No. 16 (Figure 10), or an amino acid sequence which has 75% or more, preferably 85% or more, more preferably 90% or more, even more preferably 95% or more, even more preferably 98% or more, or even more preferably 99% or more identity to SEQ ID No. 16. This enzyme could be considered a variant enzyme.

30 In one aspect, the lipid acyltransferase for use in the methods and uses of the present invention may be a lecithin:cholesterol acyltransferase (LCAT) or variant thereof (for example a variant made by molecular evolution)

Suitable LCATs are known in the art and may be obtainable from one or more of the following organisms for example: mammals, rat, mice, chickens, *Drosophila melanogaster*, plants, including *Arabidopsis* and *Oryza sativa*, nematodes, fungi and yeast.

In one embodiment the lipid acyltransferase enzyme for use in the methods and uses of the present invention may be the lipid acyltransferase obtainable, preferably obtained, from the *E. coli* strains TOP 10 harbouring pPet12aAhydro and pPet12aASalmo deposited by Danisco A/S of Langebrogade 1, DK-1001 Copenhagen K, Denmark under the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the purposes of Patent Procedure at the National Collection of Industrial, Marine and Food Bacteria (NCIMB) 23 St. Machar Street, Aberdeen Scotland, GB on 22 December 2003 under accession numbers NCIMB 41204 and NCIMB 41205, respectively.

Highly preferred lipid acyl transferases for use in the methods of the invention include those isolated from *Aeromonas spp.*, preferably *Aeromonas hydrophila* or *A. salmonicida*, most preferable *A. salmonicida*. Most preferred lipid acyl transferases for use in the present invention are encoded by SEQ ID No.s 1, 3, 4, 15, 16. It will be recognised by the skilled person that it is preferable that the signal peptides of the acyl transferase has been cleaved during expression of the transferase. The signal peptide of SEQ ID 1, 3, 4, 15 and 16 are amino acids 1-18. Therefore the most preferred regions are amino acids 19-335 for SEQ ID No. 1 and SEQ ID No. 3 (*A. hydrophilia*) and amino acids 19-336 for SEQ ID No. 4, SEQ ID No. 15 and SEQ ID No. 16. (*A. salmonicida*). When used to determine the homology of identity of the amino acid sequences, it is preferred that the alignments as herein described use the mature sequence.

Therefore the most preferred regions for determining homology (identity) are amino acids 19-335 for SEQ ID No. 1 and 3 (*A. hydrophilia*) and amino acids 19-336 for SEQ ID No.s 4, 15 and 16. (*A. salmonicida*). SEQ ID 34 and 35 are mature protein

sequences of the highly preferred lipid acyl transferases from *A. hydrophilia* and *A. salmonicida* respectively.

A lipid acyl transferase for use in the invention may also be isolated from
5 *Thermobifida*, preferably *T. fusca*, most preferably that encoded by SEQ ID No. 28.

A lipid acyl transferase for use in the invention may also be isolated from
Streptomyces, preferably *S. avermitis*, most preferably that encoded by SEQ ID No. 32.
Other possible enzymes for use in the present invention from *Streptomyces* include
10 those encoded by SEQ ID No.s 5, 6, 9, 10, 11, 12, 13, 14, 31, 33. The examples show
that the enzyme encoded by SEQ ID No. 33 is highly effective in enzymatic
degumming.

An enzyme for use in the invention may also be isolated from *Corynebacterium*,
15 preferably *C. efficiens*, most preferably that encoded by SEQ ID No. 29.

Suitably, the lipid acyltransferase for use in the methods and uses according to the
present invention may be a lipid acyltransferase comprising any one of the amino acid
sequences shown as SEQ ID No.s 37, 38, 40, 41, 43, 45, or 47 or an amino acid
20 sequence which has at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97% or 98%
identity therewith, or encoded by any one of the nucleotide sequences shown as SEQ
ID No.s 36, 39, 42, 44, 46, or 48 or a nucleotide sequence which has at least 70%,
75%, 80%, 85%, 90%, 95%, 96%, 97% or 98% identity therewith.

25 Preferably, the lipid acyltransferase for use in the methods and uses according to the
present invention is a lipid acyltransferase capable of hydrolysing at least galactolipids
and/or capable of transferring an acyl group from at least a galactolipid to one or more
acyl acceptor substrates, wherein the enzyme is obtainable, preferably obtained, from
Streptomyces species.

30

In one embodiment the lipid acyltransferase for use in the methods and uses according
to the present invention is preferably a lipid acyltransferase capable of hydrolysing at

least galactolipids and/or capable of transferring an acyl group from at least a galactolipid to one or more acyl acceptor substrates, wherein the enzyme is encoded by a nucleic acid selected from the group consisting of:

- a) a nucleic acid comprising a nucleotide sequence shown in SEQ ID No. 36;
 - 5 b) a nucleic acid which is related to the nucleotide sequence of SEQ ID No. 36 by the degeneration of the genetic code; and
 - c) a nucleic acid comprising a nucleotide sequence which has at least 70% identity with the nucleotide sequence shown in SEQ ID No. 36.
- 10 In one embodiment, the lipid acyltransferase for use in the methods and uses according to the present invention is preferably a lipid acyltransferase comprising an amino acid sequence as shown in SEQ ID No. 37 or an amino acid sequence which has at least 60% identity thereto.
- 15 In another embodiment the lipid acyltransferase for use in the methods and uses according to the present invention is preferably a lipid acyltransferase capable of hydrolysing at least a galactolipid and/or capable of transferring an acyl group from at least a galactolipid to one or more acyl acceptor substrates, wherein the enzyme comprises an amino acid sequence as shown in SEQ ID No. 37 or an amino acid
- 20 sequence which has at least 60% identity thereto.

Preferably, the lipid acyltransferase for use in the methods and uses according to the present invention is a lipid acyltransferase capable of hydrolysing at least galactolipids and/or capable of transferring an acyl group from at least a galactolipid to one or more

25 acyl acceptor substrates, wherein the enzyme is obtainable, preferably obtained, from *Thermobifida* species, preferably *Thermobifida fusca*.

Preferably, the lipid acyltransferase for use in the methods and uses according to the present invention is a lipolytic enzyme capable of hydrolysing at least galactolipids

30 and/or capable of transferring an acyl group from at least a galactolipid to one or more acyl acceptor substrates, wherein the enzyme is obtainable, preferably obtained, from *Corynebacterium* species, preferably *Corynebacterium efficiens*.

In a further embodiment the lipid acyltransferase for use in the methods and uses according to the present invention may be a lipid acyltransferase comprising any one of the amino acid sequences shown as SEQ ID No. 37, 38, 40, 41, 43, 45 or 47 or an amino acid sequence which has at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97% or 98% identity therewith, or encoded by any one of the nucleotide sequences shown as SEQ ID No. 39, 42, 44, 46 or 48 or a nucleotide sequence which has at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97% or 98% identity therewith.

10 In a further embodiment the lipid acyltransferase for use in the methods and uses according to the present invention may be a lipid acyltransferase comprising any one of amino sequences shown as SEQ ID No. 38, 40, 41, 45 or 47 or an amino acid sequence which has at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97% or 98% identity therewith for the uses described herein.

15

In a further embodiment the lipid acyltransferase for use in the methods and uses according to the present invention may be a lipid acyltransferase comprising any one of amino sequences shown as SEQ ID No. 38, 40, or 47 or an amino acid sequence which has at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97% or 98% identity therewith for the uses described herein.

20

More preferably in one embodiment the lipid acyltransferase for use in the methods and uses according to the present invention may be a lipid acyltransferase comprising the amino acid sequence shown as SEQ ID No. 47 or an amino acid sequence which has at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97% or 98% identity therewith.

25

In another embodiment the lipid acyltransferase for use in the methods and uses according to the present invention may be a lipid acyltransferase comprising the amino acid sequence shown as SEQ ID No. 43 or 44 or an amino acid sequence which has at least 80%, 85%, 90%, 95%, 96%, 97% or 98% identity therewith.

30

In another embodiment the lipid acyltransferase for use in the methods and uses according to the present invention may be a lipid acyltransferase comprising the amino acid sequence shown as SEQ ID No. 41 or an amino acid sequence which has at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97% or 98% identity therewith.

5

In one embodiment the lipid acyltransferase for use in the methods and uses according to the present invention may be a lipid acyltransferase capable of hydrolysing at least galactolipids and/or capable of transferring an acyl group from at least a galactolipid to one or more acyl acceptor substrates, wherein the enzyme is encoded by a nucleic acid selected from the group consisting of:

10

- a) a nucleic acid comprising a nucleotide sequence shown in SEQ ID No. 36;
- b) a nucleic acid which is related to the nucleotide sequence of SEQ ID No. 36 by the degeneration of the genetic code; and
- c) a nucleic acid comprising a nucleotide sequence which has at least 70%

15

identity with the nucleotide sequence shown in SEQ ID No. 36.

In one embodiment the lipid acyltransferase according to the present invention may be a lipid acyltransferase obtainable, preferably obtained, from the *Streptomyces* strains L130 or L131 deposited by Danisco A/S of Langebrogade 1, DK-1001 Copenhagen K, Denmark under the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the purposes of Patent Procedure at the National Collection of Industrial, Marine and Food Bacteria (NCIMB) 23 St. Machar Street, Aberdeen Scotland, GB on 25 June 2004 under accession numbers NCIMB 41226 and NCIMB 41227, respectively.

25

Suitable lipid acyltransferases for use in accordance with the present invention and/or in the methods of the present invention may comprise any one of the following amino acid sequences and/or be encoded by the following nucleotide sequences:

30

a polynucleotide encoding a lipid acyltransferase according to the present invention (SEQ ID No. 16);
an amino acid sequence of a lipid acyltransferase according to the present invention (SEQ ID No. 17).

A suitable lipid acyl-transferase enzyme for use in the methods of the invention may also be identified by alignment to the L131 (SEQ ID No. 37) sequence using Align X, the Clustal W pairwise alignment algorithm of VectorNTI using default settings.

5

An alignment of the L131 and homologues from *S. avermitilis* and *T. fusca* illustrates that the conservation of the GDSx motif (GDSY in L131 and *S. avermitilis* and *T. fusca*), the GANDY box, which is either GGND A or GGND L, and the HPT block (considered to be the conserved catalytic histadine). These three conserved blocks are highlighted in Figure 61.

10

When aligned to either the pfam Pfam00657 consensus sequence (as described in WO04/064987) and/ or the L131 sequence herein disclosed (SEQ ID No 37) it is possible to identify three conserved regions, the GDSx block, the GANDY block and the HTP block (see WO04/064987 for further details).

15

When aligned to either the pfam Pfam00657 consensus sequence (as described in WO04/064987) and/ or the L131 sequence herein disclosed (SEQ ID No 37)

i) The lipid acyl-transferase enzyme of the invention, or for use in methods of the invention, has preferably a GDSx motif, more preferably a GDSx motif selected from GDSL or GDSY motif.

20

and/or

ii) The lipid acyl-transferase enzyme of the invention, or for use in methods of the invention, has preferably a GANDY block, more preferably a GANDY block comprising amino GGNDx, more preferably GGND A or GGND L.

25

and/or

iii) The enzyme of the invention, or for use in methods of the invention, has preferable an HTP block.

and preferably

iv) The galactolipase/lipid acyl-transferase enzyme of the invention, or for use in methods of the invention, has preferably a GDSx or GDSY motif, and a

30

GANDY block comprising amino GGNDx, preferably GGND A or GGNDL, and a HTP block (conserved histadine).

Suitably, when the lipid acyltransferase for use in the methods or uses of the present invention, may be a variant lipid acyltransferase, in which case the enzyme may be characterised in that the enzyme comprises the amino acid sequence motif GDSX, wherein X is one or more of the following amino acid residues L, A, V, I, F, Y, H, Q, T, N, M or S, and wherein the variant enzyme comprises one or more amino acid modifications compared with a parent sequence at any one or more of the amino acid residues defined in set 2 or set 4 or set 6 or set 7 (defined hereinbelow).

For instance the variant lipid acyltransferase enzyme for use in the methods or uses of the present invention may be characterised in that the enzyme comprises the amino acid sequence motif GDSX, wherein X is one or more of the following amino acid residues L, A, V, I, F, Y, H, Q, T, N, M or S, and wherein the variant enzyme comprises one or more amino acid modifications compared with a parent sequence at any one or more of the amino acid residues detailed in set 2 or set 4 or set 6 or set 7 (defined hereinbelow) identified by said parent sequence being structurally aligned with the structural model of P10480 defined herein, which is preferably obtained by structural alignment of P10480 crystal structure coordinates with 1IVN.PDB and/or 1IDEO.PDB as taught herein.

In a further embodiment the variant lipid acyltransferase enzyme for use in the methods or uses of the present invention may be characterised in that the enzyme comprises the amino acid sequence motif GDSX, wherein X is one or more of the following amino acid residues L, A, V, I, F, Y, H, Q, T, N, M or S, and wherein the variant enzyme comprises one or more amino acid modifications compared with a parent sequence at any one or more of the amino acid residues taught in set 2 identified when said parent sequence is aligned to the pfam consensus sequence (SEQ ID No. 2 – Figure 12) and modified according to a structural model of P10480 to ensure best fit overlap (see Figure 30) as taught herein.

Suitably the variant lipid acyltransferase enzyme may comprise an amino acid sequence, which amino acid sequence is shown as SEQ ID No. 34, SEQ ID No. 3, SEQ ID No. 4, SEQ ID No. 5, SEQ ID No. 6, SEQ ID No. 7, SEQ ID No. 8, SEQ ID No. 19, SEQ ID No. 10, SEQ ID No. 11, SEQ ID No. 12, SEQ ID No. 13, SEQ ID No. 14, SEQ ID No. 1, SEQ ID No. 15, SEQ ID No. 25, SEQ ID No. 26, SEQ ID No. 27, SEQ ID No. 28, SEQ ID No. 29, SEQ ID No. 30, , SEQ ID No. 32, or SEQ ID No. 33 except for one or more amino acid modifications at any one or more of the amino acid residues defined in set 2 or set 4 or set 6 or set 7 (hereinafter defined) identified by sequence alignment with SEQ ID No. 34.

10

Alternatively the variant lipid acyltransferase enzyme may be a variant enzyme comprising an amino acid sequence, which amino acid sequence is shown as SEQ ID No. 34, SEQ ID No. 3, SEQ ID No. 4, SEQ ID No. 5, SEQ ID No. 6, SEQ ID No. 7, SEQ ID No. 8, SEQ ID No. 19, SEQ ID No. 10, SEQ ID No. 11, SEQ ID No. 12, SEQ ID No. 13, SEQ ID No. 14, SEQ ID No. 1, SEQ ID No. 15, SEQ ID No. 25, SEQ ID No. 26, SEQ ID No. 27, SEQ ID No. 28, SEQ ID No. 29, SEQ ID No. 30, , SEQ ID No. 32, or SEQ ID No. 33 except for one or more amino acid modifications at any one or more of the amino acid residues defined in set 2 or set 4 or set 6 or set 7 identified by said parent sequence being structurally aligned with the structural model of P10480 defined herein, which is preferably obtained by structural alignment of P10480 crystal structure coordinates with 1IVN.PDB and/or 1DEO.PDB as taught herein.

20

Alternatively, the variant lipid acyltransferase enzyme may be a variant enzyme comprising an amino acid sequence, which amino acid sequence is shown as SEQ ID No. 34, SEQ ID No. 3, SEQ ID No. 4, SEQ ID No. 5, SEQ ID No. 6, SEQ ID No. 7, SEQ ID No. 8, SEQ ID No. 19, SEQ ID No. 10, SEQ ID No. 11, SEQ ID No. 12, SEQ ID No. 13, SEQ ID No. 14, SEQ ID No. 1, SEQ ID No. 15, SEQ ID No. 25, SEQ ID No. 26, SEQ ID No. 27, SEQ ID No. 28, SEQ ID No. 29, SEQ ID No. 30, , SEQ ID No. 32, or SEQ ID No. 33 except for one or more amino acid modifications at any one or more of the amino acid residues taught in set 2 identified when said parent sequence is aligned to the pfam consensus sequence (SEQ ID No. 2) and modified according to

30

a structural model of P10480 to ensure best fit overlap (see Figure 30) as taught hereinbelow.

The term "modifying" as used herein means adding, substituting and/or deleting.

5 Preferably the term "modifying" means "substituting".

For the avoidance of doubt, when an amino acid is substituted in the parent enzyme it is preferably substituted with an amino acid which is different from that originally found at that position in the parent enzyme thus to produce a variant enzyme. In other
10 words, the term "substitution" is not intended to cover the replacement of an amino acid with the same amino acid.

Preferably, the parent enzyme is an enzyme which comprises the amino acid sequence shown as SEQ ID No. 34 and/or SEQ ID No. 15 and/or SEQ ID No. 35.

15

Preferably, the variant enzyme is an enzyme which comprises an amino acid sequence, which amino acid sequence is shown as SEQ ID No. 34 or SEQ ID No. 35 except for one or more amino acid modifications at any one or more of the amino acid residues defined in set 2 or set 4 or set 6 or set 7.

20

In one embodiment, preferably the variant enzyme comprises one or more amino acid modifications compared with the parent sequence at at least one of the amino acid residues defined in set 4.

25 Suitably, the variant enzyme comprises one or more of the following amino acid modifications compared with the parent enzyme:

S3E, A, G, K, M, Y, R, P, N, T or G

E309Q, R or A, preferably Q or R

-318Y, H, S or Y, preferably Y.

30

Preferably, X of the GDSX motif is L. Thus, preferably the parent enzyme comprises the amino acid motif GDSL.

Preferably the method of producing a variant lipid acyltransferase enzyme further comprises one or more of the following steps:

- 1) structural homology mapping or
- 5 2) sequence homology alignment.

Suitably, the structural homology mapping may comprise one or more of the following steps:

- 10 i) aligning a parent sequence with a structural model (1IVN.PDB) shown in Figure 46;
- ii) selecting one or more amino acid residue within a 10Å sphere centred on the central carbon atom of the glycerol molecule in the active site (see Figure 47) (such as one or more of the amino acid residues defined in set 1 or set 2); and
- 15 iii) modifying one or more amino acids selected in accordance with step (ii) in said parent sequence.

In one embodiment the amino acid residue selected may reside within a 9, preferably within a 8, 7, 6, 5, 4, or 3 Å sphere centred on the central carbon atom of the glycerol molecule in the active site (see Figure 47).

20

Suitably, the structural homology mapping may comprise one or more of the following steps:

- i) aligning a parent sequence with a structural model (1IVN.PDB) shown in Figure 46;
- 25 ii) selecting one or more amino acids within a 10Å sphere centred on the central carbon atom of the glycerol molecule in the active site (see Figure 47) (such as one or more of the amino acid residues defined in set 1 or set 2);
- iii) determining if one or more amino acid residues selected in accordance with step (ii) are highly conserved (particularly are active site residues and/or part of
- 30 the GDSx motif and/or part of the GANDY motif); and

iv) modifying one or more amino acids selected in accordance with step (ii), excluding conserved regions identified in accordance with step (iii) in said parent sequence.

- 5 In one embodiment the amino acid residue selected may reside within a 9, preferably within a 8, 7, 6, 5, 4, or 3 Å sphere centred on the central carbon atom of the glycerol molecule in the active site (see Figure 47).

10 Alternatively to, or in combination with, the structural homology mapping described above, the structural homology mapping can be performed by selecting specific loop regions (LRs) or intervening regions (IVRs) derived from the pfam alignment (Alignment 2, Figure 48) overlaid with the P10480 model and IIVN. The loop regions (LRs) or intervening regions (IVRs) are defined in the Table below:

	P10480 amino acid positions (SEQ ID No 34)
IVR1	1-19
Loop1 (LR1)	20-41
IVR2	42-76
Loop2 (LR2)	77-89
IVR3	90-117
Loop3 (LR3)	118-127
IVR4	128-145
Loop4 (LR4)	146-176
IVR5	177-207
Loop5 (LR5)	208-287
IVR6	288-317

15

In some embodiments of the present invention the variant acyltransferase enzyme for use in the methods and uses of the present invention not only comprises an amino acid modifications at one or more of the amino acids defined in any one of sets 1-4 and 6-7,

but also comprises at least one amino acid modification in one or more of the above defined intervening regions (IVR1-6) (preferably in one or more of the IVRs 3, 5 and 6, more preferably in IVR 5 or IVR 6) and/or in one or more of the above-defined loop regions (LR1-5) (preferably in one or more of LR1, LR2 or LR5, more preferably in
5 LR5).

In one embodiment, the variant acyltransferase for use in the methods and uses of the present invention may comprise one or more amino acid modification which is not only defined by one or more of set 2, 4, 6 and 7, but also is within one or more of the
10 IVRs 1-6 (preferably within IVR 3, 5 or 6, more preferably within in IVR 5 or IVR 6) or within one or more of the LRs 1-5 (preferably within LR1, LR2 or LR5, more preferably within LR5).

Suitably, the variant acyltransferase for use in the methods and uses of the present
15 invention may comprise one or more amino acid modification which is not only in set 1 or 2, but also is within IVR 3.

Suitably, the variant acyltransferase for use in the methods and uses of the present invention may comprise one or more amino acid modification which is not only in set
20 1 or 2, but also is within IVR 5.

Suitably, the variant acyltransferase for use in the methods and uses of the present invention may comprise one or more amino acid modification which is not only in set
25 1 or 2, but also is within IVR 6.

Suitably, the variant acyltransferase for use in the methods and uses of the present invention may comprise one or more amino acid modification which is not only in set
1 or 2, but also is within LR 1.

30 Suitably, the variant acyltransferase for use in the methods and uses of the present invention may comprise one or more amino acid modification which is not only in set 1 or 2, but also is within LR 2.

Likewise, in some embodiments of the present invention the variant acyltransferase enzyme for use in the methods and uses of the present invention not only comprises an amino acid modification at one or more amino acid residues which reside within a 10, preferably within a 9, 8, 7, 6, 5, 4, or 3, Å sphere centred on the central carbon atom of the glycerol molecule in the active site (see Figure 47), but also comprises at least one amino acid modification in one or more of the above defined intervening regions (IVR1-6) (preferably in one or more of IVRs 3, 5 and 6, more preferably in IVR 5 or IVR 6) and/or in one or more of the above-defined loop regions (LR1-5) (preferably in one or more of LR1, LR2 or LR5, more preferably in LR5).

In one embodiment, preferably the amino acid modification is at one or more amino acid residues which reside within a 10Å sphere and also within LR5.

Thus, the structural homology mapping may comprise one or more of the following steps:

- i) aligning a parent sequence with a structural model (1IVN.PDB) shown in Figure 46;
- ii) selecting one or more amino acid residue within a 10Å sphere centred on the central carbon atom of the glycerol molecule in the active site (see Figure 47) (such as one or more of the amino acid residues defined in set 1 or set 2); and/or selecting one or more amino acid residues within IVR1-6) (preferably within IVR 3, 5 or 6, more preferably within in IVR 5 or IVR 6); and/or selecting one or more amino acid residues within LR1-5 (preferably within LR1, LR2 or LR5, more preferably within LR5); and
- iii) modifying one or more amino acids selected in accordance with step (ii) in said parent sequence.

In one embodiment the amino acid residue selected may reside within a 9 Å sphere, preferably within an 8, 7, 6, 5, 4, or 3 Å sphere centred on the central carbon atom of the glycerol molecule in the active site (see Figure 47).

Suitably, the structural homology mapping may comprise one or more of the following steps:

- i) aligning a parent sequence with a structural model (1IVN.PDB) shown in Figure 46;
- 5 ii) selecting one or more amino acids within a 10Å sphere centred on the central carbon atom of the glycerol molecule in the active site (see Figure 47) (such as one or more of the amino acid residues defined in set 1 or set 2); and/or selecting one or more amino acid residues within IVR1-6 (preferably within IVR 3, 5 or 6, more preferably within in IVR 5 or IVR 6); and/or selecting one or more amino acid residues within LR1-5 (preferably within LR1, LR2 or LR5, more preferably within LR5);
- 10 iii) determining if one or more amino acid residues selected in accordance with step (ii) are highly conserved (particularly are active site residues and/or part of the GDSx motif and/or part of the GANDY motif); and
- 15 modifying one or more amino acids selected in accordance with step (ii), excluding conserved regions identified in accordance with step (iii) in said parent sequence.

Suitably, the one or more amino acids selected in the methods detailed above are not only within a 10Å sphere centred on the central carbon atom of the glycerol molecule
20 in the active site (see Figure 47) (such as one or more of the amino acid residues defined in set 1 or set 2), but are also within one or more of the IVRs 1-6 (preferably within IVR 3, 5 or 6, more preferably within in IVR 5 or IVR 6) or within one or more of the LRs 1-5 (preferably within LR1, LR2 or LR5, more preferably within LR5).

25 In one embodiment, preferably the one or more amino acid modifications is/are within LR5. When it is the case that the modification(s) is within LR5, the modification is not one which is defined in set 5. Suitably, the one or more amino acid modifications not only fall with the region defined by LR5, but also constitute an amino acid within one or more of set 2, set 4, set 6 or set 7.

30

Suitably, the sequence homology alignment may comprise one or more of the following steps:

- i) selecting a first parent lipid acyltransferase;
- ii) identifying a second related lipid acyltransferase having a desirable activity;
- iii) aligning said first parent lipid acyltransferase and the second related lipid acyltransferase;
- 5 iv) identifying amino acid residues that differ between the two sequences; and
- v) modifying one or more of the amino acid residues identified in accordance with step (iv) in said parent lipid acyltransferase.

Suitably, the sequence homology alignment may comprise one or more of the
10 following steps:

- i) selecting a first parent lipid acyltransferase;
- ii) identifying a second related lipid acyltransferase having a desirable activity;
- iii) aligning said first parent lipid acyltransferase and the second related lipid acyltransferase;
- 15 iv) identifying amino acid residues that differ between the two sequences;
- v) determining if one or more amino acid residues selected in accordance with step (iv) are highly conserved (particularly are active site residues and/or part of the GDSx motif and/or part of the GANDY motif); and
- vi) modifying one or more of the amino acid residues identified in accordance with
20 step (iv) excluding conserved regions identified in accordance with step (v) in said parent sequence.

Suitably, said first parent lipid acyltransferase may comprise any one of the following amino acid sequences: SEQ ID No. 34, SEQ ID No. 3, SEQ ID No. 4, SEQ ID No. 5,
25 SEQ ID No. 6, SEQ ID No. 7, SEQ ID No. 8, SEQ ID No. 19, SEQ ID No. 10, SEQ ID No. 11, SEQ ID No. 12, SEQ ID No. 13, SEQ ID No. 14, SEQ ID No. 1, SEQ ID No. 15, SEQ ID No. 25, SEQ ID No. 26, SEQ ID No. 27, SEQ ID No. 28, SEQ ID No. 29, SEQ ID No. 30, , SEQ ID No. 32 or SEQ ID No. 33.

30 Suitably, said second related lipid acyltransferase may comprise any one of the following amino acid sequences: SEQ ID No. 3, SEQ ID No. 34, SEQ ID No. 4, SEQ ID No. 5, SEQ ID No. 6, SEQ ID No. 7, SEQ ID No. 8, SEQ ID No. 19, SEQ ID No.

10, SEQ ID No. 11, SEQ ID No. 12, SEQ ID No. 13, SEQ ID No. 14, SEQ ID No. 1, SEQ ID No. 15, SEQ ID No. 25, SEQ ID No. 26, SEQ ID No. 27, SEQ ID No. 28, SEQ ID No. 29, SEQ ID No. 30, , SEQ ID No. 32 or SEQ ID No. 33.

- 5 The variant enzyme must comprise at least one amino acid modification compared with the parent enzyme. In some embodiments, the variant enzyme may comprise at least 2, preferably at least 3, preferably at least 4, preferably at least 5, preferably at least 6, preferably at least 7, preferably at least 8, preferably at least 9, preferably at least 10 amino acid modifications compared with the parent enzyme.

10

When referring to specific amino acid residues herein the numbering is that obtained from alignment of the variant sequence with the reference sequence shown as SEQ ID No. 34 or SEQ ID No. 35.

- 15 In one aspect preferably the variant enzyme comprises one or more of the following amino acid substitutions:

S3A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, T, V, W, or Y; and/or
L17A, C, D, E, F, G, H, I, K, M, N, P, Q, R, S, T, V, W, or Y; and/or
20 S18A, C, D, E, F, H, I, K, L, M, N, P, Q, R, T, W, or Y; and/or
K22A, C, D, E, F, G, H, I, L, M, N, P, Q, R, S, T, V, W, or Y; and/or
M23A, C, D, E, F, G, H, I, K, L, N, P, Q, R, S, T, V, W, or Y; and/or
Y30A, C, D, E, G, H, I, K, L, M, N, P, Q, R, S, T, V, or W; and/or
G40A, C, D, E, F, H, I, K, L, M, N, P, Q, R, S, T, V, W, or Y; and/or
25 N80A, C, D, E, F, G, H, I, K, L, M, P, Q, R, S, T, V, W, or Y; and/or
P81A, C, D, E, F, G, H, I, K, L, M, N, Q, R, S, T, V, W, or Y; and/or
K82A, C, D, E, F, G, H, I, L, M, N, P, Q, R, S, T, V, W, or Y; and/or
N87A, C, D, E, F, G, H, I, K, L, M, P, Q, R, S, T, V, W, or Y; and/or
N88A, C, D, E, F, G, H, I, K, L, M, P, Q, R, S, T, V, W, or Y; and/or
30 W111A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W or Y; and/or
V112A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, W, or Y; and/or
A114C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, or Y; and/or

- Y117A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, or W; and/or
L118A, C, D, E, F, G, H, I, K, M, N, P, Q, R, S, T, V, W, or Y; and/or
P156A, C, D, E, F, G, H, I, K, L, M, N, Q, R, S, T, V, W, or Y; and/or
D157A, C, E, F, G, H, I, K, L, M, P, Q, R, S, T, V, W, or Y; and/or
5 G159A, C, D, E, F, H, I, K, L, M, N, P, Q, R, S, T, V, W, or Y; and/or
Q160A, C, D, E, F, G, H, I, K, L, M, N, P, R, S, T, V, W, or Y; and/or
N161A, C, D, E, F, G, H, I, K, L, M, P, Q, R, S, T, V, W, or Y; and/or
P162A, C, D, E, F, G, H, I, K, L, M, N, Q, R, S, T, V, W, or Y; and/or
S163A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, T, V, W, or Y; and/or
10 A164C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, or Y; and/or
R165A, C, D, E, F, G, H, I, K, L, M, N, P, Q, S, T, V, W, or Y; and/or
S166A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, T, V, W, or Y; and/or
Q167A, C, D, E, F, G, H, I, K, L, M, N, P, R, S, T, V, W, or Y; and/or
K168A, C, D, E, F, G, H, I, L, M, N, P, Q, R, S, T, V, W, or Y; and/or
15 V169A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, W, or Y; and/or
V170A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, W, or Y; and/or
E171A, C, D, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, or Y; and/or
A172C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, or Y; and/or
Y179A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, or W; and/or
20 H180A, C, D, E, F, G, I, K, L, M, P, Q, R, S, T, V, W, or Y; and/or
N181A, C, D, E, F, G, H, I, K, L, M, P, Q, R, S, T, V, W, or Y; and/or
Q182A, C, D, E, F, G, H, I, K, L, M, N, P, R, S, T, V, W, or Y, preferably K; and/or
M209A, C, D, E, F, G, H, I, K, L, N, P, Q, R, S, T, V, W, or Y; and/or
L210 A, C, D, E, F, G, H, I, K, M, N, P, Q, R, S, T, V, W, or Y; and/or
25 R211 A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, or Y; and/or
N215 A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, or Y; and/or
Y226A, C, D, E, G, H, I, K, L, M, N, P, Q, R, S, T, V, or W; and/or
Y230A, C, D, E, G, H, I, K, L, M, N, P, Q, R, S, T, V or W; and/or
K284A, C, D, E, F, G, H, I, L, M, N, P, Q, R, S, T, V, W, or Y; and/or
30 M285A, C, D, E, F, G, H, I, K, L, N, P, Q, R, S, T, V, W, or Y; and/or
Q289A, C, D, E, F, G, H, I, K, L, M, N, P, R, S, T, V, W, or Y; and/or
V290A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, W, or Y; and/or

E309A, C, D, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, or Y; and/or
S310A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, T, V, W, or Y.

In addition or alternatively thereto there may be one or more C-terminal extensions.

- 5 Preferably the additional C-terminal extension is comprised of one or more aliphatic amino acids, preferably a non-polar amino acid, more preferably of I, L, V or G. Thus, the present invention further provides for a variant enzyme comprising one or more of the following C-terminal extensions: 318I, 318L, 318V, 318G.
- 10 When it is the case that the residues in the parent backbone differ from those in P10480 (SEQ ID No. 2), as determined by homology alignment and/or structural alignment to P10480 and/or 1IVN, it may be desirable to replace the residues which align to any one or more of the following amino acid residues in P10480 (SEQ ID No. 2): Ser3, Leu17, Lys22, Met23, Gly40, Asn80, Pro81, Lys82, Asn87, Asn88, Trp111,
15 Val112, Ala114, Tyr117, Leu118, Pro156, Gly159, Gln160, Asn161, Pro162, Ser163, Ala164, Arg165, Ser166, Gln167, Lys168, Val169, Val170, Glu171, Ala172, Tyr179, His180, Asn181, Gln182, Met209, Leu210, Arg211, Asn215, Lys284, Met285, Gln289, Val290, Glu309 or Ser310, with the residue found in P10480 respectively.
- 20 Variant enzymes which have a decreased hydrolytic activity against a phospholipid, such as phosphatidylcholine (PC), may also have an increased transferase activity from a phospholipid.
- Variants enzymes which have an increased transferase activity from a phospholipid,
25 such as phosphatidylcholine (PC), may also have an increased hydrolytic activity against a phospholipid.
- Suitably, one or more of the following sites may be involved in substrate binding:
Leu17; Ala114; Tyr179; His180; Asn181; Met209; Leu210; Arg211; Asn215; Lys284;
30 Met285; Gln289; Val290.

1. Modification of one or more of the following residues may result in a variant enzyme having an increased absolute transferase activity against phospholipid:

S3, D157, S310, E309, Y179, N215, K22, Q289, M23, H180, M209, L210, R211, P81,
5 V112, N80, L82, N88; N87

Specific modifications which may provide a variant enzyme having an improved transferase activity from a phospholipid may be selected from one or more of the following:

- 10 S3A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, T, V, W or Y; preferably N, E, K, R, A, P or M, most preferably S3A
D157A, C, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W or Y; preferably D157S, R, E, N, G, T, V, Q, K or C
S310A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, T, V, W or Y; preferably S310T
15 -318 E
E309A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, T, V, W or Y; preferably E309 R, E, L, R or A
Y179A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V or W; preferably Y179 D, T, E, R, N, V, K, Q or S, more preferably E, R, N, V, K or Q
20 N215A, C, D, E, F, G, H, I, K, L, M, P, Q, R, S, T, V, W or Y; preferably N215 S, L, R or Y
K22A, C, D, E, F, G, H, I, L, M, N, P, Q, R, S, T, V, W or Y; preferably K22 E, R, C or A
Q289A, C, D, E, F, G, H, I, K, L, M, N, P, R, S, T, V, W or Y; preferably Q289 R, E,
25 G, P or N
M23A, C, D, E, F, G, H, I, K, L, N, P, Q, R, S, T, V, W or Y; preferably M23 K, Q, L, G, T or S
H180A, C, D, E, F, G, I, K, L, M, P, Q, R, S, T, V, W or Y; preferably H180 Q, R or K
M209 A, C, D, E, F, G, H, I, K, L, N, P, Q, R, S, T, V, W or Y; preferably M209 Q, S,
30 R, A, N, Y, E, V or L
L210A, C, D, E, F, G, H, I, K, M, N, P, Q, R, S, T, V, W or Y; preferably L210 R, A, V, S, T, I, W or M

- R211A, C, D, E, F, G, H, I, K, L, M, N, P, Q, S, T, V, W or Y; preferably R211T
 P81A, C, D, E, F, G, H, I, K, L, M, N, Q, R, S, T, V, W or Y; preferably P81G
 V112A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, W or Y; preferably V112C
 N80A, C, D, E, F, G, H, I, K, L, M, P, Q, R, S, T, V, W or Y; preferably N80 R, G, N,
 5 D, P, T, E, V, A or G
 L82A, C, D, E, F, G, H, I, M, N, P, Q, R, S, T, V, W or Y; preferably L82N, S or E
 N88A, C, D, E, F, G, H, I, K, L, M, P, Q, R, S, T, V, W or Y; preferably N88C
 N87A, C, D, E, F, G, H, I, K, L, M, P, Q, R, S, T, V, W or Y; preferably N87M or G
- 10 Modification of one or more of the following residues results in a variant enzyme
 having an increased absolute transferase activity against phospholipid:
- S3 N, R, A, G
 M23 K, Q, L, G, T, S
 15 H180 R
 L82 G
 Y179 E, R, N, V, K or Q
 E309 R, S, L or A
- 20 One preferred modification is N80D. This is particularly the case when using the
 reference sequence SEQ ID No. 35. Therefore in a preferred embodiment of the
 present invention the lipid acyltransferase according to the present invention comprises
 SEQ ID No. 35.
- 25 As noted above, when referring to specific amino acid residues herein the numbering
 is that obtained from alignment of the variant sequence with the reference sequence
 shown as SEQ ID No. 34 or SEQ ID No. 35
- 30 Much by preference, the lipid acyltransferase for use in the method and uses of the
 present invention may be a lipid acyltransferase comprising the amino acid sequence
 shown as SEQ ID No. 16 (Figure 10), or an amino acid sequence which has 75% or
 more, preferably 85% or more, more preferably 90% or more, even more preferably

95% or more, even more preferably 98% or more, or even more preferably 99% or more identity to SEQ ID No. 16. This enzyme may be considered a variant enzyme.

For the avoidance of doubt, when a particular amino acid is taught at a specific site, for instance L118 for instance, this refers to the specific amino acid at residue number 118 in SEQ ID No. 34 unless otherwise stated. However, the amino acid residue at site 118 in a different parent enzyme may be different from leucine.

Thus, when taught to substitute an amino acid at residue 118, although reference may be made to L118 it would be readily understood by the skilled person that when the parent enzyme is other than that shown in SEQ ID No. 34, the amino acid being substituted may not be leucine. It is, therefore, possible that when substituting an amino acid sequence in a parent enzyme which is not the enzyme having the amino acid sequence shown as SEQ ID No. 34, the new (substituting) amino acid may be the same as that taught in SEQ ID No. 34. This may be the case, for instance, where the amino acid at say residue 118 is not leucine and is, therefore different from the amino acid at residue 118 in SEQ ID No. 34. In other words, at residue 118 for example, if the parent enzyme has at that position an amino acid other than leucine, this amino acid may be substituted with leucine in accordance with the present invention.

20

For the purposes of the present invention, the degree of identity is based on the number of sequence elements which are the same. The degree of identity in accordance with the present invention may be suitably determined by means of computer programs known in the art, such as GAP provided in the GCG program package (Program Manual for the Wisconsin Package, Version 8, August 1994, Genetics Computer Group, 575 Science Drive, Madison, Wisconsin, US53711) (Needleman & Wunsch (1970), J. of Molecular Biology 48, 443-45) using the following settings for polypeptide sequence comparison: GAP creation penalty of 3.0 and GAP extension penalty of 0.1. Suitably, the degree of identity with regard to an amino acid sequence is determined over at least 20 contiguous amino acids, preferably over at least 30 contiguous amino acids, preferably over at least 40 contiguous amino acids, preferably

over at least 50 contiguous amino acids, preferably over at least 60 contiguous amino acids.

Suitably, the lipid acyltransferase enzyme according to the present invention may be obtainable, preferably obtained, from organisms from one or more of the following genera: Aeromonas, Streptomyces, Saccharomyces, Lactococcus, Mycobacterium, Streptococcus, Lactobacillus, Desulfitobacterium, Bacillus, Campylobacter, Vibrionaceae, Xylella, Sulfolobus, Aspergillus, Schizosaccharomyces, Listeria, Neisseria, Mesorhizobium, Ralstonia, Xanthomonas, Candida, Thermobifida and Corynebacterium.

Suitably, the lipid acyltransferase enzyme according to the present invention may be obtainable, preferably obtained, from one or more of the following organisms: *Aeromonas hydrophila*, *Aeromonas salmonicida*, *Streptomyces coelicolor*, *Streptomyces rimosus*, *Mycobacterium*, *Streptococcus pyogenes*, *Lactococcus lactis*, *Streptococcus pyogenes*, *Streptococcus thermophilus*, *Streptomyces thermosacchari*, *Streptomyces avermitilis*, *Lactobacillus helveticus*, *Desulfitobacterium dehalogenans*, *Bacillus sp*, *Campylobacter jejuni*, *Vibrionaceae*, *Xylella fastidiosa*, *Sulfolobus solfataricus*, *Saccharomyces cerevisiae*, *Aspergillus terreus*, *Schizosaccharomyces pombe*, *Listeria innocua*, *Listeria monocytogenes*, *Neisseria meningitidis*, *Mesorhizobium loti*, *Ralstonia solanacearum*, *Xanthomonas campestris*, *Xanthomonas axonopodis*, *Candida parapsilosis*, *Thermobifida fusca* and *Corynebacterium efficiens*.

In one aspect, preferably the lipid acyltransferase enzyme according to the present invention is obtainable, preferably obtained, from one or more of *Aeromonas hydrophila* or *Aeromonas salmonicida*.

In one embodiment suitably the sterol and/or stanol may comprise one or more of the following structural features:

- i) a 3-beta hydroxy group or a 3-alpha hydroxy group; and/or
- ii) A:B rings in the cis position or A:B rings in the trans position or C5-C6 is unsaturated.

Suitable sterol acyl acceptors include cholesterol and phytosterols, for example alpha-sitosterol, beta-sitosterol, stigmasterol, ergosterol, campesterol, 5,6-dihydrosterol, brassicasterol, alpha-spinasterol, beta-spinasterol, gamma-spinasterol, deltaspinasterol, fucosterol, dimosterol, ascosterol, serebisterol, episterol, anasterol, hyposterol, chondrillasterol, desmosterol, chalinosterol, poriferasterol, clionasterol, sterol glycosides, tocopherol, tocotrienol and other natural or synthetic isomeric forms and derivatives.

- 5
- 10 Advantageously, in one embodiment, the sterol acyl acceptor is tocopherol. Suitably the tocopherol may be one or more of gamma, delta, beta or d-alpha tocopherol – including d-alpha tocopherol acid succinate for example. In one embodiment, preferably the sterol acyl acceptor is alpha-tocopherol.
- 15 In one embodiment, preferably the method according to the present invention includes the step of adding tocopherol, preferably alpha-tocopherol, to the oil.

In one aspect, preferably the sterol acyl acceptor is cholesterol.

- 20 In one aspect, preferably the sterol and/or stanol acyl acceptor is a sterol and/or a stanol other than cholesterol.

- In one aspect of the present invention suitably more than one sterol and/or stanol may act as the acyl acceptor, suitably more than two sterols and/or stanols may act as the acyl acceptor. In other words, in one aspect of the present invention, suitably more than one sterol ester and/or stanol ester may be produced. Suitably, when cholesterol is the acyl acceptor one or more further sterols or one or more stanols may also act as the acyl acceptor. Thus, in one aspect, the present invention provides a method for the in situ production of both a tocopherol ester and at least one other sterol or stanol ester in combination. In other words, the lipid acyltransferase for some aspects of the present invention may transfer an acyl group from a lipid to both tocopherol and at least one further sterol and/or at least one stanol.
- 25
- 30

In some aspects, the oil prepared in accordance with the present invention may be used to reduce the risk of cardiovascular diseases.

- 5 In one aspect, the oil prepared in accordance with the present invention may be used to reduce blood serum cholesterol and/or to reduce low density lipoprotein. Blood serum cholesterol and low density lipoproteins have both been associated with certain diseases in humans, such as atherosclerosis and/or heart disease for example. Thus, it is envisaged that the oils prepared in accordance with the present invention may be used to reduce the risk of such diseases.
- 10

In another aspect the present invention provides the use of an edible oil according to the present invention for use in the treatment and/or prevention of cardiovascular diseases.

15

Thus, in one aspect the present invention provides the use of an edible oil according to the present invention for use in the treatment and/or prevention of atherosclerosis and/or heart disease.

- 20 In a further aspect, the present invention provides a medicament comprising an edible oil according to the present invention.

- In a further aspect, the present invention provides a method of treating and/or preventing a disease in a human or animal patient which method comprising administering to the patient an effective amount of an edible oil according to the present invention.
- 25

Suitably the sterol acyl acceptor may be one which is naturally found in edible or vegetable oils.

30

Alternatively, or in addition, the sterol acyl acceptor may be one which added to the edible or vegetable oil.

When it is the case that a sterol and/or a stanol is added to the edible oil, the sterol and/or stanol may be added before, simultaneously with, and/or after the addition of the lipid acyltransferase according to the present invention. Suitably, the present invention may encompass the addition of exogenous sterols/stanols, particularly 5 phytosterols/phytostanols, to an edible or vegetable oil prior to or simultaneously with the addition of the enzyme according to the present invention.

For some aspects, one or more sterols present in the edible oil may be converted to one 10 or more stanols prior to or at the same time as the lipid acyltransferase is added according to the present invention. Any suitable method for converting sterols to stanols may be employed. For example, the conversion may be carried out by chemical hydrogenation for example. The conversion may be conducted prior to the addition of the lipid acyltransferase in accordance with the present invention or simultaneously 15 with the addition of the lipid acyltransferase in accordance with the present invention. Suitably enzymes for the conversion of sterols to stanols are taught in WO00/061771.

Suitably the present invention may be employed to produce phytostanol esters *in situ* in an edible oil. Phytostanol esters have increased solubility through lipid membranes, 20 bioavailability and enhanced health benefits (see for example WO92/99640).

An advantage of the present invention is that sterol and/or stanol esters are produced in the edible oil during the degumming thereof. A further advantage is that enzyme is degummed without an increase, or a substantial, increase, in the free fatty acid content 25 of the edible oil. The production of free fatty acids can be detrimental in the edible oil. Preferably, the method according to the present invention results in the degumming of an edible oil wherein the accumulation of free fatty acids is reduced and/or eliminated. Without wishing to be bound by theory, in accordance with the present invention the fatty acid which is removed from the lipid is transferred by the lipid acyltransferase to 30 an acyl acceptor, for example a sterol and/or a stanol. Thus, the overall level of free fatty acids in the foodstuff does not increase or increases only to an insignificant degree. This is in sharp contradistinction to the situation when phospholipases, such as

Lecitase Ultra™ are used in enzymatic degumming of edible oils. In particular, the use of such phospholipases can result in an increased amount of free fatty acid in the edible oil, which can be detrimental. In accordance with the present invention, the accumulation of free fatty acids is reduced and/or eliminated when compared with the amount of free fatty acids which would have been accumulated had a phospholipase A enzyme, such as Lecitase Ultra™, been used in place of the lipid acyltransferase in accordance with the present invention.

A lipid acyl transferase according to the present invention may be suitable for use in the enzymatic degumming of vegetable or edible oils. In processing of vegetable or edible oil the edible or vegetable oil is treated with a lipid acyl transferase according to the present invention so as to hydrolyse a major part of the phospholipid. Preferably, the fatty acyl groups are transferred from the polar lipids to an acyl acceptor. The degumming process typically results in the reduction of the content of the polar lipids, particularly of phospholipids, in an edible oil due to hydrolysis of a major part (i.e. more than 50%) of the phospholipid. Typically, the aqueous phase containing the hydrolysed phospholipid is separated from the oil. Suitably, the edible or vegetable oil may initially (pre-treatment with the enzyme according to the present invention) have a phosphorus content of 50-250 ppm.

20

As the skilled person is aware, the term "degumming" as used herein means the refining of oil by converting phosphatides (such as lecithin, phospholipids and occluded oil) into hydratable phosphatides. Oil which has been degummed is more fluid and thus has better handling properties than oil which has not been degummed.

25

The term "transferase" as used herein is interchangeable with the term "lipid acyltransferase".

Suitably, the lipid acyltransferase as defined herein catalyses one or more of the following reactions: interesterification, transesterification, alcoholysis, hydrolysis.

30

The term "interesterification" refers to the enzymatic catalysed transfer of acyl groups between a lipid donor and lipid acceptor, wherein the lipid donor is not a free acyl group.

- 5 The term "transesterification" as used herein means the enzymatic catalysed transfer of an acyl group from a lipid donor (other than a free fatty acid) to an acyl acceptor (other than water).

As used herein, the term "alcoholysis" refers to the enzymatic cleavage of a covalent
10 bond of an acid derivative by reaction with an alcohol ROH so that one of the products combines with the H of the alcohol and the other product combines with the OR group of the alcohol.

As used herein, the term "alcohol" refers to an alkyl compound containing a hydroxyl
15 group.

As used herein, the term "hydrolysis" refers to the enzymatic catalysed transfer of an acyl group from a lipid to the OH group of a water molecule.

- 20 The term "without increasing or without substantially increasing the free fatty acids" as used herein means that preferably the lipid acyl transferase according to the present invention has 100% transferase activity (i.e. transfers 100% of the acyl groups from an acyl donor onto the acyl acceptor, with no hydrolytic activity); however, the enzyme may transfer less than 100% of the acyl groups present in the lipid acyl donor to the
25 acyl acceptor. In which case, preferably the acyltransferase activity accounts for at least 5%, more preferably at least 10%, more preferably at least 20%, more preferably at least 30%, more preferably at least 40%, more preferably 50%, more preferably at least 60%, more preferably at least 70%, more preferably at least 80%, more preferably at least 90% and more preferably at least 98% of the total enzyme activity.
- 30 The % transferase activity (i.e. the transferase activity as a percentage of the total enzymatic activity) may be determined by the following protocol:

Enzyme suitable for use in the methods of the invention preferably have phospholipase activity in a standard phospholipase activity assay taught hereinbelow.

Determination of phospholipase activity (phospholipase activity assay (PLU-7)):

5

Substrate

0.6% L- α Phosphatidylcholine 95% Plant (Avanti #441601), 0.4% Triton-X 100 (Sigma X-100) and 5 mM CaCl₂ was dispersed in 0.05M HEPES buffer pH 7.

Assay procedure:

10 400 μ L substrate was added to a 1.5 mL Eppendorf tube and placed in an Eppendorf Thermomixer at 37°C for 5 minutes. At time $t=0$ min, 50 μ L enzyme solution was added. Also a blank with water instead of enzyme was analyzed. The sample was mixed at 10x100 rpm in an Eppendorf Thermomixer at 37°C for 10 minutes. At time $t=10$ min the Eppendorf tube was placed in another thermomixer at 99°C for 15 minutes to stop the reaction.

Free fatty acid in the samples was analyzed by using the NEFA C kit from WAKO GmbH.

Enzyme activity PLU-7 at pH 7 was calculated as micromole fatty acid produced per minute under assay conditions.

20

More preferably the lipid acyl-transferase will also have transferase activity as defined by the protocol below:

Protocol for the determination of % acyltransferase activity:

25

An edible oil to which a lipid acyltransferase according to the present invention has been added may be extracted following the enzymatic reaction with CHCl₃:CH₃OH 2:1 and the organic phase containing the lipid material is isolated and analysed by GLC and HPLC according to the procedure detailed hereinbelow. From the GLC and HPLC analyses the amount of free fatty acids and one or more of sterol/stanol esters; 30 are determined. A control edible oil to which no enzyme according to the present invention has been added, is analysed in the same way.

Calculation:

From the results of the GLC and HPLC analyses the increase in free fatty acids and sterol/stanol esters can be calculated:

Δ % fatty acid = % Fatty acid(enzyme) - % fatty acid(control); Mv fatty acid =

5 average molecular weight of the fatty acids;

$A = \Delta$ % sterol ester/Mv sterol ester (where Δ % sterol ester = % sterol/stanol ester(enzyme) - % sterol/stanol ester(control) and Mv sterol ester = average molecular weight of the sterol/stanol esters);

10 The transferase activity is calculated as a percentage of the total enzymatic activity:

$$\% \text{ transferase activity} = \frac{A \times 100}{A + \Delta \% \text{ fatty acid} / (\text{Mv fatty acid})}$$

15 If the free fatty acids are increased in the edible oil they are preferably not increased substantially, i.e. to a significant degree. By this we mean, that the increase in free fatty acid does not adversely affect the quality of the edible oil.

20 The edible oil used for the acyltransferase activity assay is preferably the soya bean oil supplemented with plant sterol (1%) and phosphatidylcholine (2%) oil using the method in Example 3. For the assay the enzyme dosage used is preferably 0.2 PLU-7/g oil, more preferably 0.08 PLU-7/g oil. The level of phospholipid present in the oil and/or the % conversion of sterol is preferably determined after 4 hours, more preferably after 20 hours.

25

In some aspects of the present invention, the term "without substantially increasing free fatty acids" as used herein means that the amount of free fatty acid in a edible oil treated with an lipid acyltransferase according to the present invention is less than the amount of free fatty acid produced in the edible oil when an enzyme other than a lipid acyltransferase according to the present invention had been used, such as for example
30 as compared with the amount of free fatty acid produced when a conventional

phospholipase enzyme, e.g. Lecitase Ultra™ (Novozymes A/S, Denmark), had been used.

In addition to, or instead of, assessing the % transferase activity in an oil (above), to
5 identify the lipid acyl transferase enzymes most preferable for use in the methods of
the invention the following assay entitled "Protocol for identifying lipid
acyltransferases for use in the present invention" can be employed.

Protocol for identifying lipid acyltransferases

10

A lipid acyltransferase in accordance with the present invention is on which results in:

i) the removal of phospholipid present in a soya bean oil supplemented with
plant sterol (1%) and phosphatidylcholine (2%) oil using the method taught
in Example 3.

15

and/or

ii) the conversion (% conversion) of the added sterol to sterol-ester when
using the method taught in Example 3. The GLC method for determining
the level of sterol and sterol esters as taught in Example 5 may be used.

20

For the assay the enzyme dosage used may be 0.2 PLU-7/g oil, preferably 0.08 PLU-
7/g oil. The level of phospholipid present in the oil and/or the conversion (%
conversion) of sterol is preferably determined after 4 hours, more preferably after 20
hours.

25

In the protocol for identifying lipid acyl transferases, after enzymatic treatment, 5%
water is preferably added and thoroughly mixed with the oil. The oil is then separated
into an oil and water phase using centrifugation (see "Enzyme-catalyzed degumming
of vegetable oils" by Buchold, H. and Laurgi A.-G., Fett Wissenschaft Technologie
(1993), 95(8), 300-4, ISSN: 0931-5985), and the oil phase can then be analysed for

30

phosphorus content using the following protocol ("Assay for Phosphorus Content"):

Assay for Phosphorus Content

The level of phospholipid present in an oil after degumming is determined by first preparing the oil sample according to the sample preparation taught in the AOAC Official Method 999.10 (>Lead, Cadmium, Zinc, Copper, and Iron in Foods Atomic Absorption Spectrophotometry after Microwave Digestion, First Action 1999 NMKL-AOAC Method). The amount of phospholipids in the oil is then measured by analysing the phosphorus content in the oil sample after degumming according to the AOAC Official Method 985.01 (>Metals and Other Elements in Plants and Pet Foods Inductively Coupled Plasma Spectroscopic Method First Action 1985 Final Action 1988).

The amount of phosphorus present in the oil after degumming is preferably less than 50 ppm, preferably less than 40ppm, preferably less than 30ppm, preferably less than 20ppm, preferably less than 10ppm, preferably less than 5ppm. The oil after degumming, as illustrated in the examples may be substantially free of phospholipid, i.e. contain less than 1ppm phospholipid.

The % conversion of the sterol present in the oil is at least 1%, preferably at least 5%, preferably at least 10%, preferably at least 20%, preferably at least 30%, preferably at least 40%, preferably at least 50%, preferably at least 60%, preferably at least 70%, preferably at least 80%, preferably at least 90%, preferably at least 95%.

In one embodiment the % conversion of the sterol present in the oil is at least 5%, preferably at least 20%.

25

Low Water Degumming

It has surprisingly been found that when a lipid acyl transferase is used in a process of enzymatic degumming of an edible oil, the enzymatic degumming can be performed in a very low water environment. Some water may still be required, for example when adding the enzyme to the oil the enzyme may be added in small amount of water, such

30

as less than 1%, preferably 0.5%, more preferably less than 0.2%, more preferably less than 1%.

5 Preferably the water content of the edible oil in the processes and uses according to the present invention is less than 1%, preferably less than 0.5%, more preferably less than 0.2%, more preferably less than 0.1%.

10 Thus, one advantage of the present invention is that when only a small amount of water (i.e. <5%, preferably <1%, preferably <0.5%, preferably <0.2%) is used during the enzymatic degumming the gums (i.e. the phosphorus containing portion) separates from the oil, for example in the form of a solid precipitate. The solid precipitate can be readily removed from the degummed oil by methods such as simply decanting the oil or removing or the gum by filtration for example.

15 This contrasts sharply with conventional enzymatic degumming processes in which a significant amount of water is added to the oil. This is because in the conventional enzymatic degumming processes post-degumming because of the high water content, one obtains a water layer which comprises the phosphorus containing portion (for example that portion comprising lysophospholipids). This water layer must be removed
20 and can be removed by centrifugation for example. However, the removal of the water layer is significantly more difficult than the removal of the solid precipitate obtained when using the process of the present invention.

25 Therefore the enzymatic degumming process according to the present invention could be considered as a "low water degumming process".

In one embodiment of the present invention, the gum may be removed by adjusting the oil to 5% water followed by centrifugation of the oil. (see "Enzyme-catalyzed degumming of vegetable oils" by Buchold, H. and Laurgi A.-G., Fett Wissenschaft
30 Technologie (1993), 95(8), 300-4).

Therefore, the invention provides a process for the degumming of an edible oil, such as a crude edible oil (for example a crude soya oil), without the need for either a prewashing step prior to degumming and/or a step of removing the water added during degumming, which is required when using conventional phospholipases such as
5 pancreatic phospholipase and Lecitase Ultra™.

Preferably, the edible oil has a less than a 4.5% water content, more preferably less than 4%, less than 3%, less than 2%, less than 1%, less than 0.5%.

10 Suitably, the edible oil may contain at least 0.1% water, such as at least 0.3%, 0.4% or 0.5%.

Preferred lipid acyltransferases for use in the present invention are identified as those which have a high activity such as high phospholipid hydrolytic activity or high
15 phospholipid transferase activity on phospholipids in an oil environment, most preferably lipid acyl transferases for use in enzymatic degumming have a high phospholipid to sterol transferase activity.

As detailed above, other acyl-transferases suitable for use in the methods of the
20 invention may be identified by identifying the presence of the GDSx, GANDY and HPT blocks either by alignment of the pFam00657 consensus sequence (SEQ ID No 1), and/or alignment to a GDSx acyltransferase, for example SEQ ID No 28. In order to assess their suitability for degumming, i.e. identify those enzymes which have a transferase activity of at least 5%, more preferably at least 10%, more preferably at
25 least 20%, more preferably at least 30%, more preferably at least 40%, more preferably 50%, more preferably at least 60%, more preferably at least 70%, more preferably at least 80%, more preferably at least 90% and more preferably at least 98% of the total enzyme activity, such acyltransferases are tested using the "Protocol for the determination of % acyltransferase activity" assay detailed hereinabove.

30

The present invention relates to the use of a lipid acyl transferase according to the present invention in degumming edible vegetable oils and/or edible oils and to methods for degumming edible or vegetable oils.

- 5 In one aspect, the present invention may provide a method comprising using a lipid acyl transferase to remove the non-hydratable phosphorus (NHP) content in oil comprising a relatively high amount of NHP.

The term "edible oil" as uses herein may encompass vegetable oils.

10

Preferably, the edible oil prior to treatment in accordance with the present invention comprises a non-hydratable phosphorus content of 50-250ppm, preferably at least 60 ppm, more preferably at least 100 ppm, and even more preferably at least 200 ppm, even more preferably above 250ppm.

15

More preferably, the edible oil prior to treatment in accordance with the present invention comprises a non-hydratable phosphorous content in the range of 60-500 ppm, more preferably in the range of 100-500 ppm, and even more preferably in the range of 200-500 ppm.

20

An edible oil as referred to herein may be any oil having a relatively high amount of a non-hydratable phosphorus, this may include water degummed oil, or more preferably this is a crude-oil or a semi-crude oil.

- 25 In one aspect, the crude edible oil has, prior to carrying out the method of the invention, a phosphorous content above 350 ppm, more preferably above 400 ppm, even more preferably above 500 ppm, and most preferably above 600 ppm.

30 Oils encompassed by the method according to the present invention may include, but are not limited to, one or more of soya bean oil, canola oil, corn oil, cottonseed oil, palm oil, coconut oil, peanut oil, olive oil, safflower oil, palm kernel oil, rape seed oil and sunflower oil.

Preferably, the oil is one or more of soya bean oil, sunflower oil and rape seed oil (sometimes referred to as canola oil).

- 5 More preferably, the oil is one or more of soya bean oil, sunflower oil or rape seed oil.

Most preferably, the oil is soya bean oil.

- 10 These oils may be in the form of a crude oil, a semicrude oil, or a water-degummed oil.

- As used herein, "crude oil" (also referred to herein as a non-degummed oil) may be a pressed or extracted oil or a mixture thereof from e.g. rapeseed, soybean, or sunflower. The phosphatide content in a crude oil may vary from 0.5-3% w/w corresponding
15 to a phosphorus content in the range of 200-1200 ppm, more preferably in the range of 250-1200 ppm. Apart from the phosphatides the crude oil also contains small concentrations of carbohydrates, sugar compounds and metal/phosphatide acid complexes of Ca, Mg and Fe.

- 20 As used herein, "semicrude oil" refers to any oil which is not a crude oil, but which has a phosphatide content above 250 ppm, more preferably above 500 ppm. Such an oil could e.g. be obtained by subjecting a crude oil to a process similar to the "water degumming" process described below.

- 25 As used herein, "water-degummed oil" may be typically be obtained by a "water degumming process" comprising mixing 1-3% w/w of hot water with warm (60-90°C) crude oil. Usual treatment periods are 30-60 minutes. The water-degumming step removes the phosphatides and mucilaginous gums which become insoluble in the oil when hydrated. The hydrated phosphatides and gums can be separated from the oil by
30 settling, filtration or centrifugation - centrifugation being the more prevalent practice. The essential object in said water-degumming process is to separate the hydrated phosphatides from the oil. The mixing of hot water into the oil, described above,

should herein be understood broadly as mixing of an aqueous solution into the oil according to standard water-degumming procedures in the art.

Advantageously, the method and uses of the present invention enable degumming of edible oils in a low water (<5%, preferably less than 2%, more preferably less than 1%) environments. Therefore degumming can be performed with adding less water than when using conventional enzymes. A further advantage of the present invention is the production of sterol esters (in particular tocopherol esters) in the oil. A yet further advantage of the present invention is removal (preferably complete removal) of phospholipids. A further advantage of the present invention is the removal (preferably complete removal) of phospholipids without removal of phytosterol, and in particular tocopherol. It is preferred that, due to the esterification of the phytosterol, there is no significant removal of phytosterols such as tocopherol from the oil instead they are simply esterified. However, in one embodiment the amount of phytosterol such as tocopherol may be reduced. In such embodiments the absolute levels of phytosterol such as tocopherol may be reduced by preferably no more than 10%, alternatively no more than 25%, alternatively no more than 50%, alternatively no more than 75%. A yet further advantage of the present invention is the removal (preferably complete removal) of phospholipids without hydrolysis of triglycerides.

For the ease of reference, these and further aspects of the present invention are now discussed under appropriate section headings. However, the teachings under each section are not necessarily limited to each particular section.

25 DEFINITION OF SETS

Amino acid set 1:

Amino acid set 1

30 Gly8, Asp9, Ser10, Leu11, Ser12, Tyr15, Gly44, Asp45, Thr46, Glu69, Leu70, Gly71, Gly72, Asn73, Asp74, Gly75, Leu76, Gln106, Ile107, Arg108, Leu109, Pro110,

Tyr113, Phe121, Phe139, Phe140, Met141, Tyr145, Met151, Asp154, His157, Gly155, Ile156, Pro158

The highly conserved motifs, such as GDSx and catalytic residues, were deselected from set 1 (residues underlined). For the avoidance of doubt, set 1 defines the amino acid residues within 10Å of the central carbon atom of a glycerol in the active site of the 1IVN model.

Amino acid set 2:

10

Amino acid set 2 (note that the numbering of the amino acids refers to the amino acids in the P10480 mature sequence)

Leu17, Lys22, Met23, Gly40, Asn80, Pro81, Lys82, Asn87, Asn88, Trp111, Val112, Ala114, Tyr117, Leu118, Pro156, Gly159, Gln160, Asn161, Pro162, Ser163, Ala164, 15 Arg165, Ser166, Gln167, Lys168, Val169, Val170, Glu171, Ala172, Tyr179, His180, Asn181, Met209, Leu210, Arg211, Asn215, Lys284, Met285, Gln289 and Val290.

Table of selected residues in Set 1 compared with Set 2:

IVN model			P10480 Mature sequence Residue Number
IVN	A.hyd homologue		
	PFAM	Structure	
Gly8	Gly32		
Asp9	Asp33		
Ser10	Ser34		
Leu11	Leu35		Leu17
Ser12	Ser36		Ser18
			Lys22
			Met23
Tyr15	Gly58		Gly40

Gly44	Asn98		Asn80
Asp45	Pro99		Pro81
Thr46	Lys100		Lys82
			Asn87
			Asn88
Glu69	Trp129		Trp111
Leu70	Val130		Val112
Gly71	Gly131		
Gly72	Ala132		Ala114
Asn73	Asn133		
Asp74	Asp134		
Gly75	Tyr135		Tyr117
Leu76	Leu136		Leu118
Gln106		Pro174	Pro156
Ile107		Gly177	Gly159
Arg108		Gln178	Gln160
Leu109		Asn179	Asn161
Pro110		180 to 190	Pro162
Tyr113			Ser163
			Ala164
			Arg165
			Ser166
			Gln167
			Lys168
			Val169
			Val170
			Glu171
			Ala172
Phe121	His198	Tyr197	Tyr179
		His198	His180
		Asn199	Asn181

Phe139	Met227		Met209
Phe140	Leu228		Leu210
Met141	Arg229		Arg211
Tyr145	Asn233		Asn215
			Lys284
Met151	Met303		Met285
Asp154	Asp306		
Gly155	Gln307		Gln289
Ile156	Val308		Val290
His157	His309		
Pro158	Pro310		

Amino acid set 3:

5 Amino acid set 3 is identical to set 2 but refers to the *Aeromonas salmonicida* (SEQ ID No. 28) coding sequence, i.e. the amino acid residue numbers are 18 higher in set 3 as this reflects the difference between the amino acid numbering in the mature protein (SEQ ID No. 2) compared with the protein including a signal sequence (SEQ ID No. 28).

10

The mature proteins of *Aeromonas salmonicida* GDSX (SEQ ID No. 28) and *Aeromonas hydrophila* GDSX (SEQ ID No. 26) differ in five amino acids. These are Thr3Ser, Gln182Lys, Glu309Ala, Ser310Asn, Gly318-, where the *salmonicida* residue is listed first and the *hydrophila* residue is listed last (FIGURE 59). The *hydrophila* protein is only 317 amino acids long and lacks a residue in position 318. The *Aeromonas salmonicidae* GDSX has considerably high activity on polar lipids such as galactolipid substrates than the *Aeromonas hydrophila* protein. Site scanning was performed on all five amino acid positions.

20

Amino acid set 4:

Amino acid set 4 is S3, Q182, E309, S310, and -318.

5 Amino acid set 5:

F13S, D15N, S18G, S18V, Y30F, D116N, D116E, D157 N, Y226F, D228N Y230F.

Amino acid set 6:

10

Amino acid set 6 is Ser3, Leu17, Lys22, Met23, Gly40, Asn80, Pro81, Lys82, Asn 87, Asn88, Trp111, Val112, Ala114, Tyr117, Leu118, Pro156, Gly159, Gln160, Asn161, Pro162, Ser163, Ala164, Arg165, Ser166, Gln167, Lys168, Val169, Val170, Glu171, Ala172, Tyr179, His180, Asn181, Gln182, Met209, Leu210, Arg211, Asn215,

15 Lys284, Met285, Gln289, Val290, Glu309, Ser310, -318.

The numbering of the amino acids in set 6 refers to the amino acids residues in P10480 (SEQ ID No. 2) – corresponding amino acids in other sequence backbones can be determined by homology alignment and/or structural alignment to P10480 and/or

20 HIVN.

Amino acid set 7:

Amino acid set 7 is Ser3, Leu17, Lys22, Met23, Gly40, Asn80, Pro81, Lys82, Asn 87, Asn88, Trp111, Val112, Ala114, Tyr117, Leu118, Pro156, Gly159, Gln160, Asn161, Pro162, Ser163, Ala164, Arg165, Ser166, Gln167, Lys168, Val169, Val170, Glu171, Ala172, Tyr179, His180, Asn181, Gln182, Met209, Leu210, Arg211, Asn215, Lys284, Met285, Gln289, Val290, Glu309, Ser310, -318, Y30X (where X is selected from A, C, D, E, G, H, I, K, L, M, N, P, Q, R, S, T, V, or W), Y226X (where X is selected from A, C, D, E, G, H, I, K, L, M, N, P, Q, R, S, T, V, or W), Y230X (where X is selected from A, C, D, E, G, H, I, K, L, M, N, P, Q, R, S, T, V, or W), S18X

(where X is selected from A, C, D, E, F, H, I, K, L, M, N, P, Q, R, T, W or Y), D157X
(where X is selected from A, C, E, F, G, H, I, K, L, M, P, Q, R, S, T, V, W or Y).

The numbering of the amino acids in set 7 refers to the amino acids residues in P10480
5 (SEQ ID No. 2) – corresponding amino acids in other sequence backbones can be
determined by homology alignment and/or structural alignment to P10480 and/or
11VN).

ISOLATED

10

In one aspect, preferably the polypeptide or protein for use in the present invention is
in an isolated form. The term “isolated” means that the sequence is at least
substantially free from at least one other component with which the sequence is
naturally associated in nature and as found in nature.

15

PURIFIED

In one aspect, preferably the polypeptide or protein for use in the present invention is
in a purified form. The term “purified” means that the sequence is in a relatively pure
20 state – e.g. at least about 51% pure, or at least about 75%, or at least about 80%, or at
least about 90% pure, or at least about 95% pure or at least about 98% pure.

CLONING A NUCLEOTIDE SEQUENCE ENCODING A POLYPEPTIDE ACCORDING TO THE PRESENT INVENTION

25

A nucleotide sequence encoding either a polypeptide which has the specific properties
as defined herein or a polypeptide which is suitable for modification may be isolated
from any cell or organism producing said polypeptide. Various methods are well
known within the art for the isolation of nucleotide sequences.

30

For example, a genomic DNA and/or cDNA library may be constructed using chromosomal DNA or messenger RNA from the organism producing the polypeptide. If the amino acid sequence of the polypeptide is known, labelled oligonucleotide probes may be synthesised and used to identify polypeptide-encoding clones from the genomic library prepared from the organism. Alternatively, a labelled oligonucleotide probe containing sequences homologous to another known polypeptide gene could be used to identify polypeptide-encoding clones. In the latter case, hybridisation and washing conditions of lower stringency are used.

Alternatively, polypeptide-encoding clones could be identified by inserting fragments of genomic DNA into an expression vector, such as a plasmid, transforming enzyme-negative bacteria with the resulting genomic DNA library, and then plating the transformed bacteria onto agar containing an enzyme inhibited by the polypeptide, thereby allowing clones expressing the polypeptide to be identified.

In a yet further alternative, the nucleotide sequence encoding the polypeptide may be prepared synthetically by established standard methods, e.g. the phosphoroamidite method described by Beucage S.L. *et al* (1981) Tetrahedron Letters 22, p 1859-1869, or the method described by Matthes *et al* (1984) EMBO J. 3, p 801-805. In the phosphoroamidite method, oligonucleotides are synthesised, e.g. in an automatic DNA synthesiser, purified, annealed, ligated and cloned in appropriate vectors.

The nucleotide sequence may be of mixed genomic and synthetic origin, mixed synthetic and cDNA origin, or mixed genomic and cDNA origin, prepared by ligating fragments of synthetic, genomic or cDNA origin (as appropriate) in accordance with standard techniques. Each ligated fragment corresponds to various parts of the entire nucleotide sequence. The DNA sequence may also be prepared by polymerase chain reaction (PCR) using specific primers, for instance as described in US 4,683,202 or in Saiki R K *et al* (Science (1988) 239, pp 487-491).

NUCLEOTIDE SEQUENCES

The present invention also encompasses nucleotide sequences encoding polypeptides having the specific properties as defined herein. The term "nucleotide sequence" as used
5 herein refers to an oligonucleotide sequence or polynucleotide sequence, and variant, homologues, fragments and derivatives thereof (such as portions thereof). The nucleotide sequence may be of genomic or synthetic or recombinant origin, which may be double-stranded or single-stranded whether representing the sense or antisense strand.

10 The term "nucleotide sequence" in relation to the present invention includes genomic DNA, cDNA, synthetic DNA, and RNA. Preferably it means DNA, more preferably cDNA for the coding sequence.

In a preferred embodiment, the nucleotide sequence *per se* encoding a polypeptide having
15 the specific properties as defined herein does not cover the native nucleotide sequence in its natural environment when it is linked to its naturally associated sequence(s) that is/are also in its/their natural environment. For ease of reference, we shall call this preferred embodiment the "non-native nucleotide sequence". In this regard, the term "native nucleotide sequence" means an entire nucleotide sequence that is in its native
20 environment and when operatively linked to an entire promoter with which it is naturally associated, which promoter is also in its native environment. Thus, the polypeptide of the present invention can be expressed by a nucleotide sequence in its native organism but wherein the nucleotide sequence is not under the control of the promoter with which it is naturally associated within that organism.

25

Preferably the polypeptide is not a native polypeptide. In this regard, the term "native polypeptide" means an entire polypeptide that is in its native environment and when it has been expressed by its native nucleotide sequence.

30 Typically, the nucleotide sequence encoding polypeptides having the specific properties as defined herein is prepared using recombinant DNA techniques (i.e. recombinant DNA). However, in an alternative embodiment of the invention, the

nucleotide sequence could be synthesised, in whole or in part, using chemical methods well known in the art (see Caruthers MH *et al* (1980) Nuc Acids Res Symp Ser 215-23 and Horn T *et al* (1980) Nuc Acids Res Symp Ser 225-232).

5 MOLECULAR EVOLUTION

Once an enzyme-encoding nucleotide sequence has been isolated, or a putative enzyme-encoding nucleotide sequence has been identified, it may be desirable to modify the selected nucleotide sequence, for example it may be desirable to mutate the
10 sequence in order to prepare an enzyme in accordance with the present invention.

Mutations may be introduced using synthetic oligonucleotides. These oligonucleotides contain nucleotide sequences flanking the desired mutation sites.

15 A suitable method is disclosed in Morinaga *et al* (Biotechnology (1984) 2, p646-649). Another method of introducing mutations into enzyme-encoding nucleotide sequences is described in Nelson and Long (Analytical Biochemistry (1989), 180, p 147-151).

Instead of site directed mutagenesis, such as described above, one can introduce
20 mutations randomly for instance using a commercial kit such as the GeneMorph PCR mutagenesis kit from Stratagene, or the Diversify PCR random mutagenesis kit from Clontech. EP 0 583 265 refers to methods of optimising PCR based mutagenesis, which can also be combined with the use of mutagenic DNA analogues such as those
25 described in EP 0 866 796. Error prone PCR technologies are suitable for the production of variants of lipid acyl transferases with preferred characteristics. WO0206457 refers to molecular evolution of lipases.

A third method to obtain novel sequences is to fragment non-identical nucleotide sequences, either by using any number of restriction enzymes or an enzyme such as
30 Dnase I, and reassembling full nucleotide sequences coding for functional proteins. Alternatively one can use one or multiple non-identical nucleotide sequences and introduce mutations during the reassembly of the full nucleotide sequence. DNA

shuffling and family shuffling technologies are suitable for the production of variants of lipid acyl transferases with preferred characteristics. Suitable methods for performing 'shuffling' can be found in EP0 752 008, EP1 138 763, EP1 103 606. Shuffling can also be combined with other forms of DNA mutagenesis as described in
5 US 6,180,406 and WO 01/34835.

Thus, it is possible to produce numerous site directed or random mutations into a nucleotide sequence, either *in vivo* or *in vitro*, and to subsequently screen for improved functionality of the encoded polypeptide by various means. Using *in silico* and *exo*
10 mediated recombination methods (see WO 00/58517, US 6,344,328, US 6,361,974), for example, molecular evolution can be performed where the variant produced retains very low homology to known enzymes or proteins. Such variants thereby obtained may have significant structural analogy to known transferase enzymes, but have very low amino acid sequence homology.

15

As a non-limiting example, in addition, mutations or natural variants of a polynucleotide sequence can be recombined with either the wild type or other mutations or natural variants to produce new variants. Such new variants can also be screened for improved functionality of the encoded polypeptide.

20

The application of the above-mentioned and similar molecular evolution methods allows the identification and selection of variants of the enzymes of the present invention which have preferred characteristics without any prior knowledge of protein structure or function, and allows the production of non-predictable but beneficial
25 mutations or variants. There are numerous examples of the application of molecular evolution in the art for the optimisation or alteration of enzyme activity, such examples include, but are not limited to one or more of the following: optimised expression and/or activity in a host cell or *in vitro*, increased enzymatic activity, altered substrate and/or product specificity, increased or decreased enzymatic or structural stability,
30 altered enzymatic activity/specificity in preferred environmental conditions, e.g. temperature, pH, and/or substrate.

As will be apparent to a person skilled in the art, using molecular evolution tools an enzyme may be altered to improve the functionality of the enzyme.

Suitably, the lipid acyltransferase used in the invention may be a variant, i.e. may
5 contain at least one amino acid substitution, deletion or addition, when compared to a parental enzyme. Variant enzymes retain at least 1%, 2%, 3%, 5%, 10%, 15%, 20%, 30%, 40%, 50 %, 60%, 70%, 80%, 90%, 95%, 97%, 99% homology with the parent enzyme. Suitable parent enzymes may include any enzyme with esterase or lipase activity. Preferably, the parent enzyme aligns to the pfam00657 consensus sequence.

10

In a preferable embodiment a variant lipid acyltransferase enzyme retains or incorporates at least one or more of the pfam00657 consensus sequence amino acid residues found in the GDSx, GANDY and HPT blocks.

15 Enzymes, such as lipases with no or low lipid acyltransferase activity in an aqueous environment may be mutated using molecular evolution tools to introduce or enhance the transferase activity, thereby producing a lipid acyltransferase enzyme with significant transferase activity suitable for use in the compositions and methods of the present invention.

20

Suitably, the lipid acyltransferase for use in the invention may be a variant with enhanced enzyme activity phospholipids when compared to the parent enzyme. Preferably, such variants also have low or no activity on lyso polar lipids. The enhanced activity on phospholipids may be the result of hydrolysis and/or transferase
25 activity or a combination of both.

Variant lipid acyltransferases for use in the invention may have decreased activity on triglycerides, and/or monoglycerides and/or diglycerides compared with the parent enzyme.

30

Suitably the variant enzyme may have no activity on triglycerides and/or monoglycerides and/or diglycerides.

Alternatively, the variant enzyme for use in the invention may have increased activity on triglycerides, and/or may also have increased activity on one or more of the following, polar lipids, phospholipids, lecithin, phosphatidylcholine.

5

Variants of lipid acyltransferases are known, and one or more of such variants may be suitable for use in the methods and uses according to the present invention and/or in the enzyme compositions according to the present invention. By way of example only, variants of lipid acyltransferases are described in the following references may be used in accordance with the present invention: Hilton & Buckley *J Biol. Chem.* 1991 Jan 15; 266 (2): 997-1000; Robertson *et al J. Biol. Chem.* 1994 Jan 21; 269(3):2146-50; Brumlik *et al J. Bacteriol* 1996 Apr; 178 (7): 2060-4; Peelman *et al Protein Sci.* 1998 Mar; 7(3):587-99.

15 AMINO ACID SEQUENCES

The present invention also encompasses amino acid sequences of polypeptides having the specific properties as defined herein.

20 As used herein, the term "amino acid sequence" is synonymous with the term "polypeptide" and/or the term "protein". In some instances, the term "amino acid sequence" is synonymous with the term "peptide".

The amino acid sequence may be prepared/isolated from a suitable source, or it may be made synthetically or it may be prepared by use of recombinant DNA techniques.

25

Suitably, the amino acid sequences may be obtained from the isolated polypeptides taught herein by standard techniques.

30 One suitable method for determining amino acid sequences from isolated polypeptides is as follows:

Purified polypeptide may be freeze-dried and 100 µg of the freeze-dried material may be dissolved in 50 µl of a mixture of 8 M urea and 0.4 M ammonium hydrogen carbonate, pH 8.4. The dissolved protein may be denatured and reduced for 15 minutes at 50°C following overlay with nitrogen and addition of 5 µl of 45 mM dithiothreitol.

5 After cooling to room temperature, 5 µl of 100 mM iodoacetamide may be added for the cysteine residues to be derivatized for 15 minutes at room temperature in the dark under nitrogen.

135 µl of water and 5 µg of endoproteinase Lys-C in 5 µl of water may be added to the

10 above reaction mixture and the digestion may be carried out at 37°C under nitrogen for 24 hours.

The resulting peptides may be separated by reverse phase HPLC on a VYDAC C18 column (0.46x15cm;10µm; The Separation Group, California, USA) using solvent A:

15 0.1% TFA in water and solvent B: 0.1% TFA in acetonitrile. Selected peptides may be re-chromatographed on a Develosil C18 column using the same solvent system, prior to N-terminal sequencing. Sequencing may be done using an Applied Biosystems 476A sequencer using pulsed liquid fast cycles according to the manufacturer's instructions (Applied Biosystems, California, USA).

20

SEQUENCE IDENTITY OR SEQUENCE HOMOLOGY

The present invention also encompasses the use of sequences having a degree of

25 sequence identity or sequence homology with amino acid sequence(s) of a polypeptide having the specific properties defined herein or of any nucleotide sequence encoding such a polypeptide (hereinafter referred to as a "homologous sequence(s)"). Here, the term "homologue" means an entity having a certain homology with the subject amino acid sequences and the subject nucleotide sequences. Here, the term "homology" can

30 be equated with "identity".

The homologous amino acid sequence and/or nucleotide sequence should provide and/or encode a polypeptide which retains the functional activity and/or enhances the activity of the enzyme.

5 In the present context, a homologous sequence is taken to include an amino acid sequence which may be at least 75, 85 or 90% identical, preferably at least 95 or 98% identical to the subject sequence. Typically, the homologues will comprise the same active sites etc. as the subject amino acid sequence. Although homology can also be considered in terms of similarity (i.e. amino acid residues having similar chemical
10 properties/functions), in the context of the present invention it is preferred to express homology in terms of sequence identity.

In the present context, a homologous sequence is taken to include a nucleotide sequence which may be at least 75, 85 or 90% identical, preferably at least 95 or 98%
15 identical to a nucleotide sequence encoding a polypeptide of the present invention (the subject sequence). Typically, the homologues will comprise the same sequences that code for the active sites etc. as the subject sequence. Although homology can also be considered in terms of similarity (i.e. amino acid residues having similar chemical properties/functions), in the context of the present invention it is preferred to express
20 homology in terms of sequence identity.

Homology comparisons can be conducted by eye, or more usually, with the aid of readily available sequence comparison programs. These commercially available computer programs can calculate % homology between two or more sequences.
25

% homology may be calculated over contiguous sequences, i.e. one sequence is aligned with the other sequence and each amino acid in one sequence is directly compared with the corresponding amino acid in the other sequence, one residue at a time. This is called an "ungapped" alignment. Typically, such ungapped alignments
30 are performed only over a relatively short number of residues.

Although this is a very simple and consistent method, it fails to take into consideration that, for example, in an otherwise identical pair of sequences, one insertion or deletion will cause the following amino acid residues to be put out of alignment, thus potentially resulting in a large reduction in % homology when a global alignment is performed. Consequently, most sequence comparison methods are designed to produce optimal alignments that take into consideration possible insertions and deletions without penalising unduly the overall homology score. This is achieved by inserting "gaps" in the sequence alignment to try to maximise local homology.

5

10 However, these more complex methods assign "gap penalties" to each gap that occurs in the alignment so that, for the same number of identical amino acids, a sequence alignment with as few gaps as possible - reflecting higher relatedness between the two compared sequences - will achieve a higher score than one with many gaps. "Affine gap costs" are typically used that charge a relatively high cost for the existence of a gap and a smaller penalty for each subsequent residue in the gap. This is the most commonly used gap scoring system. High gap penalties will of course produce optimised alignments with fewer gaps. Most alignment programs allow the gap penalties to be modified. However, it is preferred to use the default values when using such software for sequence comparisons. For example when using the GCG

15

20 Wisconsin Bestfit package the default gap penalty for amino acid sequences is -12 for a gap and -4 for each extension.

Calculation of maximum % homology therefore firstly requires the production of an optimal alignment, taking into consideration gap penalties. A suitable computer program for carrying out such an alignment is the GCG Wisconsin Bestfit package (Devereux *et al* 1984 Nuc. Acids Research 12 p387). Examples of other software that can perform sequence comparisons include, but are not limited to, the BLAST package (see Ausubel *et al* 1999 Short Protocols in Molecular Biology, 4th Ed - Chapter 18), FASTA (Altschul *et al* 1990 J. Mol. Biol. 403-410) and the GENWORKS suite of comparison tools. Both BLAST and FASTA are available for offline and online searching (see Ausubel *et al* 1999, pages 7-58 to 7-60). However, for some applications, it is preferred to use the GCG Bestfit program. A new tool, called

25

30

BLAST 2 Sequences is also available for comparing protein and nucleotide sequence (see FEMS Microbiol Lett 1999 174(2): 247-50; FEMS Microbiol Lett 1999 177(1): 187-8 and tatiana@ncbi.nlm.nih.gov).

5 Although the final % homology can be measured in terms of identity, the alignment process itself is typically not based on an all-or-nothing pair comparison. Instead, a scaled similarity score matrix is generally used that assigns scores to each pairwise comparison based on chemical similarity or evolutionary distance. An example of such a matrix commonly used is the BLOSUM62 matrix - the default matrix for the
10 BLAST suite of programs. GCG Wisconsin programs generally use either the public default values or a custom symbol comparison table if supplied (see user manual for further details). For some applications, it is preferred to use the public default values for the GCG package, or in the case of other software, the default matrix, such as BLOSUM62.

15

Alternatively, percentage homologies may be calculated using the multiple alignment feature in DNASIS™ (Hitachi Software), based on an algorithm, analogous to CLUSTAL (Higgins DG & Sharp PM (1988), *Gene* 73(1), 237-244).

20 Once the software has produced an optimal alignment, it is possible to calculate % homology, preferably % sequence identity. The software typically does this as part of the sequence comparison and generates a numerical result.

In a preferable aspect of the present invention the following software and settings for
25 calculating percentage homology/identity are used. For amino acid sequences percentage of identities (homology) or "positives" are calculated by the AlignX VectorNTI (Vector NTI Advance 9.1 from Invitrogen Corporation, Carlsbad, California, USA.), for each possible pair of amino acid sequences Settings are default parameters (Gap opening penalty - 10, Gap extension penalty 0.1).

30

The sequences may also have deletions, insertions or substitutions of amino acid residues which produce a silent change and result in a functionally equivalent

substance. Deliberate amino acid substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues as long as the secondary binding activity of the substance is retained. For example, negatively charged amino acids include aspartic acid and

5 glutamic acid; positively charged amino acids include lysine and arginine; and amino acids with uncharged polar head groups having similar hydrophilicity values include leucine, isoleucine, valine, glycine, alanine, asparagine, glutamine, serine, threonine, phenylalanine, and tyrosine.

- 10 Conservative substitutions may be made, for example according to the Table below. Amino acids in the same block in the second column and preferably in the same line in the third column may be substituted for each other:

ALIPHATIC	Non-polar	G A P
		I L V
	Polar – uncharged	C S T M
		N Q
	Polar – charged	D E
		K R
AROMATIC		H F W Y

15

The present invention also encompasses homologous substitution (substitution and replacement are both used herein to mean the interchange of an existing amino acid residue, with an alternative residue) that may occur i.e. like-for-like substitution such as basic for basic, acidic for acidic, polar for polar etc. Non-homologous substitution may also occur i.e. from one class of residue to another or alternatively involving the inclusion of unnatural amino acids such as ornithine (hereinafter referred to as Z), diaminobutyric acid ornithine (hereinafter referred to as B), norleucine ornithine (hereinafter referred to as O), pyrilylalanine, thienylalanine, naphthylalanine and phenylglycine.

20

Replacements may also be made by unnatural amino acids.

Variant amino acid sequences may include suitable spacer groups that may be inserted
5 between any two amino acid residues of the sequence including alkyl groups such as
methyl, ethyl or propyl groups in addition to amino acid spacers such as glycine or β -
alanine residues. A further form of variation, involves the presence of one or more
amino acid residues in peptoid form, will be well understood by those skilled in the art.
For the avoidance of doubt, "the peptoid form" is used to refer to variant amino acid
10 residues wherein the α -carbon substituent group is on the residue's nitrogen atom
rather than the α -carbon. Processes for preparing peptides in the peptoid form are
known in the art, for example Simon RJ et al., PNAS (1992) 89(20), 9367-9371 and
Horwell DC, Trends Biotechnol. (1995) 13(4), 132-134.

15 Nucleotide sequences for use in the present invention or encoding a polypeptide
having the specific properties defined herein may include within them synthetic or
modified nucleotides. A number of different types of modification to oligonucleotides
are known in the art. These include methylphosphonate and phosphorothioate
backbones and/or the addition of acridine or polylysine chains at the 3' and/or 5' ends
20 of the molecule. For the purposes of the present invention, it is to be understood that
the nucleotide sequences described herein may be modified by any method available in
the art. Such modifications may be carried out in order to enhance the *in vivo* activity
or life span of nucleotide sequences.

25 The present invention also encompasses the use of nucleotide sequences that are
complementary to the sequences discussed herein, or any derivative, fragment or
derivative thereof. If the sequence is complementary to a fragment thereof then that
sequence can be used as a probe to identify similar coding sequences in other
organisms etc.

30

Polynucleotides which are not 100% homologous to the sequences of the present
invention but fall within the scope of the invention can be obtained in a number of ways.

Other variants of the sequences described herein may be obtained for example by probing DNA libraries made from a range of individuals, for example individuals from different populations. In addition, other viral/bacterial, or cellular homologues particularly cellular homologues found in mammalian cells (e.g. rat, mouse, bovine and primate cells), may
5 be obtained and such homologues and fragments thereof in general will be capable of selectively hybridising to the sequences shown in the sequence listing herein. Such sequences may be obtained by probing cDNA libraries made from or genomic DNA libraries from other animal species, and probing such libraries with probes comprising all or part of any one of the sequences in the attached sequence listings under conditions of
10 medium to high stringency. Similar considerations apply to obtaining species homologues and allelic variants of the polypeptide or nucleotide sequences of the invention.

Variants and strain/species homologues may also be obtained using degenerate PCR
15 which will use primers designed to target sequences within the variants and homologues encoding conserved amino acid sequences within the sequences of the present invention. Conserved sequences can be predicted, for example, by aligning the amino acid sequences from several variants/homologues. Sequence alignments can be performed using computer software known in the art. For example the GCG Wisconsin PileUp
20 program is widely used.

The primers used in degenerate PCR will contain one or more degenerate positions and will be used at stringency conditions lower than those used for cloning sequences with single sequence primers against known sequences.

25 Alternatively, such polynucleotides may be obtained by site directed mutagenesis of characterised sequences. This may be useful where for example silent codon sequence changes are required to optimise codon preferences for a particular host cell in which the polynucleotide sequences are being expressed. Other sequence changes may be desired
30 in order to introduce restriction polypeptide recognition sites, or to alter the property or function of the polypeptides encoded by the polynucleotides.

Polynucleotides (nucleotide sequences) of the invention may be used to produce a primer, e.g. a PCR primer, a primer for an alternative amplification reaction, a probe e.g. labelled with a revealing label by conventional means using radioactive or non-radioactive labels, or the polynucleotides may be cloned into vectors. Such primers, probes and other
5 fragments will be at least 15, preferably at least 20, for example at least 25, 30 or 40 nucleotides in length, and are also encompassed by the term polynucleotides of the invention as used herein.

Polynucleotides such as DNA polynucleotides and probes according to the invention may
10 be produced recombinantly, synthetically, or by any means available to those of skill in the art. They may also be cloned by standard techniques.

In general, primers will be produced by synthetic means, involving a stepwise manufacture of the desired nucleic acid sequence one nucleotide at a time. Techniques
15 for accomplishing this using automated techniques are readily available in the art.

Longer polynucleotides will generally be produced using recombinant means, for example using a PCR (polymerase chain reaction) cloning techniques. This will involve making a pair of primers (e.g. of about 15 to 30 nucleotides) flanking a region of the lipid
20 targeting sequence which it is desired to clone, bringing the primers into contact with mRNA or cDNA obtained from an animal or human cell, performing a polymerase chain reaction under conditions which bring about amplification of the desired region, isolating the amplified fragment (e.g. by purifying the reaction mixture on an agarose gel) and recovering the amplified DNA. The primers may be designed to contain suitable
25 restriction enzyme recognition sites so that the amplified DNA can be cloned into a suitable cloning vector.

HYBRIDISATION

The present invention also encompasses sequences that are complementary to the
30 sequences of the present invention or sequences that are capable of hybridising either

to the sequences of the present invention or to sequences that are complementary thereto.

The term "hybridisation" as used herein shall include "the process by which a strand of
5 nucleic acid joins with a complementary strand through base pairing" as well as the process of amplification as carried out in polymerase chain reaction (PCR) technologies.

The present invention also encompasses the use of nucleotide sequences that are
10 capable of hybridising to the sequences that are complementary to the subject sequences discussed herein, or any derivative, fragment or derivative thereof.

The present invention also encompasses sequences that are complementary to
15 sequences that are capable of hybridising to the nucleotide sequences discussed herein.

Hybridisation conditions are based on the melting temperature (T_m) of the nucleotide
binding complex, as taught in Berger and Kimmel (1987, Guide to Molecular Cloning
Techniques, Methods in Enzymology, Vol. 152, Academic Press, San Diego CA), and
confer a defined "stringency" as explained below.

20 Maximum stringency typically occurs at about $T_m - 5^\circ\text{C}$ (5°C below the T_m of the probe); high stringency at about 5°C to 10°C below T_m ; intermediate stringency at about 10°C to 20°C below T_m ; and low stringency at about 20°C to 25°C below T_m .
As will be understood by those of skill in the art, a maximum stringency hybridisation
25 can be used to identify or detect identical nucleotide sequences while an intermediate (or low) stringency hybridisation can be used to identify or detect similar or related polynucleotide sequences.

Preferably, the present invention encompasses sequences that are complementary to
30 sequences that are capable of hybridising under high stringency conditions or intermediate stringency conditions to nucleotide sequences encoding polypeptides having the specific properties as defined herein.

More preferably, the present invention encompasses sequences that are complementary to sequences that are capable of hybridising under high stringent conditions (e.g. 65°C and 0.1xSSC {1xSSC = 0.15 M NaCl, 0.015 M Na-citrate pH 7.0}) to nucleotide
5 sequences encoding polypeptides having the specific properties as defined herein.

The present invention also relates to nucleotide sequences that can hybridise to the nucleotide sequences discussed herein (including complementary sequences of those discussed herein).

10

The present invention also relates to nucleotide sequences that are complementary to sequences that can hybridise to the nucleotide sequences discussed herein (including complementary sequences of those discussed herein).

15 Also included within the scope of the present invention are polynucleotide sequences that are capable of hybridising to the nucleotide sequences discussed herein under conditions of intermediate to maximal stringency.

In a preferred aspect, the present invention covers nucleotide sequences that can
20 hybridise to the nucleotide sequences discussed herein, or the complement thereof, under stringent conditions (e.g. 50°C and 0.2xSSC).

In a more preferred aspect, the present invention covers nucleotide sequences that can
25 hybridise to the nucleotide sequences discussed herein, or the complement thereof, under high stringent conditions (e.g. 65°C and 0.1xSSC).

EXPRESSION OF POLYPEPTIDES

A nucleotide sequence for use in the present invention or for encoding a polypeptide
30 having the specific properties as defined herein can be incorporated into a recombinant replicable vector. The vector may be used to replicate and express the nucleotide sequence, in polypeptide form, in and/or from a compatible host cell. Expression may

be controlled using control sequences which include promoters/enhancers and other expression regulation signals. Prokaryotic promoters and promoters functional in eukaryotic cells may be used. Tissue specific or stimuli specific promoters may be used. Chimeric promoters may also be used comprising sequence elements from two
5 or more different promoters described above.

The polypeptide produced by a host recombinant cell by expression of the nucleotide sequence may be secreted or may be contained intracellularly depending on the sequence and/or the vector used. The coding sequences can be designed with signal
10 sequences which direct secretion of the substance coding sequences through a particular prokaryotic or eukaryotic cell membrane.

EXPRESSION VECTOR

15 The term "expression vector" means a construct capable of *in vivo* or *in vitro* expression.

Preferably, the expression vector is incorporated in the genome of the organism. The term "incorporated" preferably covers stable incorporation into the genome.

20 The nucleotide sequence of the present invention or coding for a polypeptide having the specific properties as defined herein may be present in a vector, in which the nucleotide sequence is operably linked to regulatory sequences such that the regulatory sequences are capable of providing the expression of the nucleotide sequence by a suitable host organism, i.e. the vector is an expression vector.

25

The vectors of the present invention may be transformed into a suitable host cell as described below to provide for expression of a polypeptide having the specific properties as defined herein.

30 The choice of vector, e.g. plasmid, cosmid, virus or phage vector, will often depend on the host cell into which it is to be introduced.

The vectors may contain one or more selectable marker genes – such as a gene which confers antibiotic resistance e.g. ampicillin, kanamycin, chloramphenicol or tetracyclin resistance. Alternatively, the selection may be accomplished by co-transformation (as
5 described in WO91/17243).

Vectors may be used *in vitro*, for example for the production of RNA or used to transfect or transform a host cell.

10 Thus, in a further embodiment, the invention provides a method of making nucleotide sequences of the present invention or nucleotide sequences encoding polypeptides having the specific properties as defined herein by introducing a nucleotide sequence into a replicable vector, introducing the vector into a compatible host cell, and growing the host cell under conditions which bring about replication of the vector.

15 The vector may further comprise a nucleotide sequence enabling the vector to replicate in the host cell in question. Examples of such sequences are the origins of replication of plasmids pUC19, pACYC177, pUB110, pE194, pAMB1 and pIJ702.

20 REGULATORY SEQUENCES

In some applications, a nucleotide sequence for use in the present invention or a nucleotide sequence encoding a polypeptide having the specific properties as defined herein may be operably linked to a regulatory sequence which is capable of providing
25 for the expression of the nucleotide sequence, such as by the chosen host cell. By way of example, the present invention covers a vector comprising the nucleotide sequence of the present invention operably linked to such a regulatory sequence, i.e. the vector is an expression vector.

30 The term "operably linked" refers to a juxtaposition wherein the components described are in a relationship permitting them to function in their intended manner. A regulatory sequence "operably linked" to a coding sequence is ligated in such a way

that expression of the coding sequence is achieved under conditions compatible with the control sequences.

The term "regulatory sequences" includes promoters and enhancers and other
5 expression regulation signals.

The term "promoter" is used in the normal sense of the art, e.g. an RNA polymerase binding site.

10 Enhanced expression of the nucleotide sequence encoding the enzyme having the specific properties as defined herein may also be achieved by the selection of heterologous regulatory regions, e.g. promoter, secretion leader and terminator regions.

15 Preferably, the nucleotide sequence of the present invention may be operably linked to at least a promoter.

Examples of suitable promoters for directing the transcription of the nucleotide sequence in a bacterial, fungal or yeast host are well known in the art.

20 CONSTRUCTS

The term "construct" - which is synonymous with terms such as "conjugate", "cassette" and "hybrid" - includes a nucleotide sequence encoding a polypeptide having the specific properties as defined herein for use according to the present invention directly or
25 indirectly attached to a promoter. An example of an indirect attachment is the provision of a suitable spacer group such as an intron sequence, such as the Sh1-intron or the ADH intron, intermediate the promoter and the nucleotide sequence of the present invention. The same is true for the term "fused" in relation to the present invention which includes direct or indirect attachment. In some cases, the terms do not cover the natural
30 combination of the nucleotide sequence coding for the protein ordinarily associated with the wild type gene promoter and when they are both in their natural environment.

The construct may even contain or express a marker which allows for the selection of the genetic construct.

- 5 For some applications, preferably the construct comprises at least a nucleotide sequence of the present invention or a nucleotide sequence encoding a polypeptide having the specific properties as defined herein operably linked to a promoter.

HOST CELLS

10

The term "host cell" - in relation to the present invention includes any cell that comprises either a nucleotide sequence encoding a polypeptide having the specific properties as defined herein or an expression vector as described above and which is used in the recombinant production of a polypeptide having the specific properties as

15 defined herein.

Thus, a further embodiment of the present invention provides host cells transformed or transfected with a nucleotide sequence of the present invention or a nucleotide sequence that expresses a polypeptide having the specific properties as defined herein.

- 20 The cells will be chosen to be compatible with the said vector and may for example be prokaryotic (for example bacterial), fungal, yeast or plant cells. Preferably, the host cells are not human cells.

Examples of suitable bacterial host organisms are gram negative bacterium or gram

25 positive bacteria.

Depending on the nature of the nucleotide sequence encoding a polypeptide having the specific properties as defined herein, and/or the desirability for further processing of the expressed protein, eukaryotic hosts such as yeasts or other fungi may be preferred.

- 30 In general, yeast cells are preferred over fungal cells because they are easier to manipulate. However, some proteins are either poorly secreted from the yeast cell, or

in some cases are not processed properly (e.g. hyperglycosylation in yeast). In these instances, a different fungal host organism should be selected.

5 The use of suitable host cells, such as yeast, fungal and plant host cells – may provide for post-translational modifications (e.g. myristoylation, glycosylation, truncation, lipidation and tyrosine, serine or threonine phosphorylation) as may be needed to confer optimal biological activity on recombinant expression products of the present invention.

10 The host cell may be a protease deficient or protease minus strain.

ORGANISM

15 The term "organism" in relation to the present invention includes any organism that could comprise a nucleotide sequence according to the present invention or a nucleotide sequence encoding for a polypeptide having the specific properties as defined herein and/or products obtained therefrom.

Suitable organisms may include a prokaryote, fungus, yeast or a plant.

20

The term "transgenic organism" in relation to the present invention includes any organism that comprises a nucleotide sequence coding for a polypeptide having the specific properties as defined herein and/or the products obtained therefrom, and/or wherein a promoter can allow expression of the nucleotide sequence coding for a polypeptide having the specific properties as defined herein within the organism. Preferably the nucleotide sequence is incorporated in the genome of the organism.

25

The term "transgenic organism" does not cover native nucleotide coding sequences in their natural environment when they are under the control of their native promoter which is also in its natural environment.

30

Therefore, the transgenic organism of the present invention includes an organism comprising any one of, or combinations of, a nucleotide sequence coding for a polypeptide having the specific properties as defined herein, constructs as defined herein, vectors as defined herein, plasmids as defined herein, cells as defined herein, or the products thereof. For example the transgenic organism can also comprise a nucleotide sequence coding for a polypeptide having the specific properties as defined herein under the control of a heterologous promoter.

TRANSFORMATION OF HOST CELLS/ORGANISM

10

As indicated earlier, the host organism can be a prokaryotic or a eukaryotic organism. Examples of suitable prokaryotic hosts include *E. coli* and *Bacillus subtilis*.

15

In one embodiment the host cell is a bacteria, preferably a gram-positive bacteria, preferably a host cell selected from *Actinobacteria*, such as *Biofidobacteria* and *Aeromonas*, particularly preferably *Aeromonas salmonicida*. Still more preferred are Actinomycetales such as *Corynebacteria*, in particular *Corynebacterium glutamicum* and *Nocardia*. Particularly preferred are *Streptomycetaceae*, such as *Streptomyces*, especially *S. lividans*.

20

A microbial host can be used for expression of the galactolipase gene, e.g. *Eubacteria*, *Archea* or *Fungi*, including yeast. Preferred are *Eubacteria*, for example, *Firmicutes* (low GC-Gram positive bacteria), such as *Bacillus subtilis* and other *bacillus* species, lactic acid bacteria such as species of genera *Lactobacillus* and *Lactococcus*.

25

Also preferred are Gram-negative *Proteobacteria*, in particular *Gammaproteobacteria*, such as host species belonging to the genera *Pseudomonas*, *Xanthomonas*, *Citrobacter* and *Escherichia*, especially *Escherichia coli*.

30

Preferably the host species is a Gram positive expression host such as *Aeromonas salmonicida*, *Streptomyces lividans* or *Corynebacterium glutamicum* as detailed in GB application number 0513859.9

In another embodiment the host cell is the same genus as the native host species, i.e. the recombinant gene is re-introduced and expressed in a species from the same genus as the species from which the recombinant gene was isolated.

5

In another embodiment the host cell is the native host species, i.e. the recombinant gene is re-introduced and expressed in the same species from which the recombinant gene was isolated.

10

Teachings on the transformation of prokaryotic hosts is well documented in the art, for example see Sambrook *et al* (Molecular Cloning: A Laboratory Manual, 2nd edition, 1989, Cold Spring Harbor Laboratory Press). If a prokaryotic host is used then the nucleotide sequence may need to be suitably modified before transformation - such as

15

by removal of introns.

In another embodiment the transgenic organism can be a yeast.

20

Filamentous fungi cells may be transformed using various methods known in the art - such as a process involving protoplast formation and transformation of the protoplasts followed by regeneration of the cell wall in a manner known. The use of *Aspergillus* as a host microorganism is described in EP 0 238 023.

25

Another host organism can be a plant. A review of the general techniques used for transforming plants may be found in articles by Potrykus (*Annu Rev Plant Physiol Plant Mol Biol* [1991] 42:205-225) and Christou (Agro-Food-Industry Hi-Tech March/April 1994 17-27). Further teachings on plant transformation may be found in EP-A-0449375.

30

General teachings on the transformation of fungi, yeasts and plants are presented in following sections.

TRANSFORMED FUNGUS

A host organism may be a fungus - such as a filamentous fungus. Examples of suitable such hosts include any member belonging to the genera *Thermomyces*, *Acremonium*,
5 *Aspergillus*, *Penicillium*, *Mucor*, *Neurospora*, *Trichoderma* and the like.

Teachings on transforming filamentous fungi are reviewed in US-A-5741665 which states that standard techniques for transformation of filamentous fungi and culturing the fungi are well known in the art. An extensive review of techniques as applied to *N.*
10 *crassa* is found, for example in Davis and de Serres, *Methods Enzymol* (1971) 17A: 79-143.

Further teachings on transforming filamentous fungi are reviewed in US-A-5674707.

15 In one aspect, the host organism can be of the genus *Aspergillus*, such as *Aspergillus niger*.

A transgenic *Aspergillus* according to the present invention can also be prepared by following, for example, the teachings of Turner G. 1994 (Vectors for genetic
20 manipulation. In: Martinelli S.D., Kinghorn J.R. (Editors) *Aspergillus: 50 years on*. Progress in industrial microbiology vol 29. Elsevier Amsterdam 1994. pp. 641-666).

Gene expression in filamentous fungi has been reviewed in Punt *et al.* (2002) *Trends Biotechnol* 2002 May;20(5):200-6, Archer & Peberdy *Crit Rev Biotechnol* (1997)
25 17(4):273-306.

TRANSFORMED YEAST

30 In another embodiment, the transgenic organism can be a yeast.

A review of the principles of heterologous gene expression in yeast are provided in, for example, *Methods Mol Biol* (1995), 49:341-54, and *Curr Opin Biotechnol* (1997) Oct;8(5):554-60

- 5 In this regard, yeast -- such as the species *Saccharomyces cerevisi* or *Pichia pastoris* (see FEMS Microbiol Rev (2000 24(1):45-66), may be used as a vehicle for heterologous gene expression.

10 A review of the principles of heterologous gene expression in *Saccharomyces cerevisiae* and secretion of gene products is given by E Hinchcliffe E Kenny (1993, "Yeast as a vehicle for the expression of heterologous genes", *Yeasts*, Vol 5, Anthony H Rose and J Stuart Harrison, eds, 2nd edition, Academic Press Ltd.).

15 For the transformation of yeast, several transformation protocols have been developed. For example, a transgenic *Saccharomyces* according to the present invention can be prepared by following the teachings of Hinnen *et al.*, (1978, *Proceedings of the National Academy of Sciences of the USA* 75, 1929); Beggs, J D (1978, *Nature*, London, 275, 104); and Ito, H *et al* (1983, *J Bacteriology* 153, 163-168).

20 The transformed yeast cells may be selected using various selective markers -- such as auxotrophic markers dominant antibiotic resistance markers.

25 A suitable yeast host organism can be selected from the biotechnologically relevant yeasts species such as, but not limited to, yeast species selected from *Pichia* spp., *Hansenula* spp., *Kluyveromyces*, *Yarrowinia* spp., *Saccharomyces* spp., including *S. cerevisiae*, or *Schizosaccharomyce* spp. including *Schizosaccharomyce pombe*.

A strain of the methylotrophic yeast species *Pichia pastoris* may be used as the host organism.

30

In one embodiment, the host organism may be a *Hansenula* species, such as *H. polymorpha* (as described in WO01/39544).

TRANSFORMED PLANTS/PLANT CELLS

A host organism suitable for the present invention may be a plant. A review of the
5 general techniques may be found in articles by Potrykus (*Annu Rev Plant Physiol Plant
Mol Biol* [1991] 42:205-225) and Christou (*Agro-Food-Industry Hi-Tech* March/April
1994 17-27), or in WO01/16308.

SECRETION

10

Often, it is desirable for the polypeptide to be secreted from the expression host into
the culture medium from where the enzyme may be more easily recovered. According
to the present invention, the secretion leader sequence may be selected on the basis of
the desired expression host. Hybrid signal sequences may also be used with the
15 context of the present invention.

Typical examples of heterologous secretion leader sequences are those originating
from the fungal amyloglucosidase (AG) gene (*glaA* - both 18 and 24 amino acid
versions e.g. from *Aspergillus*), the a-factor gene (yeasts e.g. *Saccharomyces*,
20 *Khyveromyces* and *Hansenula*) or the α -amylase gene (*Bacillus*).

DETECTION

A variety of protocols for detecting and measuring the expression of the amino acid
25 sequence are known in the art. Examples include enzyme-linked immunosorbent
assay (ELISA), radioimmunoassay (RIA) and fluorescent activated cell sorting
(FACS).

A wide variety of labels and conjugation techniques are known by those skilled in the
30 art and can be used in various nucleic and amino acid assays.

A number of companies such as Pharmacia Biotech (Piscataway, NJ), Promega (Madison, WI), and US Biochemical Corp (Cleveland, OH) supply commercial kits and protocols for these procedures.

5 Suitable reporter molecules or labels include those radionuclides, enzymes, fluorescent, chemiluminescent, or chromogenic agents as well as substrates, cofactors, inhibitors, magnetic particles and the like. Patents teaching the use of such labels include US-A-3,817,837; US-A-3,850,752; US-A-3,939,350; US-A-3,996,345; US-A-4,277,437; US-A-4,275,149 and US-A-4,366,241.

10

Also, recombinant immunoglobulins may be produced as shown in US-A-4,816,567.

FUSION PROTEINS

15

A polypeptide having the specific properties as defined herein may be produced as a fusion protein, for example to aid in extraction and purification thereof. Examples of fusion protein partners include glutathione-S-transferase (GST), 6xHis, GAL4 (DNA binding and/or transcriptional activation domains) and β -galactosidase. It may also be convenient to include a proteolytic cleavage site between the fusion protein partner and the protein sequence of interest to allow removal of fusion protein sequences. Preferably the fusion protein will not hinder the activity of the protein sequence.

20

Gene fusion expression systems in *E. coli* have been reviewed in Curr. Opin. Biotechnol. (1995) 6(5):501-6.

25

In another embodiment of the invention, the amino acid sequence of a polypeptide having the specific properties as defined herein may be ligated to a heterologous sequence to encode a fusion protein. For example, for screening of peptide libraries for agents capable of affecting the substance activity, it may be useful to encode a chimeric substance expressing a heterologous epitope that is recognised by a commercially available antibody.

30

The invention will now be described, by way of example only, with reference to the following figures and examples.

- 5 Figure 1 shows the profile of the lipid acyltransferase activity (PNP-caprylate assay) obtained after anion exchange chromatography (IEC);

Figure 2 shows the results of SDS-PAGE analyses of purified the lipid acyltransferase fractions (4-12% Mes, +DTT, 40/10 μ l sample was applied to the gel):

- 10 Lane 1. Lipid acyltransferase sample after desalting, 40 μ l was applied to the gel
Lane 2. Lipid acyltransferase sample after desalting, 10 μ l was applied to the gel
Lane 3. Purified Lipid acyltransferase lipase after IEC (pool 27-39), 40 μ l was applied to the gel
Lane 4. Purified Lipid acyltransferase lipase after IEC (pool 27-39, 10 μ l was applied
15 to the gel;

Figure 3 shows a TLC (Solvent 4) of reaction products from the lipid acyltransferase treatment of soya bean oil samples according to Table 2. As a reference phosphatidylcholine (PC) was also analysed;

20

Figure 4 shows a TLC (Solvent 1) of reaction products from the lipid acyltransferase treatment of soya bean oil samples according to Table 2. As reference free fatty acid (FFA) and Mono-di-triglyceride (TRI/DI/MONO) were also analysed;

- 25 Figure 5 shows a TLC (Solvent 5) of reaction products from the lipid acyltransferase treatment of soya bean oil samples according to Table 2. As reference Cholesterol (CHL) and Cholesterol ester (CHL-ester) were also analysed;

- 30 Figure 6 shows a TLC (Solvent 4) of reaction products from the lipid acyltransferase or Lecitase Ultra™ treatment of soya bean oil samples according to Table 3 for 20 hours;

Figure 7 shows a TLC (Solvent 5) of reaction products from the lipid acyltransferase or Lecitase Ultra™ treatment of soya bean oil samples according to Table 3 for 20 hours. Cholesterol ester (CHL ester); Mono-di-Triglyceride(MONO/DI/TRI) and
5 plant sterol were also analysed as references. Identification of free fatty acid (FFA) is also indicated;

Figure 8 shows a TLC (Solvent 4) of reaction products from the lipid acyltransferase or Lecitase Ultra™ treatment of soya bean oil samples according to Table 3 for 4
10 hours;

Figure 9 shows a TLC (Solvent 5) of reaction products from the lipid acyltransferase or Lecitase Ultra™ treatment of soya bean oil samples according to Table 3 for 4 hours. Cholesterol ester (CHL ester); Mono-di-Triglyceride (MONO/DI/TRI) and
15 plant sterol were also analysed as references. Identification of free fatty acid (FFA) is also indicated;

Figure 10 shows the amino acid sequence of a mutant *Aeromonas salmonicida* mature lipid acyltransferase (GCAT) with a mutation of Asn80Asp (notably, amino acid 80 is
20 in the mature sequence);

Figure 11 shows an amino acid sequence (SEQ ID No. 1) a lipid acyl transferase from *Aeromonas hydrophila* (ATCC #7965);

25 Figure 12 shows a pfam00657 consensus sequence from database version 6 (SEQ ID No. 2);

Figure 13 shows an amino acid sequence (SEQ ID No. 3) obtained from the organism *Aeromonas hydrophila* (P10480; GI:121051);
30

Figure 14 shows an amino acid sequence (SEQ ID No. 4) obtained from the organism *Aeromonas salmonicida* (AAG098404; GI:9964017);

Figure 15 shows an amino acid sequence (SEQ ID No. 5) obtained from the organism *Streptomyces coelicolor* A3(2) (Genbank accession number NP_631558);

- 5 Figure 16 shows an amino acid sequence (SEQ ID No. 6) obtained from the organism *Streptomyces coelicolor* A3(2) (Genbank accession number: CAC42140);

Figure 17 shows an amino acid sequence (SEQ ID No. 7) obtained from the organism *Saccharomyces cerevisiae* (Genbank accession number P41734);

10

Figure 18 shows an amino acid sequence (SEQ ID No. 8) obtained from the organism *Ralstonia* (Genbank accession number: AL646052);

- Figure 19 shows SEQ ID No. 9. Scoe1 NCBI protein accession code CAB39707.1
15 GI:4539178 conserved hypothetical protein [*Streptomyces coelicolor* A3(2)];

Figure 20 shows an amino acid shown as SEQ ID No. 10. Scoe2 NCBI protein
accession code CAC01477.1 GI:9716139 conserved hypothetical protein
[*Streptomyces coelicolor* A3(2)];

20

Figure 21 shows an amino acid sequence (SEQ ID No. 11) Scoe3 NCBI protein
accession code CAB88833.1 GI:7635996 putative secreted protein. [*Streptomyces*
coelicolor A3(2)];

- 25 Figure 22 shows an amino acid sequence (SEQ ID No. 12) Scoe4 NCBI protein
accession code CAB89450.1 GI:7672261 putative secreted protein. [*Streptomyces*
coelicolor A3(2)];

Figure 23 shows an amino acid sequence (SEQ ID No. 13) Scoe5 NCBI protein
30 accession code CAB62724.1 GI:6562793 putative lipoprotein [*Streptomyces*
coelicolor A3(2)];

Figure 24 shows an amino acid sequence (SEQ ID No. 14) Srim1 NCBI protein accession code AAK84028.1 GI:15082088 GDSL-lipase [*Streptomyces rimosus*];

5 Figure 25 shows an amino acid sequence (SEQ ID No. 15) of a lipid acyltransferase from *Aeromonas salmonicida* subsp. *Salmonicida* (ATCC#14174);

Figure 26 shows a TLC (solvent 4) of sample 1 to 10 of crude soya oil treated 20 hours with enzymes according to Table 4. PC is phosphatidylcholine added in 5 different concentrations (reference material).

10

Figure 27 shows a TLC (Solvent 5) of reaction products from lipid acyl transferase or Lecitase Ultra™ treatment of crude soya oil samples according to Table 4 (20 hours). Cholesterol ester (CHL-ester), Mono-di-Triglyceride (MONO/DI/TRI), and plant sterol were also analysed as references. Identification of free fatty acid is also

15 indicated.

Figure 28 shows SEQ ID No 17 which is the amino acid sequence of a lipid acyltransferase from *Candida parapsilosis*;

20 Figure 29 shows SEQ ID No 18 which is the amino acid sequence of a lipid acyltransferase from *Candida parapsilosis*;

Figure 30 shows alignment 1;

25 Figure 31 shows SEQ ID No. 19. Scoe1 NCBI protein accession code CAB39707.1 GI:4539178 conserved hypothetical protein [*Streptomyces coelicolor* A3(2)];

30 Figure 32 shows an amino acid sequence (SEQ ID No. 25) of the fusion construct used for mutagenesis of the *Aeromonas hydrophila* lipid acyltransferase gene.. The underlined amino acids is a xylanase signal peptide;

Figure 33 shows a polypeptide sequence of a lipid acyltransferase enzyme from *Streptomyces* (SEQ ID No. 26);

Figure 34 shows a polypeptide sequence of a lipid acyltransferase enzyme from
5 *Thermobifida* (SEQ ID No. 27);

Figure 35 shows a polypeptide sequence of a lipid acyltransferase enzyme from *Thermobifida* (SEQ ID No. 28);

10 Figure 36 shows a polypeptide of a lipid acyltransferase enzyme from *Corynebacterium efficiens* GDSx 300 amino acid (SEQ ID No. 29);

Figure 37 shows a polypeptide of a lipid acyltransferase enzyme from *Novosphingobium aromaticivorans* GDSx 284 amino acid (SEQ ID No. 30);

15

Figure 38 shows a polypeptide of a lipid acyltransferase enzyme from *Streptomyces coelicolor* GDSx 269 aa (SEQ ID No. 31)

Figure 39 shows a polypeptide of a lipid acyltransferase enzyme from *Streptomyces avermitilis* \ GDSx 269 amino acid (SEQ ID No. 32);
20

Figure 40 shows a polypeptide of a lipid acyltransferase enzyme from *Streptomyces* (SEQ ID No. 33);

25 Figure 41 shows a ribbon representation of the 1IVN.PDB crystal structure which has glycerol in the active site. The Figure was made using the Deep View Swiss-PDB viewer;

Figure 42 shows 1IVN.PDB Crystal Structure – Side View using Deep View Swiss-
30 PDB viewer, with glycerol in active site - residues within 10Å of active site glycerol are coloured black;

Figure 43 shows alignment 2;

Figure 44 shows an amino acid sequence (SEQ ID No. 34) obtained from the organism *Aeromonas hydrophila* (P10480; GI:121051) (notably, this is the mature sequence).

5

Figure 45 shows the amino acid sequence (SEQ ID No. 35) of a mutant *Aeromonas salmonicida* mature lipid acyltransferase (GCAT) (notably, this is the mature sequence)

10 Figure 46 shows a nucleotide sequence (SEQ ID No. 36) from *Streptomyces thermosacchari*

Figure 47 shows an amino acid sequence (SEQ ID No. 37) from *Streptomyces thermosacchari*

15

Figure 48 shows an amino acid sequence (SEQ ID No. 38) from *Thermobifida fusca*/GDSx 548 amino acid

Figure 49 shows a nucleotide sequence (SEQ ID No. 39) from *Thermobifida fusca*

20 Figure 50 shows an amino acid sequence (SEQ ID No. 40) from *Thermobifida fusca*/GDSx

Figure 51 shows an amino acid sequence (SEQ ID No. 41) from *Corynebacterium efficiens*/GDSx 300 amino acid

25

Figure 52 shows a nucleotide sequence (SEQ ID No. 42) from *Corynebacterium efficiens*

30 Figure 53 shows an amino acid sequence (SEQ ID No. 43) from *S. coelicolor*/ GDSx 268 amino acid

Figure 54 shows a nucleotide sequence (SEQ ID No. 44) from *S. coelicolor*

Figure 55 shows an amino acid sequence (SEQ ID No. 45) from *S. avermitilis*

5 Figure 56 shows a nucleotide sequence (SEQ ID No. 46) from *S. avermitilis*

Figure 57 shows an amino acid sequence (SEQ ID No. 47) from *Thermobifida fusca/GDSx*

10 Figure 58 shows a nucleotide sequence (SEQ ID No. 48) from *Thermobifida fusca/GDSx*

Fig 59 shows TLC (Solvent 4) of reaction products from enzyme treatment of crude soya oil samples according to table 6. As reference, phosphatidylcholine (PC) was also
15 analysed. PE (phosphatidylethanolamine(PE) and lysophosphatidylcholine (LPC) are also indicated.

Fig 60 shows TLC (Solvent 5) of reaction products from enzyme treatment of crude soya oil samples according to table 6. References Cholesterol ester, mono-di-
20 triglyceride and plant sterol. Free fatty acid (FFA) is also indicated

Figure 61 shows an alignment of the L131 and homologues from *S. avermitilis* and *T. fusca* illustrates that the conservation of the GDSx motif (GDSY in L131 and *S. avermitilis* and *T. fusca*), the GANDY box, which is either GGND A or GGND L, and
25 the HPT block (considered to be the conserved catalytic histadine). These three conserved blocks are highlighted

EXAMPLES

30

The purpose of this study was to investigate the possible use of a lipid acyltransferase (sometimes referred to herein as a glycerophospholipid Cholesterol Acyl-Transferase

(GCAT)) for degumming of vegetable oil like soya bean oil, sunflower oil and rape seed oil.

- One purpose of this study was to investigate whether in particular a lipid acyltransferase mutant (N80D) is a more suitable enzyme for degumming. From earlier studies it is known that lipid acyltransferases (particularly GCATs) catalyse the acyl-transfer of fatty acid from phospholipid to sterols to form lysolecithin and sterol esters.
- 10 The present study was conducted in a model based on refined soya bean oil where phosphatidylcholine and plant sterols were added. This model was selected because it is easier to analyse reaction product in a model system, instead of using crude soya oil.

- Enzymatic degumming processes of plant oils including soya oil and rape seed oil is expanding in recent years because this process is a cheaper and better process to remove lecithins from oil. The enzyme used for oil degumming is a phospholipase A1 (Lecitase Ultra™ or pancreatic phospholipase A2 - Novozymes A/S, Denmark).
- 15

- One advantage of the enzyme of the present invention when used in degumming compared with prior art phospholipase A1 is that the enzyme according to the present invention facilitates the formation of sterol esters during the degumming process and contributes to the accumulation of sterol esters, which is not achieved with the currently used phospholipase A1 (Lecitase Ultra™).
- 20

- 25 **Materials and methods.**

Enzymes

- Lipid acyltransferase according to the present invention: *Aeromonas salmonicidae* enzyme with a mutation Asn80Asp (amino acid 80 of the mature enzyme) (SEQ ID No. 16 (see Figure 10));
 - Lecitase Ultra (#3108) from Novozymes, Denmark
- 30

Soya bean oil: Soya olie IP (Item No. 005018/ batch nr T -618-4)

Lecithin: L- α Phosphatidylcholine 95% Plant (Avanti #441601)

Plant Sterol: Generol 122 N from Henkel, Germany.

Tocopherol: Alpha-tocopherol (Item no. .050908/lot.nr 4010140554)

5

Phospholipase activity

Substrate

0.6% L- α Phosphatidylcholine 95% Plant (Avanti #441601), 0.4% Triton-X 100 (Sigma X-100) and 5 mM CaCl₂ was dissolved in 0.05M HEPES buffer pH 7.

10 Assay procedure:

400 μ l substrate was added to an 1.5 ml Eppendorf tube and placed in an Eppendorf Thermomixer at 37°C for 5 minutes. At time T= 0 min, 50 μ l enzyme solution was added. Also a blank with water instead of enzyme was analyzed. The sample was mixed at 10*100 rpm in an Eppendorf Thermomixer at 37°C for 10 minutes. At time

15 T=10 min the Eppendorf tube was placed in another thermomixer at 99°C for 10 minutes to stop the reaction.

Free fatty acid in the samples was analyzed by using the NEFA C kit from WAKO GmbH.

20 Enzyme activity PLU-NEFA pH 7 was calculated as micromole fatty acid produced per minute under assay conditions.

HPTLC

Applicator: Automatic TLC Sampler 4, CAMAG

HPTLC plate: 20 x 10 cm, Merck no. 1.05641. Activated 30 min. at 160°C before use.

25 Application: 1 μ l of a 8% solution of oil in buffer is applied to the HPTLC plate using Automatic TLC applicator.

Running buffer 1: P-ether : Methyl-tert-butyl-ether : Acetic acid 60:40:1

Running buffer 4: Chloroform:Methanol:Water 75:25:4

Running buffer 5: P-ether : Methyl-tert-butylether : Acetic acid 70:30:1

30

Application/Elution time: Running buffer 1: 12 min

Running buffer 4: 20 min

Running buffer 5: 10 min

Developing

The plate is dried in an oven at 160°C for 10 minutes, cooled, and dipped into 6% cupri acetate in 16% H₃PO₄. Dried additionally 10 minutes at 160°C and evaluated directly.

EXAMPLE 1: Enzyme purification

10 Sample: The sample lipid acyltransferase (Asn80Asp) (SEQ ID No. 16) was filtered through 0.8/0.22 µm filter. 510 ml filtrate was collected.

Step 1. Desalting, Sephadex 25 G, 3.2 l gel (10 cm id)

The Sephadex column was prepared as described by the manufacturer (Amersham biosciences). The column was equilibrated with 20 mM Na-P-buffer, pH 8.0. The sample (510 ml) was applied to the column at a flow rate of 25 ml/min. 815 ml desalted sample was collected and kept at +4°C.

Step 2. Anion exchange chromatography, Q-Sepharose FF 300 ml gel (XK 50)

20 Q-Sepharose FF column was prepared as described by the manufacturer (Amersham biosciences). The column was equilibrated with 20 mM Na-P-buffer, pH 8.0. The desalted sample was applied to the column at a flow rate of 15 ml/min. The column was then washed with buffer A. The lipase was eluted with a linear gradient of 0-0.4 M NaCl in 20 mM Na-P-buffer (pH 8.0, buffer B). Fractions of 15 ml were collected during the entire run. The lipase was eluted at approx. 0.2 M NaCl, and no lipase activity was detected in running through fractions.

Enzyme Assay based on PNP-caprylate

The assay was performed using PNP-Caprylate as substrate as follows:

30 10 mg of substrate solved in 1 ml ethanol and was mixed with 9 ml of 50 mM Tris-HCL buffer (pH 7.3) containing 0.4% TX100.

240 µl of substrate was pre-incubated at 35 degree C. The reaction was initiated by the addition of 25 µl of sample/blank. The mixture was incubated at 35°C for 5 min with shaking. Using a spectrophotometer, the formation of PNP was measured continually at 410 nm. The blank run contains all the components with buffer instead of sample.

- 5 One unit of lipase activity was defined as the amount of enzyme releasing 1 µl of free caprylic acid per minute at 35°C.

Determination of molecule weight and purity.

- 10 SDS-PAGE was carried out on a 4-12% Nu-PAGE gel (+DTT) and Coomassie stained according to the manufacturers instructions (Novex, USA). The standard marker was See Blue Plus2 and was obtained from Novex, USA.

Results

- 15 The chromatogram from Ion Exchange Chromatography (IEC) purification of the lipid acyltransferase mutant N80D is shown in Fig.1. The fractions collected were analyzed for lipase activity (based on PNP-Caprylate assay). The activity of the fractions is illustrated in Fig 1-a.

- 20 The fractions containing lipid acyltransferase activity (27-39, 195 ml) were pooled. The final recovery of the partly purified lipid acyltransferase was approx. 80% (based on pNP-Caprylate assay).

- 25 Fractions of the purified lipid acyltransferase were subjected to SDS-PAGE gel electrophoresis.

- The SDS-PAGE gel revealed lipid acyltransferase protein with a molecular weight of approx. 28 KDa. The partly purified lipid acyltransferase contained a minor impurity
30 at approx 10 KDa (see Figure 2).

The lipid acyltransferase pool 27-39 after IEC was analysed for phospholipase activity with the result of 20.4 PLU-7/ml.

The overall purification scheme is presented in Table 1, in which the lipid
5 acyltransferase was partly purified with a recovery of 80%.

Table 1. Purification of the lipid acyltransferase

	Sample	Vol.	V _{Max}	Dilution	Tot. Units	%Recovery
10	Crude (Q3+Q4)	510	1.150	100	58650	100.
	Desalted crude	815	0.697	100	56806	97
	Pool 27-39, Q-Sep.	195	1.203	200	46898	80

15

EXAMPLE 2: Degumming experiment

The lipid acyltransferase sample from Example 1 was used for degumming studies in the formulations shown in Table 2.

20

Plant sterol, alpha-tocopherol and phosphatidylcholine were dissolved in soya bean oil by heating the oil to 90 °C. The oil was then cooled to approx 40 °C and the enzyme was added. The sample was placed at 40 °C for 17 hours during agitation and then a sample was taken out for HPTLC analysis by dissolving the sample in Chloroform

25 :Methanol 2:1.

30

Table 2. Soya bean oil models with alpha-tocopherol and plant sterol, used for testing of the lipid acyltransferase.

		1	2	3	4	5	6	7	8	9	10
Soya bean oil	%	98	97	97	96	97	96	96	95	96	92
Alpha-tocopherol	%					1	1	1	1	1	1
Plant Sterol	%			1	1			1	1	1	1
Phosphatidylcholine	%	2	2	2	2	2	2	2	2	2	2
lipid acyltransferase pool 27-39	%		1		1		1		1		4

The results from the HPTLC analysis are shown in Figure 3 and Figure 4.

5

The TLC results shown in Figure 3 clearly show that phosphatidylcholine is almost 100% removed by adding the lipid acyltransferase to the oil. Only sample no. 10 contains small amount of phosphatidylcholine. Sample no. 10 has the highest amount of water, which indicates that for degumming the enzyme may work better in low water formulations, or it could be explained by the fact that because sample no. 10 contain 5% water a two-phase system is formed, which might cause less contact between the reactants and the enzyme.

15 From the results shown in Figure 4 is was observed that small amount of fatty acids are formed, but when sterol or alpha-tocopherol is also available in the oil the amount of free fatty acids is lower, because the fatty acids from phosphatidylcholine it transferred to the sterol or tocopherol to form sterol-esters and tocopherol-esters.

20 The formation of sterol esters is clearly seen from the TLC results shown in Figure 5. It should be noted that the reference material used, cholesterol ester, has the same retention time as plant-sterol-esters.

25

EXAMPLE 3: Degumming experiment (2)

In another experiment the lipid acyltransferase pool 27-39 from IEC chromatography, was tested at different enzyme dosages and water concentrations in soya bean oil with phosphatidylcholine and plant sterol. In this experiment a commercial phospholipase
 5 Lecitase Ultra™ was also tested in a concentration recommended by the supplier for degumming. The composition of the samples for this experiment are shown in Table 3.

Table 3. Soya bean oil model with plant sterol used for testing of the lipid
 10 acyltransferase, and Lecitase Ultra™.

		1	2	3	4	5	6	7	8	9	10
Soya bean oil	%	96,6	96,6	96	92	96	92	95	92	96	92
Plant Sterol	%	1	1	1	1	1	1	1	1	1	1
Phosphatidylcholine	%	2	2	2	2	2	2	2	2	2	2
Lipid acyltransferase pool 27-39	%		0,4	0,4	0,4	1	1	2	2		
Lecitase Ultra™, 1% solution	%									0,3	0,3
Water		0,4		0,6	4,6	0	4	0	3	0,7	4,7
Units /g oil (PLU-7/g)		0	0,08	0,08	0,08	0,2	0,2	0,4	0,4	1,03	1,03

Plant sterol and phosphatidylcholine were dissolved in soya bean oil by heating to 95°C during agitation. The oil was then cooled to 40 °C and the enzymes were added. The sample was maintained at 40 °C with magnetic stirring and samples were taken
 15 out after 4 and 20 hours and analysed by TLC. The results from the HPTLC analysis of samples taken out after 4 and 20 hours are shown in Figures 6 to 9.

The HPTLC results indicate that the lowest dosage of the lipid acyltransferase (0.4% corresponding to 0.08 PLU-7/g oil) is sufficient to remove phosphatidylcholine in soya
 20 bean oil after 20h reaction time. It is also observed that the highest dosage of water (5%) seems to have a detrimental effect on the lipid acyltransferase for the hydrolysis of phosphatidylcholine in the oil. It is therefore expected that the lower degree of

hydrolysis in the sample with highest dosage of the lipid acyltransferase conversion is explained by that fact that more water is also added to the sample. Contrary to this it is observed that Lecitase Ultra™ has a lower degree of hydrolysis of phosphatidylcholine in the lowest dosage of water (1%), whereas Lecitase Ultra™ almost completely
5 removes phosphatidylcholine in the sample with 5% water.

The results from Figure 7 also indicate that the main part of the plant sterol is converted to plant sterol ester in samples treated with the lipid acyltransferase whereas no sterol esters are formed in the samples treated with Lecitase Ultra™. Figure 7
10 indicates that Lecitase Ultra™ produce more free fatty acids (FFA) than the lipid acyltransferase.

Conclusion

15 Degumming experiments with a model soya bean oil containing phosphatidylcholine, plant sterol and tocopherol has shown that a partially purified lipid acyltransferase enzyme is able to remove all phosphatidylcholine concomitant with the formation of plant sterol esters, and only to a small extent free fatty acids are formed.

20 One further advantage of the lipid acyltransferase is the formation of sterol esters, and in particular tocopherol ester, because sterols esters (including tocopherol ester) provide beneficial health properties. In conventional edible oil processing, following degumming the aqueous phase containing the hydrolysed polar lipid (e.g. phospholipid and/or glycolipid) is separated from the oil. Conventionally sterols are removed from
25 the edible oil during the oil refining process (this is sometimes referred to as deodorising). However, the sterol esters (and tocopherol ester) resist deodorisation and thus remain in the oil. Accumulation of sterol esters in the oil is attractive because it has been shown that higher intake of plant sterol esters reduces the risk for cardiovascular diseases in humans.

30

The experiment also indicates that the lipid acyltransferase is able to make tocopherol esters, which will also accumulate in the oil.

This will contribute to improved oxidative stability of the oil and thus is a further benefit to using the lipid acyltransferase in accordance with the present invention for degumming.

5

EXAMPLE 4: Degumming experiment in crude oil

In another experiment, the lipid acyltransferase pool 27-39 from IEC chromatography was tested at different enzyme dosages and water concentrations in crude soya oil (before degumming) obtained from The Solae Company, Aarhus, Denmark. In this experiment, a commercial phospholipase Lecitase Ultra™ was also tested in a concentration recommended for degumming by the supplier. The composition of the samples for this experiment is shown in Table 4.

15 The samples were placed in a heating block at 40 °C during agitation with a magnetic stirrer. Samples were taken out after 20 hours for analysis.

Table 4

		1	2	3	4	5	6	7	8	9	10
Crude soya oil	%	99,5	99,5	99	98	97	98	95	99,7	99	95
Lipid Acyltransferase	%		0,5	1	1	1	2	5			
Lecitase Ultra™ #3108, 1% solution	%								0,3	0,3	0,3
Water	%	0,5	0	0	1	2	0	0	0	0,7	4,7

20

The oil samples were analysed by HPTLC with the results shown in Figure 26 and 27.

The TLC analysis in Figure 26 indicate that the lipid acyltransferase efficiently removes the phospholipids in crude soya oil without leaving any lysolecithin in the sample (sample 3, 4, 6 and 7). Lecitase Ultra™ also removes the phospholipid (PC),

25

but some bands are remaining in the chromatogram, which is expected to be lysolecithin. It is also observed that lipid acyltransferase works in very low water environment, but Lecitase Ultra™ needs 1% to 5% water to work.

- 5 The results in Figure 27 confirm that lipid acyl transferase converts the free sterol to sterolesters and Lecitase Ultra™ has no effect on sterols. Figure 27 also indicates that some free fatty acids are formed both in samples with lipid acyl transferase and Lecitase Ultra™. The reason for the free fatty acid formation with lipid acyl transferase is explained by the fact that there is not enough acyl-donor (sterol)
- 10 available, and therefore some hydrolysis also occurs.

Sample 1, 2, 3, 6, 8 and 10 from table 4 were analysed by GLC and the amount of sterol and sterol esters were quantified. The results are shown in Table 5.

- 15 Table 5. GLC analysis of sterol and sterol esters
In crude soya oil treated with enzyme (Table 4)

Sample no	Enzyme	Sterol %	Sterolester %
1	Control	0,25	0,07
2	0,5% Lipid acyltransferase pool 27-39	0,13	0,13
3	1% Lipid acyltransferase pool 27-39	0	0,26
6	2% Lipid acyltransferase pool 27-39	0	0,22
8	0,3% Lecitase Ultra™ 1% solution	0,25	0,03
10	0,3% Lecitase Ultra™ 1% solution+ 5% water	0,27	0,05

- The results in Table 5 confirm the ability of the lipid acyl transferase of the present invention to convert all sterol in crude soya oil to sterol ester, and a commercial
- 20 phospholipase Lecitase Ultra™ showed no effect on sterol.

CONCLUSION

The effect of the lipid acyl transferase of the present invention on crude soya oil confirms that the lipid acyl transferase of the present invention effectively removes phospholipids in the crude soya oil concomitant with the formation of sterol esters.

Example 5

In another experiment, phospholipase from *Streptomyces thermosacchari* L131 was tested in crude soya oil.

The results confirm that phospholipase *Streptomyces thermosacchari* L131 effectively hydrolyses phospholipids in crude soya oil and is a suitable alternative enzyme for degumming of plant oils.

Enzymatic degumming processes of plant oils including soya oil and rape seed oil are currently expanding because this process is a less expensive and better process to remove lecithins from plant oils. The enzyme commercially used for oil degumming is a microbial phospholipase A1 or an animal derived phospholipase A2.

A (phospho)lipid acyl transferase *Streptomyces thermosacchari* L131 is another enzyme, which can be used for degumming.

Introduction

The purpose of this study was to investigate the possible use of a lipid acyltransferase from *Streptomyces thermosacchari* L131 for degumming of vegetable oil like soya oil, sunflower oil, and rape seed oil.

Traditionally, two processes have been used for degumming of oils, namely the physical degumming and the chemical degumming. Back in the 1990'es, the

enzymatic degumming process was developed, based on the use of pancreatic phospholipase. Because this enzyme was non-kosher, the phospholipase was substituted by microbial phospholipase A1. The enzymatic process has several advantages over the chemical or the physical degumming processes including cost savings, higher yield, and a more environmentally desirable process.

The purpose of this study was to investigate whether lipid acyltransferase from *Streptomyces thermosacchari* L131 would be a suitable enzyme for degumming. From the studies described above *Streptomyces thermosacchari* L131 is known to have hydrolytic properties against galactolipids and phospholipids without showing any activity on triglycerides, and it is expected that this enzyme also facilitates transferase reactions in certain environments with low water content. This study was conducted in crude soya oil with the natural content of phospholipids.

15 Materials and methods

Enzyme

K371(jour 2390-30): *Streptomyces thermosacchari* L131 /*S. lividans* freeze dried on starch.

(Activity: 108 PLU-7/g).

20 Lecitase Ultra (#3108) from Novozymes, Denmark

Cholesterolester, Fluka 26950

Plant Sterol: Generol 122 N from Henkel, Germany

Crude soya oil from The Solae Company, Aarhus Denmark

25 Lecithin: L- α Phosphatidylcholine 95% Plant (Avanti #441601)

Phospholipase activity

Substrate:

0.6% L- α Phosphatidylcholine 95% Plant (Avanti #441601), 0.4% Triton-X 100 (Sigma X-100), and 5 mM CaCl₂ were dissolved in 0.05M HEPES buffer pH 7.

Assay procedure:

400 μ l substrate was added to a 1.5 ml Eppendorf tube and placed in an Eppendorf Thermomixer at 37°C for 5 minutes. At time T= 0 min, 50 μ l enzyme solution was added. Also a blank with water instead of enzyme was analyzed. The sample was mixed at 10*100 rpm in an Eppendorf Thermomixer at 37°C for 10 minutes. At time

5 T=10 min the reaction was stopped by placing the Eppendorf tube in another thermomixer at 99°C for 10 minutes.

The free fatty acid content of samples was analyzed by using the NEFA C kit from WAKO GmbH.

Enzyme activity PLU-NEFA pH 7 was calculated as micromole fatty acid produced

10 per minute under assay conditions.

GLC (Gas Chromatography)

Perkin Elmer 8420 Capillary Gas Chromatography equipped with WCOT fused silica

15 column 12.5 m x 0.25 mm ID x 0.1 μ m 5%phenyl-methyl-silicone (CP Sil 8 CB from Crompack).

Carrier: Helium.

Injection: 1.5 μ L with split.

Detector: FID. 385 °C.

20 Oven program:	1	2	3	4
Oven temperature [°C]	80	200	240	360
Isothermal, time [min]	2	0	0	10
Temperature rate [°C/min]	20	10	12	

25 Sample preparation: Lipid extracted from 0,2 gram sample was dissolved in 2 mL heptane: pyridine 2:1 containing an internal standard heptadecane, 2 mg/mL. 500 μ L of the sample was transferred to a crimp vial. 100 μ L MSTFA (N-Methyl-N-trimethylsilyl-trifluoroacetamid) was added and the reaction incubated for 15 minutes at 90°C.

HPTLC

Applicator: Automatic TLC Sampler 4, CAMAG

HPTLC plate: 20 x 10 cm, Merck no. 1.05641. Activated 30 minutes at 160°C before use.

- 5 Application: 1 µl of a 8% solution of oil in buffer was applied to the HPTLC plate using Automatic TLC applicator.

Running buffer 4: Chloroform:Methanol:Water 75:25:4

Running buffer 5: P-ether : Methyl-tert-butyl-ether : Acetic acid 70:30:1

10

Application/Elution time:

Running buffer 4: 20 min

Running buffer 5: 10 min

- 15 Development

The plate was dried in an oven for 10 minutes at 160°C, cooled, and dipped into 6% cupri acetate in 16% H₃PO₄. Dried additionally 10 minutes at 160°C and evaluated directly.

- 20 Results.

Degumming experiment.

Streptomyces thermosacchari L131 was used for degumming studies in the formulations shown in table 6.

- 25 The samples were placed at 40°C for 18 hours with agitation, after which time a sample was collected for HPTLC analysis by dissolving the sample in Chloroform :Methanol 2:1

30

Table 6. Degumming of crude soya oil with *Streptomyces thermosacchari* L131
And Lecitase Ultra

		1	2	3	4	5	6
Crude soya oil	%	99	99	98	97	99,7	99
K371, 10% in water	%		1	2	3		
Lecitase Ultra™ #3108, 1% in water	%					0,3	0,3
Water	%	1	0	0	0		0,7

The results from the HPTLC analysis are shown in fig. 59 and 60.

5

Fig 59 TLC (Solvent 4) of reaction products from enzyme treatment of crude soya oil samples according to table 6. As reference, phosphatidylcholine (PC) was also analysed. PE (phosphatidylethanolamine(PE) and lysophosphatidylcholine (LPC) are also indicated.

10

Fig 60 TLC (Solvent 5) of reaction products from enzyme treatment of crude soya oil samples according to table 6. References Cholesterol ester, monoglyceride, diglyceride, triglyceride and plant sterol. Free fatty acid (FFA) is also indicated

15 The TLC results in Figure 59 clearly show that phosphatidylcholine was completely removed by adding *Streptomyces thermosacchari* L131 to the oil. Only the lowest dosage (sample 2) did not completely hydrolyse the phospholipids. Lecitase Ultra™ also hydrolysed the phospholipids in the oil when 5% water was available (sample 6) but without adding extra water (sample 5) only part of the phospholipids were
20 hydrolysed.

The results shown in fig. 60 indicate that the hydrolysis of phospholipids is coincident with the formation of free fatty acid.

25 Conclusion.

The lipid acyltransferase from *Streptomyces thermosacchari* L131 effectively hydrolysis phospholipids in crude soya oil during formation of free fatty acids.

All publications mentioned in the above specification are herein incorporated by
5 reference. Various modifications and variations of the described methods and system
of the present invention will be apparent to those skilled in the art without departing
from the scope of the present invention. Although the present invention has been
described in connection with specific preferred embodiments, it should be understood
that the invention as claimed should not be unduly limited to such specific
10 embodiments. Indeed, various modifications of the described modes for carrying out
the invention which are obvious to those skilled in biochemistry and biotechnology or
related fields are intended to be within the scope of the following claims.


**BUDAPEST TREATY ON THE INTERNATIONAL
RECOGNITION OF THE DEPOSIT OF MICROORGANISMS
FOR THE PURPOSES OF PATENT PROCEDURE**

INTERNATIONAL FORM

**RECEIPT IN THE CASE OF AN ORIGINAL DEPOSIT
issued pursuant to Rule 7.1 by the
INTERNATIONAL DEPOSITARY AUTHORITY
identified at the bottom of this page**

Danisco A/S
Langebrogade 1
DK-1001 Copenhagen
Denmark

NAME AND ADDRESS OF DEPOSITOR

I. IDENTIFICATION OF THE MICROORGANISM	
Identification reference given by the DEPOSITOR: <i>Escherichia coli</i> TOP10pPet12aAhydro	Accession number given by the INTERNATIONAL DEPOSITARY AUTHORITY: NCIMB 41204
II. SCIENTIFIC DESCRIPTION AND/OR PROPOSED TAXONOMIC DESIGNATION	
The microorganism identified under I above was accompanied by:	
<input type="checkbox"/> a scientific description	
<input checked="" type="checkbox"/> a proposed taxonomic designation	
(Mark with a cross where applicable)	
III. RECEIPT AND ACCEPTANCE	
This International Depositary Authority accepts the microorganism identified under I above, which was received by it on 22 December 2003 (date of the original deposit) ¹	
IV. RECEIPT OF REQUEST FOR CONVERSION	
The microorganism identified under I above was received by this International Depositary Authority on (date of the original deposit) and a request to convert the original deposit to a deposit under the Budapest Treaty was received by it on (date of receipt of request for conversion)	
V. INTERNATIONAL DEPOSITARY AUTHORITY	
Name: NCIMB Ltd., Address: 23 St Machar Drive, Aberdeen AB24 3RY Scotland, UK.	Signature(s) of person(s) having the power to represent the International Depositary Authority or of authorised official(s):  Date: 9 January 2004

¹ Where Rule 6/4(d) applies, such date is the date on which the status of International Depositary Authority was acquired.
Form ID/A (only name)

**BUDAPEST TREATY ON THE INTERNATIONAL
RECOGNITION OF THE DEPOSIT OF MICROORGANISMS
FOR THE PURPOSES OF PATENT PROCEDURE**

INTERNATIONAL FORM

Danisco A/S
Langebrogade 1
DK-1001 Copenhagen
Denmark

VIABILITY STATEMENT
issued pursuant to Rule 10.2 by the
INTERNATIONAL DEPOSITARY AUTHORITY
identified on the following page


**NAME AND ADDRESS OF THE PARTY
TO WHOM THE VIABILITY STATEMENT
IS ISSUED**

<p>I. DEPOSITOR</p> <p>Name: AS ABOVE</p> <p>Address:</p>	<p>II. IDENTIFICATION OF THE MICROORGANISM</p> <p>Accession number given by the INTERNATIONAL DEPOSITARY AUTHORITY: NCIMB 41204</p> <p>Date of the deposit or of the transfer¹: 22 December 2003</p>
<p>III. VIABILITY STATEMENT</p> <p>The viability of the microorganism identified under II above was tested on 22 December 2003². On that date, the said microorganism was:</p> <p><input checked="" type="checkbox"/> viable</p> <p><input type="checkbox"/> no longer viable</p>	

¹ Indicate the date of the original deposit or, where a new deposit or a transfer has been made, the most recent relevant date (date of the new deposit or date of the transfer).

² In the cases referred to in Rule 10.2(a)(ii) and (iii), refer to the most recent viability test.

³ Mark with a cross the applicable box.

IV. CONDITIONS UNDER WHICH THE VIABILITY TEST HAS BEEN PERFORMED⁴	
V. INTERNATIONAL DEPOSITARY AUTHORITY	
Name: NCIMB Ltd, Address: 23 St Machar Drive Aberdeen AB24 3RY Scotland	Signature(s) of person(s) having the power to represent the International Depositary Authority or of authorised official(s):  Date: 9 January 2004

⁴ Fill in if the information has been requested and if the results of the test were negative.


**BUDAPEST TREATY ON THE INTERNATIONAL
RECOGNITION OF THE DEPOSIT OF MICROORGANISMS
FOR THE PURPOSES OF PATENT PROCEDURE**

Danisco A/S
Langebrogade 1
DK-1001 Copenhagen
Denmark

INTERNATIONAL FORM

RECEIPT IN THE CASE OF AN ORIGINAL DEPOSIT
issued pursuant to Rule 7.1 by the
INTERNATIONAL DEPOSITARY AUTHORITY
identified at the bottom of this page

NAME AND ADDRESS OF DEPOSITOR

I. IDENTIFICATION OF THE MICROORGANISM	
Identification reference given by the DEPOSITOR: <i>Escherichia coli</i> TOP10pPet12aAsalmo	Accession number given by the INTERNATIONAL DEPOSITARY AUTHORITY: NCIMB 41205
II. SCIENTIFIC DESCRIPTION AND/OR PROPOSED TAXONOMIC DESIGNATION	
The microorganism identified under I above was accompanied by:	
<input type="checkbox"/> a scientific description <input checked="" type="checkbox"/> a proposed taxonomic designation (Mark with a cross where applicable)	
III. RECEIPT AND ACCEPTANCE	
This International Depositary Authority accepts the microorganism identified under I above, which was received by it on 22 December 2003 (date of the original deposit) ¹	
IV. RECEIPT OF REQUEST FOR CONVERSION	
The microorganism identified under I above was received by this International Depositary Authority on (date of the original deposit) and a request to convert the original deposit to a deposit under the Budapest Treaty was received by it on (date of receipt of request for conversion)	
V. INTERNATIONAL DEPOSITARY AUTHORITY	
Name: NCIMB Ltd., Address: 23 St Machar Drive Aberdeen AB24 3RY Scotland, UK.	Signature(s) of person(s) having the power to represent the International Depositary Authority or of authorised official(s):  Date: 9 January 2004

¹ Where Rule 6/4(d) applies, such date is the date on which the status of International Depositary Authority was acquired.
Form BP/4 (sole name)

**BUDAPEST TREATY ON THE INTERNATIONAL
RECOGNITION OF THE DEPOSIT OF MICROORGANISMS
FOR THE PURPOSES OF PATENT PROCEDURE**

INTERNATIONAL FORM

Damisco A/S
Langebrogade 1
DK-1001 Copenhagen
Denmark

VIABILITY STATEMENT
issued pursuant to Rule 10.2 by the
INTERNATIONAL DEPOSITARY AUTHORITY
identified on the following page


NAME AND ADDRESS OF THE PARTY
TO WHOM THE VIABILITY STATEMENT
IS ISSUED

<p>I. DEPOSITOR</p> <p>Name: AS ABOVE</p> <p>Address:</p>	<p>II. IDENTIFICATION OF THE MICROORGANISM</p> <p>Accession number given by the INTERNATIONAL DEPOSITARY AUTHORITY: NCIMB 41205</p> <p>Date of the deposit or of the transfer¹: 22 December 2003</p>
<p>III. VIABILITY STATEMENT</p> <p>The viability of the microorganism identified under II above was tested on 22 December 2003². On that date, the said microorganism was:</p> <p><input checked="" type="checkbox"/> ³ viable</p> <p><input type="checkbox"/> ³ no longer viable</p>	

¹ Indicate the date of the original deposit or, where a new deposit or a transfer has been made, the most recent relevant date (date of the new deposit or date of the transfer).

² In the cases referred to in Rule 10.2(a)(ii) and (iii), refer to the most recent viability test.

³ Mark with a cross the applicable box.

<p>IV. CONDITIONS UNDER WHICH THE VIABILITY TEST HAS BEEN PERFORMED⁴</p>	
<p> </p>	
<p>V. INTERNATIONAL DEPOSITARY AUTHORITY</p>	
<p>Name: NCIMB Ltd., Address: 23 St Machar Drive Aberdeen AB24 3RY Scotland</p>	<p>Signature(s) of person(s) having the power to represent the International Depositary Authority or of authorised official(s):  Date: 9 January 2004</p>

⁴ Fill in if the information has been requested and if the results of the test were negative.


**BUDAPEST TREATY ON THE INTERNATIONAL
RECOGNITION OF THE DEPOSIT OF MICROORGANISMS
FOR THE PURPOSES OF PATENT PROCEDURE**

INTERNATIONAL FORM

Danisco Intellectual Assets
Danisco A/S
Langebrogade 1
DK-1001 Copenhagen
Denmark

RECEIPT IN THE CASE OF AN ORIGINAL DEPOSIT
issued pursuant to Rule 7.1 by the
INTERNATIONAL DEPOSITARY AUTHORITY
identified at the bottom of this page

NAME AND ADDRESS OF DEPOSITOR

I. IDENTIFICATION OF THE MICROORGANISM	
Identification reference given by the DEPOSITOR: <i>Streptomyces</i> sp. L130	Accession number given by the INTERNATIONAL DEPOSITARY AUTHORITY: NCIMB 41226
II. SCIENTIFIC DESCRIPTION AND/OR PROPOSED TAXONOMIC DESIGNATION	
The microorganism identified under I above was accompanied by: <input type="checkbox"/> a scientific description <input checked="" type="checkbox"/> a proposed taxonomic designation (Mark with a cross where applicable)	
III. RECEIPT AND ACCEPTANCE	
This International Depositary Authority accepts the microorganism identified under I above, which was received by it on 23 June 2004 (date of the original deposit) ¹	
IV. RECEIPT OF REQUEST FOR CONVERSION	
The microorganism identified under I above was received by this International Depositary Authority on (date of the original deposit) and a request to convert the original deposit to a deposit under the Budapest Treaty was received by it on (date of receipt of request for conversion)	
V. INTERNATIONAL DEPOSITARY AUTHORITY	
Name: NCIMB Ltd, Address: 23 St Machar Drive Aberdeen AB24 3RY Scotland, UK.	Signature(s) of person(s) having the power to represent the International Depositary Authority or of authorised official(s):  Date: 28 June 2004

¹ Where Rule 6/4(d) applies, such date is the date on which the status of International Depositary Authority was acquired.
Form BP/4 (sole page)

**BUDAPEST TREATY ON THE INTERNATIONAL
RECOGNITION OF THE DEPOSIT OF MICROORGANISMS
FOR THE PURPOSES OF PATENT PROCEDURE**

INTERNATIONAL FORM

Danisco Intellectual Assets
Danisco A/S
Langebrogade 1
DK-1001 Copenhagen
Denmark

VIABILITY STATEMENT
issued pursuant to Rule 10.2 by the
INTERNATIONAL DEPOSITARY AUTHORITY
identified on the following page


**NAME AND ADDRESS OF THE PARTY
TO WHOM THE VIABILITY STATEMENT
IS ISSUED**

I. DEPOSITOR	II. IDENTIFICATION OF THE MICROORGANISM
Name: AS ABOVE Address:	Accession number given by the INTERNATIONAL DEPOSITARY AUTHORITY: NCIMB 41226 Date of the deposit or of the transfer ¹ : 23 June 2004
III. VIABILITY STATEMENT	
The viability of the microorganism identified under II above was tested on 25 June 2004 ² . On that date, the said microorganism was:	
<input checked="checked" type="checkbox"/> ³	viable
<input type="checkbox"/>	no longer viable

¹ Indicate the date of the original deposit or, where a new deposit or a transfer has been made, the most recent relevant date (date of the new deposit or date of the transfer).

² In the cases referred to in Rule 10.2(a)(ii) and (iii), refer to the most recent viability test.

³ Mark with a cross the applicable box.

IV. CONDITIONS UNDER WHICH THE VIABILITY TEST HAS BEEN PERFORMED ⁴ .	
V. INTERNATIONAL DEPOSITARY AUTHORITY	
Name: NCIMB Ltd, Address: 23 St Machar Drive Aberdeen AB24 3RY Scotland	Signature(s) of person(s) having the power to represent the International Depository Authority or of authorised official(s):  Date: 28 June 2004

⁴ Fill in if the information has been requested and if the results of the test were negative.

BUDAPEST TREATY ON THE INTERNATIONAL
 RECOGNITION OF THE DEPOSIT OF MICROORGANISMS
 FOR THE PURPOSES OF PATENT PROCEDURE

Danisco Intellectual Assets
 Danisco A/S
 Langebrogade 1
 DK-1001 Copenhagen
 Denmark

INTERNATIONAL FORM

RECEIPT IN THE CASE OF AN ORIGINAL DEPOSIT
 issued pursuant to Rule 7.1 by the
 INTERNATIONAL DEPOSITARY AUTHORITY
 identified at the bottom of this page

NAME AND ADDRESS OF DEPOSITOR

I IDENTIFICATION OF THE MICROORGANISM	
Identification reference given by the DEPOSITOR: <i>Streptomyces</i> sp. L131	Accession number given by the INTERNATIONAL DEPOSITARY AUTHORITY: NCIMB 41227
II SCIENTIFIC DESCRIPTION AND/OR PROPOSED TAXONOMIC DESIGNATION	
The microorganism identified under I above was accompanied by:	
<input type="checkbox"/> a scientific description	
<input checked="" type="checkbox"/> a proposed taxonomic designation	
(Mark with a cross where applicable)	
III RECEIPT AND ACCEPTANCE	
This International Depositary Authority accepts the microorganism identified under I above, which was received by it on 23 June 2004 (date of the original deposit) ¹	
IV. RECEIPT OF REQUEST FOR CONVERSION	
The microorganism identified under I above was received by this International Depositary Authority on (date of the original deposit) and a request to convert the original deposit to a deposit under the Budapest Treaty was received by it on (date of receipt of request for conversion)	
V. INTERNATIONAL DEPOSITARY AUTHORITY	
Name: NCIMB Ltd., Address: 23 St Machar Drive Aberdeen AB24 3RY Scotland, UK.	Signature(s) of person(s) having the power to represent the International Depositary Authority or of authorised official(s): <i>Terence Dando</i> Date: 28 June 2004

¹ Where Rule 6/4(d) applies, such date is the date on which the status of International Depositary Authority was acquired.
 Form BP/4 (sole page)

**BUDAPEST TREATY ON THE INTERNATIONAL
RECOGNITION OF THE DEPOSIT OF MICROORGANISMS
FOR THE PURPOSES OF PATENT PROCEDURE**

Danisco Intellectual Assets Danisco A/S Langebrogade 1 DK-1001 Copenhagen Denmark

INTERNATIONAL FORM

VIABILITY STATEMENT
 issued pursuant to Rule 10.2 by the
INTERNATIONAL DEPOSITARY AUTHORITY
 identified on the following page


NAME AND ADDRESS OF THE PARTY
 TO WHOM THE VIABILITY STATEMENT
 IS ISSUED

<p>I. DEPOSITOR</p> <p>Name: AS ABOVE</p> <p>Address:</p>	<p>II. IDENTIFICATION OF THE MICROORGANISM</p> <p>Accession number given by the INTERNATIONAL DEPOSITARY AUTHORITY: NCIMB 41227</p> <p>Date of the deposit or of the transfer¹: 23 June 2003</p>
<p>III. VIABILITY STATEMENT</p> <p>The viability of the microorganism identified under II above was tested on 25 June 2004². On that date, the said microorganism was:</p> <p><input checked="" type="checkbox"/>³ viable</p> <p><input type="checkbox"/>³ no longer viable</p>	

¹ Indicate the date of the original deposit or, where a new deposit or a transfer has been made, the most recent relevant date (date of the new deposit or date of the transfer).

² In the cases referred to in Rule 10.2(a)(ii) and (iii), refer to the most recent viability test.

³ Mark with a cross the applicable box.

IV. CONDITIONS UNDER WHICH THE VIABILITY TEST HAS BEEN PERFORMED ⁴	
V. INTERNATIONAL DEPOSITARY AUTHORITY	
Name: NCIMB Ltd, Address: 23 St Machar Drive Aberdeen AB24 3RY Scotland	Signature(s) of person(s) having the power to represent the International Depositary Authority or of authorised official(s):  Date: 28 June 2004

⁴ Fill in if the information has been requested and if the results of the test were negative.

CLAIMS

1. A process of enzymatic degumming edible oils, comprising treating the edible oil with a lipid acyltransferase so as to transfer an acyl group from a major part of the phospholipid to one or more acyl acceptors.
5
3. A process according to claim 1 wherein the acyl acceptor is any compound comprising a hydroxy group.
4. A process according to claim 1 wherein the acyl acceptor is water.
10
5. A process according to claim 1 or 2 wherein the acyl acceptor is one or more sterols and/or stanols.
6. A process according to claim 4 wherein a sterol ester and/or a stanol ester is
15 formed.
7. A process according to claim 4 wherein the acyl acceptor is a sterol.
8. A process according to any one of the preceding claims wherein the phospholipid
20 is a lecithin.
9. A process according to any one of claims 4 to 6 wherein the lipid acyl transferase, as well as being able to transfer an acyl group from a lipid to a sterol and/or a stanol, additionally transfers the acyl group from a lipid to one or more of a
25 carbohydrate, a protein, a protein subunit, and glycerol.
10. A process according to any one of the preceding claims wherein the lipid acyltransferase is a natural lipid acyltransferase.
- 30 11. A process according to any one of the preceding claims wherein the lipid acyltransferase is a variant lipid acyltransferase.

12. A process according to any one of the preceding claims wherein said lipid acyltransferase is obtainable from an organism from one or more of the following
5 genera: *Aeromonas*, *Streptomyces*, *Saccharomyces*, *Lactococcus*, *Mycobacterium*,
Streptococcus, *Lactobacillus*, *Desulfitobacterium*, *Bacillus*, *Campylobacter*,
Vibrionaceae, *Xylella*, *Sulfolobus*, *Aspergillus*, *Schizosaccharomyces*, *Listeria*,
Neisseria, *Mesorhizobium*, *Ralstonia*, *Xanthomonas*, *Candida*, *Thermobifida* and
Corynebacterium.
- 10
13. A process according to any one of the preceding claims wherein said lipid acyltransferase is obtainable from one or more of *Aeromonas hydrophila*, *Aeromonas salmonicida*, *Streptomyces coelicolor*, *Streptomyces rimosus*, *Streptomyces thermosacchari*, *Streptomyces avermitilis*, *Mycobacterium*, *Streptococcus pyogenes*,
15 *Lactococcus lactis*, *Streptococcus pyogenes*, *Streptococcus thermophilus*,
Lactobacillus helveticus, *Desulfitobacterium dehalogenans*, *Bacillus sp.*,
Campylobacter jejuni, *Vibrionaceae*, *Xylella fastidiosa*, *Sulfolobus solfataricus*,
Saccharomyces cerevisiae, *Aspergillus terreus*, *Schizosaccharomyces pombe*, *Listeria innocua*, *Listeria monocytogenes*, *Neisseria meningitidis*, *Mesorhizobium loti*,
20 *Ralstonia solanacearum*, *Xanthomonas campestris*, *Xanthomonas axonopodis*,
Candida parapsilosis, *Thermobifida fusca* and *Corynebacterium efficiens*.
14. A process according to any one of the preceding claims wherein the lipid acyl transferase is characterised in that:
- 25 (a) the lipid acyltransferase possesses acyltransferase activity is defined as ester transfer activity whereby the acyl part of an original ester bond of a lipid acyl donor is transferred to an acyl acceptor to form a new ester; and
(b) the enzyme comprises the amino acid sequence motif GDSX, wherein X is one or more of the following amino acid residues L, A, V, I, F, Y, H, Q, T, N, M or S.
- 30
15. A process according to claim 14 wherein the X of the GDSX motif is L

16. A process according to any one of the preceding claims wherein the lipid acyltransferase comprises one or more of the following amino acid sequences: SEQ ID No. 1, SEQ ID No. 3, SEQ ID No. 4, SEQ ID No. 5, SEQ ID No. 6, SEQ ID No. 7, SEQ ID No. 8, SEQ ID No. 9, SEQ ID No. 10, SEQ ID No. 11, SEQ ID No. 12, SEQ ID No. 13, SEQ ID No. 14, or SEQ ID No. 15, SEQ ID No. 16, SEQ ID No. 17, SEQ ID No. 18, SEQ ID No. 36, SEQ ID No. 38, SEQ ID No. 40, SEQ ID No. 41, SEQ ID No. 45, SEQ ID No. 47, SEQ ID No. 50 or an amino acid sequence which has 75% or more identity thereto.
17. A process according to claim 16 wherein the lipid acyltransferase comprises one or more of the following amino acid sequences: SEQ ID No. 3, SEQ ID No. 4, SEQ ID No. 1 or SEQ ID No. 15 or SEQ ID No. 15, or an amino acid sequence which has 75% or more identity thereto.
18. A process according to claim 16 wherein the lipid acyltransferase comprises one or more of the following amino acid sequences: SEQ ID No. 36, SEQ ID No. 38, SEQ ID No. 40, SEQ ID No. 41, SEQ ID No. 45, SEQ ID No. 47, SEQ ID No. 50, or an amino acid sequence with at least 70% identity thereto.
19. A process according to claim 16 wherein the lipid acyltransferase comprises one or more of SEQ ID No. 17 or SEQ ID No. 18, or an amino acid sequence with 70% or more homology thereto.
20. A process according to claim 16 wherein the lipid acyltransferase comprises the amino acid sequence shown as SEQ ID No. 16, or an amino acid sequence which has 75% or more homology thereto.
21. A process according to claim 16 wherein the lipid acyltransferase comprises the amino acid sequence shown as SEQ ID No. 16.
22. A process according to claim 10 wherein the lipid acyltransferase is characterised in that the enzyme comprises the amino acid sequence motif

GDSX, wherein X is one or more of the following amino acid residues L, A, V, I, F, Y, H, Q, T, N, M or S, and wherein the variant enzyme comprises one or more amino acid modifications compared with a parent sequence at any one or more of the amino acid residues defined in set 2 or set 4 or set 6 or set 7.

5

23. A process according to claim 22 wherein the lipid acyltransferase comprises an amino acid sequence shown as SEQ ID No. 34, SEQ ID No. 3, SEQ ID No. 4, SEQ ID No. 5, SEQ ID No. 6, SEQ ID No. 7, SEQ ID No. 8, SEQ ID No. 19, SEQ ID No. 10, SEQ ID No. 11, SEQ ID No. 12, SEQ ID No. 13, SEQ ID No. 14, SEQ ID No. 1, SEQ ID No. 15, SEQ ID No. 25, SEQ ID No. 26, SEQ ID No. 27, SEQ ID No. 28, SEQ ID No. 29, SEQ ID No. 30, SEQ ID No. 31, SEQ ID No. 32, or SEQ ID No. 33 except for one or more amino acid modifications at any one or more of the amino acid residues defined in set 2 or set 4 or set 6 or set 7 identified by sequence alignment with SEQ ID No. 34.

10

15

24. A process according to claim 23 wherein the lipid acyltransferase comprises the sequence shown as SEQ ID No. 34 or SEQ ID No. 35 except for one or more amino acid modifications at any one or more of the amino acid residues defined in set 2 or set 4 or set 6 or set 7.

20

25. A process according to any one of claims 10, 23 or 24 wherein the lipid acyltransferase comprises the amino acid sequence shown as SEQ ID No. 16 or an amino acid sequence with 75% or more homology thereto.

25

26. A process according to any one of claims 10, 23 or 24 wherein the lipid acyltransferase comprises the amino acid sequence shown as SEQ ID No. 16.

27. A process according to any one of the preceding claims wherein there is less than 1% water in the edible oil during treatment.

30

28. A process according to claim 27 wherein there is less than 0.5% water.

29. A process according to claim 28 wherein there is less than 0.1% water.
30. A process according to any one of the preceding claims wherein the process comprises removing the lysophospholipids produced by the action of the lipid acyltransferase by filtration.
- 5
31. Use of a lipid acyltransferase in the degumming of edible oils to remove phospholipids and, optionally, to increase the formation of sterol esters and/or stanol esters in the oil.
- 10
32. Use according to claim 31 where there is no significant increase in the free fatty acids in the oil following treatment.
33. Use according to claim 31 or claim 32 wherein the phospholipid is a lecithin.
- 15
34. Use according to any one of claims 31-33 wherein the lipid acyltransferase is a natural lipid acyltransferase.
35. Use according to any one of claims 31-33 wherein the lipid acyltransferase is a variant lipid acyltransferase.
- 20
36. Use according to any one of claims 31-35 wherein said lipid acyltransferase is obtainable from organisms from one or more of the following genera: *Aeromonas*, *Streptomyces*, *Saccharomyces*, *Lactococcus*, *Mycobacterium*, *Streptococcus*, *Lactobacillus*, *Desulfitobacterium*, *Bacillus*, *Campylobacter*, *Vibrionaceae*, *Xylella*, *Sulfolobus*, *Aspergillus*, *Schizosaccharomyces*, *Listeria*, *Neisseria*, *Mesorhizobium*, *Ralstonia*, *Xanthomonas*, *Candida*, *Thermobifida* and *Corynebacterium*.
- 25
37. Use according to any one of claims 31-36 wherein the lipid acyltransferase is obtainable from one or more of *Aeromonas hydrophila*, *Aeromonas salmonicida*, *Streptomyces coelicolor*, *Streptomyces rimosus*, *Streptomyces*
- 30

thermosacchari, Streptomyces avermitilis, Mycobacterium, Streptococcus pyogenes, Lactococcus lactis, Streptococcus pyogenes, Streptococcus thermophilus, Lactobacillus helveticus, Desulfitobacterium dehalogenans, Bacillus sp, Campylobacter jejuni, Vibrionaceae, Xylella fastidiosa, Sulfolobus solfataricus, Saccharomyces cerevisiae, Aspergillus terreus, Schizosaccharomyces pombe, Listeria innocua, Listeria monocytogenes, Neisseria meningitidis, Mesorhizobium loti, Ralstonia solanacearum, Xanthomonas campestris, Xanthomonas axonopodis Candida parapsilosis, Thermobifida fusca and Corynebacterium efficiens.

10

38. Use according to any one of claims 31-37 wherein the lipid acyltransferase is characterised in that:

15

(iii) the lipid acyltransferase possesses acyltransferase activity which may be defined as ester transfer activity whereby the acyl part of an original ester bond of a lipid acyl donor is transferred to an acyl acceptor to form a new ester; and

(iv) the enzyme comprises the amino acid sequence motif GDSX, wherein X is one or more of the following amino acid residues L, A, V, I, F, Y, H, Q, T, N, M or S.

20

39. Use according to claim 38 wherein the X of the GDSX motif is L

25

40. Use according to any one of claims 31-39 wherein the lipid acyltransferase comprises one or more of the following amino acid sequences: SEQ ID No. 1, SEQ ID No. 3, SEQ ID No. 4, SEQ ID No. 5, SEQ ID No. 6, SEQ ID No. 7, SEQ ID No. 8, SEQ ID No. 9, SEQ ID No. 10, SEQ ID No. 11, SEQ ID No. 12, SEQ ID No. 13, SEQ ID No. 14, or SEQ ID No. 15, SEQ ID No. 16, SEQ ID No. 17, SEQ ID No. 18, SEQ ID No. 36, SEQ ID No. 38, SEQ ID No. 40, SEQ ID No. 41, SEQ ID No. 45, SEQ ID No. 47, SEQ ID No. 50 or an amino acid sequence which has 75% or more identity thereto.

30

- 5
41. Use according to claim 40 wherein the lipid acyltransferase comprises one or more of the following amino acid sequences: SEQ ID No. 3, SEQ ID No. 4, SEQ ID No. 1 or SEQ ID No. 15 or SEQ ID No. 15, or an amino acid sequence which has 75% or more identity thereto.
- 10
42. Use according to claim 40 wherein the lipid acyltransferase comprises one or more of the following amino acid sequences: SEQ ID No. 36, SEQ ID No. 38, SEQ ID No. 40, SEQ ID No. 41, SEQ ID No. 45, SEQ ID No. 47, SEQ ID No. 50, or an amino acid sequence with at least 70% identity thereto.
- 15
43. Use according to claim 40 wherein the lipid acyltransferase comprises one or more of SEQ ID No. 17 or SEQ ID No. 18, or an amino acid sequence with 70% or more homology thereto.
- 20
44. Use according to claim 40 wherein the lipid acyltransferase comprises the amino acid sequence shown as SEQ ID No. 16, or an amino acid sequence which has 75% or more homology thereto.
- 25
45. Use according to claim 40 wherein the lipid acyltransferase comprises the amino acid sequence shown as SEQ ID No. 16.
- 30
46. Use according to claim 35 wherein the lipid acyltransferase is characterised in that the enzyme comprises the amino acid sequence motif GDSX, wherein X is one or more of the following amino acid residues L, A, V, I, F, Y, H, Q, T, N, M or S, and wherein the variant enzyme comprises one or more amino acid modifications compared with a parent sequence at any one or more of the amino acid residues defined in set 2 or set 4 or set 6 or set 7.
- 30
47. Use according to claim 46 wherein the lipid acyltransferase comprises an amino acid sequence shown as SEQ ID No. 34, SEQ ID No. 35, SEQ ID No. 3, SEQ ID No. 4, SEQ ID No. 5, SEQ ID No. 6, SEQ ID No. 7, SEQ ID No. 8, SEQ ID No. 19, SEQ ID No. 10, SEQ ID No. 11, SEQ ID No. 12, SEQ ID No.

- 5 13, SEQ ID No. 14, SEQ ID No. 1, SEQ ID No. 15, SEQ ID No. 25, SEQ ID No. 26, SEQ ID No. 27, SEQ ID No. 28, SEQ ID No. 29, SEQ ID No. 30, SEQ ID No. 31, SEQ ID No. 32, or SEQ ID No. 33 except for one or more amino acid modifications at any one or more of the amino acid residues defined in set 2 or set 4 or set 6 or set 7 identified by sequence alignment with SEQ ID No. 34.
- 10 48. Use according to claim 47 wherein the lipid acyltransferase comprises the sequence shown as SEQ ID No. 34 or SEQ ID No. 35 except for one or more amino acid modifications at any one or more of the amino acid residues defined in set 2 or set 4 or set 6 or set 7.
- 15 49. Use according to claim 35 wherein the lipid acyltransferase comprises the amino acid sequence shown as SEQ ID No. 16 or an amino acid sequence with 75% or more homology thereto.
- 20 50. Use according to claim 49 wherein the lipid acyltransferase comprises the amino acid sequence shown as SEQ ID No. 16.
- 25 51. Use according to any one of claims 31 to 50 wherein there is less than 1% water in the edible oil during treatment.
52. Use according to claim 51 wherein there is less than 0.5% water.
- 30 53. Use according to claim 52 wherein there is less than 0.1% water.
54. A lipid acyltransferase comprising the amino acid sequence shown as SEQ ID No. 16.
55. A lipid acyltransferase as hereinbefore described with reference to the accompanying description and figures.

56. A method as hereinbefore described with reference to the accompanying description and the figures.

57. A use as hereinbefore described with reference to the accompanying description and figures.

5

FIGURE 1




FIGURE 2




FIGURE 3




FIGURE 5




FIGURE 6




FIGURE 7






FIGURE 8



9/37

FIGURE 9



10/37

FIGURE 10

SEQ ID No. 16

```

1  ADTRPAFSRI VMFGDSLSDT GKMYSKMRGY LPSSPPYYEG RFSNGPVWLE QLTQFPGLT
61  IANEAEAGGAT AVAYNKISWD PKYQVINNLD YEVTQFLQKD SFKPDDLVLV WVGANDYLAY
121 GWNTEQDAKR VRDAISDAAN RMVLNGAKQI LLFNLPLDGLQ NPSARSQKVV EAVSHVSAYH
181 NKLLLNLARQ LAPTMVKLF EIDKQFAEML RDPQNFGLSD VENPCYDGGY VWKPFATRSV
241 STDRQLSAFS PQERLAIAGN PLLAQAVASP MARRSASPLN CEGKMFWDQV HPTTVVHAAL
301 SERAATFIET QYEFLAHG

```

FIGURE 11

(SEQ ID No. 1)

```

1  MKKWFVCLLG LVALTVQAAD SRPAFSRIVM FGDSLSDTGK MYSKMRGYLP
51  SSPYYEGRF SNGPVWLEQL TKQFPGLTIA NEAEAGGATAV AYNKISWNP
101 YQVINNLDYE VTQFLQKDSF KPDDLVLVW GANDYLAYGW NTEQDAKRVR
151 DAISDAANRM VLNGAQILL FNLPDLGQNP SARSQKVVEA VSHVSAYHNQ
201 LLLNLARQLA PTGMVKLFEI DKQFAEMLRD PQNFGLSDVE NPCYDGGYVF
251 KPFATRSVST DRQLSAFSPQ ERLAIAGNPL LAQAVASPMA RRSASPLNCE
301 GKMFWDQVHP TTVVHAALSE RAATFIANQY EFLAH*

```

FIGURE 12

(SEQ ID No. 2)

```

1  ivafGDSlFd geayygsdsg ggwgagladr Ltallrlrar prgvdvfnrg isGrtsdGrl
61  ivDalvallF laqslglpnl pPYLsgdflr GANFAsagat Ilptsgpfli QvqFkdfksq
121 vlelrqalgl lqellrlpv ldakspdlvt imiGtNDlit saffgpkste sdxnvsvpef
181 kdnlrqlikr lrsnngarii vlitlvilnl gplGClPlkl alalassknv dasgclerln
241 eavadvfneal relaiskled qlrkdglp dv kgadvpyvdl ysifqldlgi qmpsayvyGF
301 ettkaCCGyG gryNynrvCG naglcnvtak aCnpssylls flfwDgfHps ekGykavAea
361 1

```

FIGURE 13

(SEQ ID No. 3)

```

1  mkkwfvcllg lvaltvqaad srpafsrivm fgdsldstgk myskmrgylyp sspyyegrif
61  sngpvwleql tnefpgltia neaeggtav aynkiswnpk yqvinnldye vtqflqkdsf
121 kpddlvlwv gandylyayw nteqdakrvr daisdaanrm vlngakeill fnlpdlgqop
181 sarsqkvvea ashvsayhnq lllnlarqla ptgmvkifei dkqfaemlrd pqnfglsdqr
241 nacyggsyvw kpfasrsast dsqlsafnpq erlaiagnpl laqavaspma arsastlnce
301 gkmfwdqvhp ttvvhalse paatfiesqy eflah

```

FIGURE 14

SEQ ID No. 4

```
1 mkkwfvcllg lialtvqaad trpafsrivm fgdsldstgk myskargylyp ssppyyegrif
61 sngpwwleql tkqfpgltia neaeggataw aynkiswmpk ygvynldye vtqflqkdsf
121 kpddlvilwv gandylaygw nteqdaqrwr daesdaanrm vlngakqill falpdilggnp
181 sarsqkvvea vshvsayhbk lllnlargla ptgmvlkfei dkqfaemlrd pqnfglsdve
241 npcydggvww kpfatrsvst drqlsafspq erlaiagnpl laqavaspmma rrsaspince
301 gkmfwdgvhp ttvhaalse raatfietqy eflahg
```

FIGURE 15

SEQ ID No. 5

```
1 mpkpalrrvm tatvaavgtl algltdatah aapaqatptl dyvalgdsys agsgvlpvdp
61 anllclrsta nyphviadtt garltdvtcg aaqtadftra qyppvapqld algtgtdlvt
121 ltiggndnst finaitacgt agvlsggkgs pckdrhgtsf ddeieantyp alkeallgvr
181 arapharvaa lgywitpat adpscflklp laagdvpylr aiqahldav rraaetgat
241 yvdfsgvsdg hdaceapgr wiepllfghs lvpvhpnalg errmaehtmd vlgld
```

FIGURE 16

SEQ ID No. 6

```
1 mpkpalrrvm tatvaavgtl algltdatah aapaqatptl dyvalgdsys agsgvlpvdp
61 anllclrsta nyphviadtt garltdvtcg aaqtadftra qyppvapqld algtgtdlvt
121 ltiggndnst finaitacgt agvlsggkgs pckdrhgtsf ddeieantyp alkeallgvr
181 arapharvaa lgywitpat adpscflklp laagdvpylr aiqahldav rraaetgat
241 yvdfsgvsdg hdaceapgr wiepllfghs lvpvhpnalg errmaehtmd vlgld
```

FIGURE 17

SEQ ID No. 7

```
1 mdyekfillfg dsitefafnt rpiedgkdqy algaalvney trkmdilqrg fkgysrwal
61 kilpeilkhe snivmatifl gandacsagg qsvplpefid nirqmvslmk sybirpiiig
121 pglvdrekwe kekseeialg yftrnenfai ysdalaklan eekvpfvaln kafqegggda
181 wqqlitdglh fsgkykifh dellkvietsf ypqyhpkmq yklkdwravl ddgsnims
```


12/37

FIGURE 18

(SEQ ID No. 8)

10	20	30	40	50	60
MNLRQWMAA	TAALALGLAA	CGGGGTDQSG	NPNVAKVQRM	VVFEDSLSDI	GTYPVVAQAV
70	80	90	100	110	120
GGGKFTTNPQ	PIWAETVAAQ	LGVILTEAVM	GYATSVQNCF	KAGCFDYAQS	GSRVTDENGI
130	140	150	160	170	180
GHNGGAGALT	YFVQQQLANF	YAASNNTFNG	NNDVVFVLAG	SNDIFFWTTA	AATSGSGVTF
190	200	210	220	230	240
AIATAQVQQA	ATDLVGVKQD	MIAKGATQVY	VFNLPDSSLT	PDGVASGTTG	QALLHALVGT
250	260	270	280	290	300
FNTTLQSGLA	GTSARIIDFN	AQLTAAIQNG	ASFGFANTSA	RACDATKINA	LVPSAGGSSL
310	320	330	340		
FCSANTLVAS	GADQSYLFAD	GVEPTTAGHR	LIASNVLARL	LADNVAH	

FIGURE 19 (SEQ ID No. 9)

1 migsyvavgd sftegvdpq pdgafvgwad riaviladr pegdfiytnl avgrldqj
 61 vaecqrvrvq lapdlvsfaa ggndirpqt dpdevaerfe lavaallaa gtvivtfgid
 121 tgvpvikhl rgklatyngh vraidnygc pvidhstns vqdmawdad rihlspgth
 181 nvaagqal glrvpadpca pwpplpprgl ldvrddvhw areyivpwig rirgessgd
 241 hvtagtlsp daikriaav a

FIGURE 20

(SEQ ID No. 10)

1 mqlnpaytsl vavgsfiteg msdlipdgsy rgwadllar maarspgfry anlavgki
 61 gqivdeqvov aaamgadvil vggindlr pkcdmarvrd liqaverla phceqvlnr
 121 spgrgqvle rfrpmealv avidlagrh gavvvdhyga qsladprmwv vdrthkaeg
 181 hrvaaavwq sighepedpe whapipalpp pgwviriad vfarqhlip wigrilrfs
 241 sgdglpakrp dlipyedpar

FIGURE 21

(SEQ ID No. 11)

1 mtrgrdggag apptkhrall aaivilvai saaiyagasa ddsrdhalq aggrprgda
 61 apastgawvg awatapaaae pgieltglag rsvmvvhts vgggaritl snlygqspit
 121 vthasialaa gpdtaaaiaad tmrlfjggs arviipaggq vmsdrtarlai pyganvvit
 181 yspipsgpvi yhpqarqtsy ladgrtadv tavaytipv ywryltadv lshadglv
 241 afgdsidga rsgsdanhrw tdvlaarthe aagdrdlpr ysvvnegisg nrllsrpgr
 301 padnpsglsr fqrdivlertn vkavvvkqv ndvlnspela drdailglr thvdrharg
 361 invgatitp fgygygytea retmrqevne eirsgvfdt vvdldkalrd pydprmrtd
 421 ydsghihpg dkgyamgav idlaakgaa pvka

FIGURE 22 (SEQ ID No. 12)

1 mlmsrara riaagaayg gggiglagaa avglvvaevq lamrvvgv pvrpnaqgl
 61 yggtpatgd pprlmmtdg staagqvhw agqlpgalla sglavaerp vrigsvaqpq
 121 acsdldlrqv alvtaepdrv pdicvrmvga ndvthmpat rsvrhissav rrltagaev
 181 vgtcpdltg iervrqbhw larrasqla aactigaveq ggrvslgd lgpfaqnpr
 241 elfgpdnyhp saegyataam avlpsvcaal glwpadeehp dairregitp varaaeaaas
 301 eagtevaam pitgrgpwal lkmmrvs eaepsspsgv

FIGURE 23 (SEQ ID No. 13)

1 mrgldqtrt ygrmarval aallaavlgv gvagcdsvgg dspapsgps krttapawd
 61 tpsasvaavg dsitrgfdac avlsdcpevs watgssakvd slavrllgka daaehswnya
 121 vlgamadt aqvtraaqre pelvavmaga ndacrstsa mlpvadfraa feeamatlrlk
 181 ktpkaqvys sipdlkrtws qgrtnplgkq vwkglcprsm lgdadsidsa atlrmtvrd
 241 rvadynevr evcakdrccr sddgavhefr fgltdqshwd wfhpvsdggq rlaeiayrav
 301 taknp

14/37

FIGURE 24 (SEQ ID No. 14)

1 mlsraata saillipala ligasaavsa priqatdyva lgdsyssvgv agsydsssgs
61 ckrstkypa lwaashtgr fnitacsgr tgdlakqtl pvnsgrdivs ifigndagf
121 admlicnlq gesacaria karayiqfl paqldqvyda idsrapaavv wlgypfyk
181 lggscavglis eksraainaa addinavtak raadhgfafg dvntifaghe kcsgapwlhs
241 vilpvensyh ptangoskgy lpvinsat

FIGURE 25 (SEQ ID No. 15)

1 MKKWFVCLLG LIALTVQAAD TRPAFSRIVM FGDSLSDTGK MYSKMRGYLP
51 SSPYYEGRF SNGPFWLEQL TKQFPGLTIA NEAEGGATAV AYNKISWNPK
101 YQVINNL DYE VTQFLQKDSF KPDDLVLWV GANDYLAYGW NTEQDAERVR
151 DAISDAANRM VLNQAKQILL FNLPLGQNP SARSQKVEA VSHVSAYHMK
201 LLLNLARQLA PTGMVKLFEI DRQFAEMLRD PQNFGLSDVE NPCYDGGYVW
251 KPFATRSVST DRQLSAFSPQ ERLATAGNPL LAQAVASPMA RRSASPLNCE
301 GRMFWDQVHP TTVVHAALSE RAATFIETQY EFLAHG*

FIGURE 26




FIGURE 27




Figure 2B (SEQ ID NO. 17)
17/37

Met Arg Tyr Phe Ala Ile Ala Phe Leu Leu Ile Asn Thr Ile Ser Ala
 1 5 10 15
 Phe Val Leu Ala Pro Lys Lys Pro Ser Gln Asp Asp Phe Tyr Thr Pro
 20 25 30
 Pro Gln Gly Tyr Glu Ala Gln Pro Leu Gly Ser Ile Leu Lys Thr Arg
 35 40 45
 Asn Val Pro Asn Pro Leu Thr Asn Val Phe Thr Pro Val Lys Val Gln
 50 55 60
 Asn Ala Trp Gln Leu Leu Val Arg Ser Glu Asp Thr Phe Gly Asn Pro
 65 70 75 80
 Asn Ala Ile Val Thr Thr Ile Ile Gln Pro Phe Asn Ala Lys Lys Asp
 85 90 95
 Lys Leu Val Ser Tyr Gln Thr Phe Glu Asp Ser Gly Lys Leu Asp Cys
 100 105 110
 Ala Pro Ser Tyr Ala Ile Gln Tyr Gly Ser Asp Ile Ser Thr Leu Thr
 115 120 125
 Thr Gln Gly Gln Met Tyr Tyr Ile Ser Ala Leu Leu Asp Gln Gly Tyr
 130 135 140
 Tyr Val Val Thr Pro Asp Tyr Glu Gly Pro Lys Ser Thr Phe Thr Val
 145 150 155 160
 Gly Leu Gln Ser Gly Arg Ala Thr Leu Asn Ser Leu Arg Ala Thr Leu
 165 170 175
 Lys Ser Gly Asn Leu Thr Gly Val Ser Ser Asp Ala Gln Thr Leu Leu
 180 185 190
 Trp Gly Tyr Ser Gly Gly Ser Leu Ala Ser Gly Trp Ala Ala Ala Ile
 195 200 205
 Gln Lys Glu Tyr Ala Pro Glu Leu Ser Lys Asn Leu Leu Gly Ala Ala
 210 215 220
 Leu Gly Gly Phe Val Thr Asn Ile Thr Ala Thr Ala Gln Ala Val Asp
 225 230 235 240
 Ser Gly Pro Phe Ala Gly Ile Ile Ser Asn Ala Leu Ala Gly Ile Gly
 245 250 255
 Asn Glu Tyr Pro Asp Phe Lys Asn Tyr Leu Leu Lys Lys Val Ser Pro
 260 265 270
 Leu Leu Ser Ile Thr Tyr Arg Leu Gly Asn Thr His Cys Leu Leu Asp
 275 280 285
 Gly Gly Ile Ala Tyr Phe Gly Lys Ser Phe Phe Ser Arg Ile Ile Arg
 290 295 300
 Tyr Phe Pro Asp Gly Trp Asp Leu Val Asn Gln Glu Pro Ile Lys Thr
 305 310 315 320
 Ile Leu Gln Asp Asn Gly Leu Val Tyr Gln Pro Lys Asp Leu Thr Pro
 325 330 335
 Gln Ile Pro Leu Phe Ile Tyr His Gly Thr Leu Asp Ala Ile Val Pro
 340 345 350

 Ile Val Asn Ser Arg Lys Thr Phe Gln Gln Trp Cys Asp Trp Gly Leu
 355 360 365
 Lys Ser Gly Glu Tyr Asn Glu Asp Leu Thr Asn Gly His Ile Thr Glu
 370 375 380
 Ser Ile Val Gly Ala Pro Ala Ala Leu Thr Trp Ile Ile Asn Arg Phe
 385 390 395 400
 Asn Gly Gln Pro Pro Val Asp Gly Cys Gln His Asn Val Arg Ala Ser
 405 410 415
 Asn Leu Glu Tyr Pro Gly Thr Pro Gln Ser Ile Lys Asn Tyr Phe Gln
 420 425 430
 Ala Ala Leu His Ala Ile Leu Gly Phe Asp Leu Gly Pro Asp Val Lys
 435 440 445
 Arg Asp Lys Val Thr Leu Gly Gly Leu Leu Lys Leu Glu Arg Phe Ala
 450 455 460
 Phe
 465

Figure 29 (SEQ No. 18)

18/37

Met Arg Tyr Phe Ala Ile Ala Phe Leu Leu Ile Asn Thr Ile Ser Ala
 1 5 10 15
 Phe Val Leu Ala Pro Lys Lys Pro Ser Gln Asp Asp Phe Tyr Thr Pro
 20 25 30
 Pro Gln Gly Tyr Glu Ala Gln Pro Leu Gly Ser Ile Leu Lys Thr Arg
 35 40 45
 Asn Val Pro Asn Pro Leu Thr Asn Val Phe Thr Pro Val Lys Val Gln
 50 55 60
 Asn Ala Trp Gln Leu Leu Val Arg Ser Glu Asp Thr Phe Gly Asn Pro
 65 70 75 80
 Asn Ala Ile Val Thr Thr Ile Ile Gln Pro Phe Asn Ala Lys Lys Asp
 85 90 95
 Lys Leu Val Ser Tyr Gln Thr Phe Glu Asp Ser Gly Lys Leu Asp Cys
 100 105 110
 Ala Pro Ser Tyr Ala Ile Gln Tyr Gly Ser Asp Ile Ser Thr Leu Thr
 115 120 125
 Thr Gln Gly Glu Met Tyr Tyr Ile Ser Ala Leu Leu Asp Gln Gly Tyr
 130 135 140
 Tyr Val Val Thr Pro Asp Tyr Glu Gly Pro Lys Ser Thr Phe Thr Val
 145 150 155 160
 Gly Leu Gln Ser Gly Arg Ala Thr Leu Asn Ser Leu Arg Ala Thr Leu
 165 170 175
 Lys Ser Gly Asn Leu Thr Gly Val Ser Ser Asp Ala Glu Thr Leu Leu
 180 185 190
 Trp Gly Tyr Ser Gly Gly Ser Leu Ala Ser Gly Trp Ala Ala Ile
 195 200 205
 Gln Lys Glu Tyr Ala Pro Glu Leu Ser Lys Asn Leu Leu Gly Ala Ala
 210 215 220
 Leu Gly Gly Phe Val Thr Asn Ile Thr Ala Thr Ala Glu Ala Val Asp
 225 230 235 240
 Ser Gly Pro Phe Ala Gly Ile Ile Ser Asn Ala Leu Ala Gly Ile Gly
 245 250 255
 Asn Glu Tyr Pro Asp Phe Lys Asn Tyr Leu Leu Lys Lys Val Ser Pro
 260 265 270
 Leu Leu Ser Ile Thr Tyr Arg Leu Gly Asn Thr His Cys Leu Leu Asp
 275 280 285
 Gly Gly Ile Ala Tyr Phe Gly Lys Ser Phe Phe Ser Arg Ile Ile Arg
 290 295 300
 Tyr Phe Pro Asp Gly Trp Asp Leu Val Asn Gln Glu Pro Ile Lys Thr
 305 310 315 320
 Ile Leu Gln Asp Asn Gly Leu Val Tyr Gln Pro Lys Asp Leu Thr Pro
 325 330 335

Gln Ile Pro Leu Phe Ile Tyr His Gly Thr Leu Asp Ala Ile Val Pro
 340 345 350
 Ile Val Asn Ser Arg Lys Thr Phe Gln Gln Trp Cys Asp Trp Gly Leu
 355 360 365
 Lys Ser Gly Glu Tyr Asn Gln Asp Leu Thr Asn Gly His Ile Thr Glu
 370 375 380
 Ser Ile Val Gly Ala Pro Ala Ala Leu Thr Trp Ile Ile Asn Arg Phe
 385 390 395 400
 Asn Gly Gln Pro Pro Val Asp Gly Cys Gln His Asn Val Arg Ala Ser
 405 410 415
 Asn Leu Glu Tyr Pro Gly Thr Pro Gln Ser Ile Lys Asn Tyr Phe Glu
 420 425 430
 Ala Ala Leu His Ala Ile Leu Gly Phe Asp Leu Gly Pro Asp Val Lys
 435 440 445
 Arg Asp Lys Val Thr Leu Gly Gly Leu Leu Lys Leu Glu Arg Phe Ala
 450 455 460
 Phe His His His His His His
 465 470

FIGURE 31
(SEQ ID No. 19)

1 migsyavgd stegvgdpg pdgafvgwad rlvliadr pegdfityni avrgiiddqi
61 vaeqvprvvg lapdvsvfaa ggndilrpgi dpdevaerfe lavaabaaa gtvivttgfd
121 tgyvpvlkhl rglklatyngb vraiadrygc pvidwslrs vqdrwadad rthlspeghl
181 nvalragqal glrvpadpdq pwpppprgt kvrmdvhw areylypwig rrlgessgd
241 hvtakgtisp daikriaav a

Figure 32

(SEQ ID No. 25)

```
1  MFKFKKWFV  GLSAALMSIS  LFSATASAAS  ADSRPAFSRI  VMFGDSLSDT
51  GRMYSKMRGY  LPSSPPYYEG  RFSNGPVWLE  QLTQFPFGLT  IANEAEGRF
101 AVAYNKISWN  PKYQVINNLD  YEVTFLOKD  SFKPDVLVIL  WVGANDYLAY
151 GWNTEQDAKR  VRDAISDAAN  RNVINGAKQI  LLFNLPDLGQ  NPSARSQKVV
201 EAVSHVSAYE  NQLLLNLRQ  LAPTGMVKLF  EIDKQFAEML  RDPQNFGLSD
251 VENPCYDGGY  VWKFFATRSV  STDRQLSAFS  PQRRLAAGN  PLLAQAVASP
301 MARRSASPLN  CEGKMFWDQV  HPTTVVHAAL  SERAATFIAN  QYEFLAH**
```

FIGURE 33

(SEQ ID NO. 26)

```
MRLTRSLAASVIVFALLLALLGISPAQAAGPAYVALGDSYSSGNGAGSYIDSSGDCHRSN
NAYPARWAAANAPSSFTFAACSGAVTTDVINNQLGALNASTGLVSIITIGCNDAGFADAMTT
CVTSSDSTCLNRLATATNYINTLLARLDAVYSQIKARAPNARVVVLGYPRMYLASNPWYC
LGLSNIKRAAINTTADTLNSVISSRATAHGFRFGDVRPTFNNHELFFGNDWLHSLTLPVWE
SYHPTSTGHQSGYLPVLNANSST
```

Figure 34

SEQ ID No. 27

ZP 00058717

1 mlphpagerg evgaffialv gtpqdrirl echetprlg rcgcgervp plllpgdgv
 61 cttsstrdae tvwrkhlqpr pdggfrphlg vgcclagqgs pgvlwcgereg crfevcrdt
 121 pglstrngd spppfragws lppkcgeisq sarkipavpr yslhtrpd gprgrfvsg
 181 praatrrlf lgipalvlt altivlavpt gretlwrnwc eatqdwclgv pvdsrgpae
 241 dgefillspv qaatwgnyya lgdsyssgdg ardyypgtav kggcwsana ypelvaeayd
 301 faghlsflac sqrgyamld aidevgsqld wnsphstlvt igiggndlgf stvktcmvr
 361 vplldskact dqedairkm akfettfeel isevtrrapd arilvgypr ifpeptgay
 421 yltasnqrw lnetiqefnq qlaeavavhd eeiaasggvg svefvdyha ldgheigsde
 481 pwvngvqhrd latgvtvdrs tflpnaaghr avgervieqi etgprplya tfavvagatv
 541 dtlagevg

FIGURE 35

(SEQ ID No. 28)

1 mngspraatr rllfgipal vlvltlvt avptgretlw rrwceatqdw clgvpvdsrg
 61 qpaedgfil lspvqaatwg nyyalgsys sgdgadyyp gtavkcgcw sanaypelva
 121 eaydfaghls flacsqrgy amldaidevg sqldwnspht slvtigign dfgstvlkt
 181 cmvrpilds kactdqedai rkrmakfett feelisevrt rapdarilvv gyprifpeep
 241 tgayytilas nqrwlnetiq efnqqlaeav avhdeeciaas ggvgsvfvd vyhaldghei
 301 gsdepwvngv qhrdlatgvt vdrstflpna aghravgerv ieqietgpr plyatfavva
 361 gatvdtlage vg

FIGURE 36

(SEQ ID No. 29)

1 mrttviaasa lllagcadg arectagapp gessgiree gaeastsitd vyialgdsya
 61 amgrdqplr gepfclrssg nypellhaev tdlcogavt gdilleptlg ertlpaqvda
 121 ltedtlvtl siggndlgfg evagcileri agenaddcvd llgetigeql dqppqldrv
 181 beairdragd aqvvtgylp lvsagdcpel gdvseadrrw aveltgqine tvreaaerhd
 241 alfvlpddad ehscappqq rwadiqqqt dayplhptsa gheamaaavr dalglepvqp

FIGURE 37

(SEQ ID No. 30)

ZP 00094165

I mgqvklfar capvllalag lapaatvare aplaegaryv algssfaagp gyvgnapgpsp
 61 ercgrgtlmy phllaealkl dlvdatsga tthhvlgpwn evppqidsvn gdtrlvltti
 121 ggndvsfvgn ifaaacekma spdprcgkwr eiteewqad eemrsivrq iharaplarv
 181 vvdvitylvp psgtaamai spdriaqsr aakrlarita rvareegasl lkfishisrrh
 241 hpcsakpwsn gksapaddgi pvhpnrlgha eaaaalvklv klmk //

FIGURE 38

SEQ ID No. 31

NP 625998

I mrrfrlvgti sslvlaagaa ltgaataqaa qpaaadyva lgdsyssvgv agsyisssgd
 61 ckrstkahpy hwaahspst fdflacsgrar tgdvlsqqlg plssgtglvs isiggnadagf
 121 admnttcvlq sessclsria taeyvdstl pgkldgyysa isdkapnahv vvigyprfyk
 181 lgttciglse tkrtainkas dhlntvlaqr aaahgftfgd vrttfighel csgspwlhsv
 241 nwlmgesyh ptaagqsqgy lpvlnгаа
 //

FIGURE 39

SEQ ID No. 32

NP 827753

I mrrsritayv tsllavgca ltgaataqas paaatgyva lgdsyssvgv agsyisssgd
 61 ckrsskaypy lwqaahspss fsfmacsgrar tgdvlnqlg tlnsstglvs luggndagf
 121 sdvmttcvlq sdsaclsrin takayvdstl pgqldsvyta istkapsahv avlgyprfyk
 181 lggscлагs etkrsaimda adylnsaiak raadhgftfg dvkstftghe icsstwlhs
 241 ldllnigqsy hptaagqsqgy ylpvmsva
 //

FIGURE 40

SEQ ID No. 33

MRLTRLSAASVIVFALLLALLGISPAQAAGPAYVALGDSYSSGNGAGSYIDSSGDCHRSN
 NAYPARWAAANAPSSFFAACSGAVTIDVINNQLGALNASTGLVSITIGGNDAGFADAMIT
 CVTSSDSTCLNRLATAATNYINTLLARLDAVYSQIKARAPNARVVVLGYPRMYLASNPWYC
 LGLSNTKRAAINTTADTLNSVISSRATAHGFRFGDVRPTFNNHELFFGNDWLHSLILPVWE
 SYHPTSTGHQSGYLPVLNANSST

FIGURE 41





FIGURE 42



27/37

FIGURE 44

(SEQ ID No. 34)

ADSRPAFSRIVMFGDSLSDTGKMYSKMRGYLPSSPPYYEGRFSNGPWWLEQLTNEFPGL
LTIANEAEGGPTAVAYNKISWNPKYQVINNLDYEVTQFLQKDSFKPDDLVLWVGANDYL
AYGWNTEQDAKRVRDAISDAANRMVLNGAKEILLFNLPLDLGQNPASRSQKVVEAASHV
SAYHNQLLLNLARQLAPTGMVKLFEIDKQFAEMLRDPQNFGLSDQRNACYGGSYVWKP
FASRSASTDSQLSAFNPQERLAIAGNPLLAQAVASPMARSASTLNCE
GKMFWDQVHPTTVVHAALSEPAATFIESQYEFLAH

FIGURE 45

(SEQ ID No. 35)

1 ADTRPAFSRI VMFGDSLSDT GKMYSKMRGY LPSSPPYYEG RFSNGPWWLE QLTQKQFPGLT
61 IANEAEAGGAT AVAYNKISWN PKYQVINNLD YEVTQFLQKD SFKPDDLVLV WVGANDYLAY
121 GWNTEQDAKR VRDAISDAAN RMVLNGAKQI LLENLPLDLGQ NPSARSQKV V EAVSHVSAYH
181 NKLLLNLARQ LAPTMVKLF EIDKQFAEML RDPQNFGLSD VENPCYDGGY VWKPFATRSV
241 STDRQLSAFS PQERLAIAGN PLLAQAVASP MARRSASPLN CEGKMFWDQV HPTTVVHAAL
301 SERAATFIET QYEFLAHG

FIGURE 46

(SEQ ID No. 36)

ACAGGCCGATGCACGGAACCGTACCTTTCCGCAGTGAAGCGCTCTCCCCCATCGTTCCG
CGGGACTTCATCCGCGATTTTGGCATGAACACTTCCTTCAACGCGCGTAGCTTGCTACAA
GTGCGGCAGCAGACCCGCTCGTTGGAGGCTCAGTGAGATTGACCCGATCCCTGTGCGCCG
CATCCGTCATCGTCTTCGCCCTGCTGCTCGCGCTGCTGGGCATCAGCCCGGCCAGGCAG
CCGGCCCGCCCTATGTGGCCCTGGGGGATTCCCTATTCTCGGGCAACGGCGCCGGAAGTT
ACATCGATTGAGCGGTGACTGTCACCCGAGCAACAACCGGTACCCCGCCCGCTGGGCGG
CGGCCAACGCACCGTCCTCCTCACCTTCGCGGCCTGCTCGGGAGCGGTGACCACGGATG
TGATCAACAATCAGCTGGGCGCCCTCAACGCGTCCACCCGGCCTGGTGAGCATCACCATCG
GCGGCAATGACGCGGGCTTCGCGGACGCGATGACCACCTGCGTCAACAGCTCGGACAGCA
CCTGCCTCAACCGGCTGGCCACCGCCACCAACTACATCAACACCACCCTGCTCGCCCGGC
TCGACGCGGTCTACAGCCAGATCAAGGCCCGTGCCCCAACGCCCGCGTGGTCTCCTCG
GCTACCCGCGCATGTACCTGGCCTCGAACCCCTGGTACTGCTGGGCTGAGCAACACCA
AGCGCGCGGCCATCAACACCACCGCCGACACCCTCAACTCGGTGATCTCCTCCCGGGCCA
CCGCCACGGATTCCGATTGCGCGATGTCCGCCCCGACCTTCAACAACCACGAAGTGTCT
TCGGCAACGACTGGCTGCACTCACTCACCCCTGCCGGTGTGGGAGTCGTACCACCCACCA
GCACGGCCATCAGAGCGGCTATCTGCCGGTCTCAACGCCAACAGCTCGACCTGATCAA
CGCACGGCCGTGCCCGCCCCGCGGTACGCTCGGCGCGGGCGCCGAGCGCGTTGATCA
GCCACAGTGCCGGTGACGGTCCCACCGTACGGTTCGAGGGTGTACGTACGGTGGCGCC
GCTCCAGAAGTGGAACGTCAGCAGGACCGTGGAGCCGTCCTGACCTCGTCAAGAAGTCT
CGGGGTCAGCGTGATCACCCCTCCCCCGTAGCCGGGGGCGAAGGCGGCGCCGAAGTCTCT
GTAGGACGTCCAGTCGTGCGGCCCGGCTTGCACCGTCCGCGTAGACCGCTTCCATGGT
CGCCAGCCGGTCCCCGCGGAAGTCCGGTGGGGATGTCCGTGCCCAAGGTGGTCCCGGTGGT
GTCCGAGAGCACCGGGGGCTCGTACCGGATGATGTGCAGATCCAAAGAATT

FIGURE 47

(SEQ ID NO. 37):

MRLTRLSAASVIVFALLLALLGISPAQAAGPAYVALGDSYSSGNGAGSYIDSSGDCHRSN
NAYPARWAAANAPSSFTFAACSGAVTTDVINNLGALNASTGLVSTIGGNDAGFADAMTT
CVTSSDSTCLNRLATATNYINTLLARLDAVYSQIKARAPNARVVVLYPRMYLASNPWYC
LGLSNTKRAINTTADTLNSVISSRATAHGFRFGDVRPTFNNHELFFGNDWLHSLTLPWWE
SYHPTSTGHQSGYLPVLNANSST

FIGURE 48

SEQ ID No. 38

1 miphpagerg evgaffallv gtpqdrtrl echetpigr rcgcgerrvp pllipgdgvl
61 ctsstrdae tvwrkhlqpr pdggfrphlg vgcclagqgs pgvlwccgreg crfevcrdt
121 pglstrmgd ssppfragws lppkcgelsq sarktpavpr yslrtidrd gprgrfvgsq
181 praatrrrf lgipalvlt alitviavpt greliwrnmc eatqdwclgv pvdsrgqpae
241 dgefillspv qaatwgnyya lgdsyssgdg ardyypgtav kggcwrsana ypelvaeayd
301 faghlsflac sgqrgyamid aidevgsqld wnsphitslv igiggndlgf stvktcmvr
361 vplidskact dqedairkm akfettfeel isevtrapd aritvgypr iipeeptgay
421 yltasnqrw lnetaqefnq qlaeavavhd eeiaasggvg svefvdyha ldgheigsde
481 pwvngvqird laigtvdrs tthpnaaghr avgerveqi etgpgriya tfavvagatv
541 dtlagevg

FIGURE 49

(SEQ ID No. 39)

1 ggfggtgaac cagaacaccc ggfcgfcggc gtagggcgtcc aggtgcaggf gcaggfctt
61 caactgctcc agcaggatgc cgcctggccc gtagcacgatc gccttgggca ggcttgggt
121 ccccgacgag tacagcacc ctagcggatg gtagaacggc agcgggggga actccagttc
181 cgcgctctc ccccgggctt cgaactccg ctaggacagg gtagcggcga caggggccga
241 gcccaggfac ggcaggacga cgggtgctg caggctgggc atgcccgtgc gcagggctt
301 gaggacgta cggcggcga agtccctacc gccctagcgg tagccgtcca cggccagcag
361 cacttccgtt tcatctgctg cgaaccggc gaggacgctg cgcaccccca agtcggggga
421 acaggacgac caggctgcac ctagcgggc gcaggcagg aatgcggcc tgcctcggc
481 gatgtcggc aggtaggcca cgaaccggc gccggggccc accccaggc tgcggagggg
541 cgcagcgaic ggcgggctg ggtcccgag tctcccccag gtagcctcgg tcaacggccc
601 gattcggac cgtgcccga tgcaccggc tagtgggta cgtcggcga agaigtctc
661 ggcgtagtg agggggcgc cggggaacca gacggcggc ggcctggcgt cggaggcag
721 cactgtggtg tacgggggg cggcggcacc ccggtatgac tccagatcg cggaccagaa
781 tctctgagg tgggtaccg accagcggc cagtgcctc tagtccggg cgtccacacc
841 gcgggtctc cgcacccagc ggtgaaacg ggtgagggt gcgctctt tgcctctc
901 gtcgggact caccagatc ggcgtcgg ctagaggtc atgaaacgc acccctctg
961 ggacggtgc gatgaggga cgtcgggtt cctccctaa cgtcccccg tagcggagt
1021 ttgtcacca catctagc cggggacgc gaaaccgat ggagaaaaca cctacaaccc
1081 cggccggacg gtaggtctc gccacacta ggggtcggg gcctgctgc cggcagggg
1141 agtcccggg tctgtggtg cggcggggg gctgtctct tagagggtg ccggcgggac
1201 actccgggc taccggtac ccgcaacgg gacagctc cctctccg ggtggatg
1261 tccctccc cgaatgccc agatctcc cagtacggc ggaacacacc cgtctgccc
1321 agctactct tctcgaac agacaggcc gacggtccac gggggagggt tgtggcagc
1381 ggaccacgt cggcggacc agacgggtt tctcggta tcccgctct tgtactgt
1441 acagcgtca cgtggtctt ggtgtccc agggggcgc agacgctg gcgctgtg
1501 tgtaggcca cccaggact gtagctggg gtagcggc actcccgg acagcctgc
1561 gaggcggc agtctctg gctctccc gtagggcag cgaactggg gaactatc
1621 gcgctggg altctact ttcggggac gggggccc actactacc cggcaccgc
1681 gtagagggc gtagtggc gtagcctaac gctatccc agctgtctc cgaagctac
1741 gactcggc gacactgt gtagctggc tgcagcggc agcggccta cgcctgct
1801 gacgctatc agaggctc ctagcagct gactggaact cccctacac gtagctgtg
1861 acgctggga tggcggcga ctagtggg tctccaccg ttgtgaagac ctgctgtg
1921 cgggtggc tctgtgac caaggcgtc acggaccag aggacgctat ccgcaagcgg
1981 atggcgaat ttagagac gttgaagag ctcatagc aagtgcgac ccgcccgg
2041 gacccggg tctgtctg ggtctccc cggatttct cggaggaaac gaccggcgc
2101 tactacagc tagcggcag caaccagcg tggctaacg aaaccattca ggagtcaac
2161 cagcagctc ccgagctgt cgcgtccac gacgaggaga tgcggcgtc gggcgggtg
2221 ggcagctg agtctgtga cgtctacc gctgtggc gccacgagat cggctcggc
2281 gaggcgtgg tagcgggtt gcagtgcg gacctggca cgggggtgac tgtgaccgc
2341 agtacctcc acccaacgc cgtgggac cggcggctg gtagcgggt catcagcag
2401 atcgaaacc gccggggcc tccgctct gccacttc cgtgggtgg gggggcacc
2461 gtagacact tgcggggc ggtgggtga cccgctac cgtccggcc gcaggctc
2521 ggcactgc gcaictgt cactgcca gtagctgc tctcggta tagcagcgc
2581 aggggagag cggatcgt agcgtgct gctttagc agcacacc cgtcaggag
2641 cgtctgac agtctctc cgtggtcc agtccggct acgtgatcc cagccacag
2701 gccgatct cggccggc ccacggct gccgaccgt tggtagggc gggcggcag
2761 caggggggc agggcggc catggtccg gtagggcc tgcggcga ggtcaccac
2821 ggcagctcc acccggcag caggggct gccggcaag gtagctcgt gctggcggg
2881 gggatcac tcaagact cgcgtgcc taccggcc gccacggca ggtgccc
2941 gcccagcgt ttccgaaca gtagatac ggcgtgact ccgctgtgt cgcaggccc

FIGURE 50

(SEQ ID No. 40)

1 vsgspraatr rrlfigipal vlvialtlvl avptgrethw rrwceatqchw cigvpvdsrg
61 qpaedgefil lsvpqaatwg nyyalgdsys sgdgardyyp gtavkggcwr sanaypeiva
121 eaydfaghls flacsggrgy amldaidevg sqldwnspht slvtigiggn dlgfstvlkt
181 cmvrpilds kacdqedai rkmakfett feelisevrt rapdarilw gyprifpeep
241 tgayytlfas nqrwlneti qefnqqlaeav avhdeelaas ggvgsvfvd vyhaldghei
301 gsdepwvngv qlrdlatgvt vdrsthpna aghravger v ieqietgpg r plyatfavva
361 gatvdlage vg

FIGURE 51

(SEQ ID No. 41)

1 mrttviaasa lllagcadg areetagapp gessggiree gaeastsitd vyialgdsya
61 amggrdqplr gepfclrssg nypellhaev tdlcqqgavt gdllprrtg ertipaqvda
121 ltedttvtl siggndlgf evagcieri agenaddc vd lletigeql dqppqldrv
181 heairdragd aqvvtgylp lvsagdcpe l gdvseadrw aveltgqine tvreaaerhd
241 alfvlpddad ehscappqq rwadiqqqt dayplhptsa gheamaaavr dalglepvqp

FIGURE 52

(SEQ ID No. 42)

1 ttctgggggt ttatgggggt gttatcggct cgtcctgggt ggaiccggcc aggtggggta
 61 ttacgggggg actttgtgt ccaacagccg agaatgagtg cctgagcgg tgggaatgag
 121 gggggcgggg ctgtgtcggc atgagggggc ggcgggctct ggggtcccc gcgaaccccc
 181 gccccgggta gcggtgaatg aatcgggct gtaatcagca tcccggtccc acccgtcgg
 241 ggaggtcagc gcccgagtg tctacgagc cggatccct cggactcggc catgctgtcg
 301 gcagatcgc gctcccgggt ctggcgtcc ctgggctgt ctgctgtcg tccctggaag
 361 gcgaaatgat caccggggag tgatacaccg ggggtctcat cccggaigcc cacttcggc
 421 caatcggcag atcggggcag ctccgggtgg aagtaggggg catccgatgc gtcggtgacg
 481 ccatagtggg cgaagatct atcctgtcgg aggggtgctca ggccactctc cggatcgata
 541 tcggggggcgt cctgatggc gtcctgtcg aaaccgaggt gcagctgtg ggctccaat
 601 ttgcaccac ggagcgggac gaggctgga tgacggccga agagcccgtg gtggacctca
 661 acgaaggtgg gtagtcccgt gicatcatg aggaacacgc cctccaccgc acccagctg
 721 tggccggagt gtcgtaggc gctggcatcc agaagggaaa cgaatcicata ttgtcggtg
 781 tgctcagaca tgatctct ttgctgtcgg tctctgttac taaccggta gggctgaatg
 841 caactgtat ttctgtta ttttagaat tggccatat cccacaggct ggctgtggc
 901 aatcgtcat caagtaatcc ctgtcacaca aatgggtgg tggagccct ggctcgggt
 961 ccgtgggagg cgcctgtccc cgcaggatcg tcggcatcgg cggatcggc cgtaccaccg
 1021 cgtgaataa aatcaltctg taaccticat cagggttgg tttagglatc cggcccttc
 1081 gtctgacct cgtcccggc gcgcgggagc ccgcgggtg cggtagacag gggagacgtg
 1141 gacacatga ggacaacggt catcgcagca agcgcaltac tctctctgc cggatcggc
 1201 gatggggccc gggagggagc cgcgggtgca ccgcccggg agtctcccgg gggatccgg
 1261 gaggggggg cggagggcgc gacaagcatic accgactct acatcgcct cggggaltcc
 1321 taicggcga tggcggggc ggtacagccg ttaccgggtg agccgtctg cctcgtcctg
 1381 tccgtaait acccggaaact ctccacgca gaggtaacc atctaccctg ccaggggggc
 1441 gtagccggg atctgtctga acccaggagc ctgggggagc gcacgctgcc ggcgcagggt
 1501 gatcgtctga cggaggacac caccctggc accctctca tgggggcaa tgacctgga
 1561 ttccgggagg tggcgggatg catccgggaa cggatcggc gggagaacgc tgatgattg
 1621 gtagacctgc tgggggaaac catcggggag cagctcagc agctcccc gcagctggac
 1681 cgcgtgcagc aggtatccc ggaaccggc ggggacgcgc aggtgtgtt caccggtac
 1741 ctgcgtcctg tctgtcggc ggaactgccc gaactgggg atgtctcca ggcggatct
 1801 cgtggggcg ttgagctgac cgggcagatc aacgagaccg tgcgcagggc ggcgaacga
 1861 cagatgccc tcttctct gcccagcat gccgatgagc acaccagtg tgcacccca
 1921 cagcagcgt gggcggatg ccagggcaa cagaccgat cclatccgt gacccggac
 1981 tcccgggc atgagcgtg gcccggcc gtcggggagc cgtgggctt ggaaccggtc
 2041 cagccgtagc gccgggccc cgtgtctga cgaaccaacc atgccaggct gcagtcacat
 2101 ccgcacatag cgcgcgcggc cgtatggatg cgcacatag aggatgagcc cgtgcccag
 2161 gatgatgagc agcacactg cgaaggggtg ttccccgagg gtgcgagag ccgagtcag
 2221 acctcggcc tctccggat catggggcca accggcgtg acgatcaaca ccccaggat
 2281 cccgaaggcg ataccacggc cgaataacc ggctgtccg gtgatgata tgcgggtccc
 2341 gacctgccc gacccgcac ccgctccag atctcccg aaatcccgg tggccccct
 2401 ccagaggtg tagacaccg ccccagtac caccagccc gcgaccaca ccagcaccac
 2461 acccagggt tgggatagga cgttggcgt gacatcgtg cgggtctcc calcggaggt
 2521 gctgcccgc cggcgaagg tggaggtgt caccgccag gagaagtaga ccatggccat
 2581 gaccgcccc tggccctt cctgaggtc ctgcccgc agcagctgc tcaatgcca
 2641 gactccagg gccgcaggc cgtgacggc aaccacagg aggaactgcc caccggagc
 2701 ctccggatg gggccaggc cactgaat cgaagcctca tcaccgaac cgcggatcc
 2761 agtggcgtg cgcaccgca tcaccgat gaggatgtc agtatccca ggacaatgaa
 2821 accacctg gccagggtg tcagcggg ggggtctc gccgtgtc cagccccgtc
 2881 gatcgtcct ttcgggatc tgggtcggc ctatcata gctccatg aaccgctg
 2941 aggggtggc gccactgc agggcggtt gtatctgaa ctgtgatgt ccatcaacc

FIGURE 53

(SEQ ID No. 43)

1 mrrfrivgfl ssMlaagaa lgaataqaa qpaaadgyva lgdsyssvgv agsyissgd
 61 ckrstkahpy lwaaahspst fdfitacgar tgdvisgqlg plssgtglvs isigndagf
 121 admtticvlq sessclsria taeayvdstl pgkldgvysa isdkapnahm vvigyrfyk
 181 lgttciglse tkrtainkas dhlnvlaqr aaahgftgd vrtftghel csqspwihsv
 241 nwlhigesyh ptaagqsggy lplvngaa

Figure 54

(SEQ ID No. 44)

1 cccggcggcc cgtgcaggag cagcagccgg cccgcgatgt cctcgggctt cgtctcacc
 61 aggccgtcca tcgctcggc gaccggcggc gtglagtgg cccggaccct gtcccagggtg
 121 cccgcggcga tctggcgggt ggtgcgggtc gggcccgcc gaggggagac gtaccagaag
 181 cccatcgtca cgtctccgg clgcggttcg ggtcgtccg ccgctccgtc cgtcgcctc
 241 ccgagcact tctcggcgg gtcggcgtg gtcgccga ccgtgacgtc ggcgccccg
 301 ctccagcgcg agatcagcag cgtccagccg tcgcoctccg ccagcgtcgc gctcgggtc
 361 tctcgcggg cgtaccag cagcgcggc cggggcggca gcagcgtggc gccggaccgt
 421 acgcggtcga lgttcggcgc gtcgagtac ggtcgtcac ccgtggcga acggccgagg
 481 aacagcgtc cagcagcgtc ggacggggag tgcgtgtcgt ccacgttgag ccggaicggc
 541 agggcttcgt gcgggtcac ggacatgtc ccatgatcgg gcacccggcc gccgcgtgca
 601 cccgcttcc cgggcaagca cagcaggggc ttctcggcc tctccgtcc gaactgaac
 661 gaggtcagc cacttctgg catggacact tccagcaac gcgcgtagct gctaccacgg
 721 tctggcagc aatcctgcta agggaggctc catgagactt tccgactfg tggcttct
 781 gagttcgtc gtcctcggc ccggcggcc cctcaccggg gcagcgaccg cccaggcggc
 841 ccaaccggcc gccgcgacg gctatgtgg cctcggcggc tctactctc cgggggtcgg
 901 agcggcagc tacatcact cagcggcga ctgcaagcgc agcaggaagg cccatcccta
 961 cctgtgggcc gccggcact cgcctccac gttcagctc accgctgtt ccggcggcc
 1021 tacgggatg gttctcggc gacagctcg cccgctcagc tccggcaccg gccctgtc
 1081 gatcagcacc ggcggcaac acgcccgtt cgcggacacc atgacgacct gttgtccta
 1141 gtccgagagc tctgcctgt cgcggtcgc caccggcgg gctacgtcgc actcagcgt
 1201 gcccgcaag ctgacggcg tctactcggc aatcagcagc aagcggcga acgcccact
 1261 cgtctcacc ggtaccgc gcttctaca gctcggcacc acctcactg gccgtcga
 1321 gaccaagcgg acggcgtatc acaaggcctc cgaccacctc aacaccgtcc tgcggcggc
 1381 cgcggcggcc cagcgttca cctcggcga cgtacgcacc acctcaccg gccacgagct
 1441 gtcctcggc agcccgtgc tgcacagct caactggctg aacatcggcg agtctgacca
 1501 cccaccggc gccggccagt ccggtggcta cctcggcgtc ctcaacggcg ccgctcacc
 1561 tcagggcga ggagaagaag aaggagcga gggagcagc gagtgggagg cccgcccga
 1621 cggggctccc gtcccgtct ccgtctcgt cccggctccg caagtaccg agaacgcc
 1681 cgcgctggc gtcggcggc ccgactccg cactccacg cgcacggcac tctgaacgc
 1741 gccggtgtc tctgctcgc taccaccac gccgtctgg cgcgagcgt cgcggccga
 1801 agcgaaggac agcgtcggc accccggatc ggagaccgac ccgtccggc taccaccg
 1861 gtagccgacc tccggcggc gccggcagc cgtgaacgt gccgtgaac cgggtgccc
 1921 gtcgtcggc ggcggacag ccccgagta gtcggtcgc gagcccacca cgtcaccct
 1981 caccgactgc gctcggggc

FIGURE 55

(SEQ ID No. 45)

1 mrrsitayv tlllavgca lgaataqas paaaatgyva lqdsyssvgv agsylsssgd
 61 ckrsskaypy iwqaahspss fsmacsgr tgdlanqlg tinsstglvs lüggndagf
 121 sdvmttcvlg sdsacisrin takayvdstl pggldsvyta istkapsahv avlgyprfyk
 181 lggscclags etkrainda adylnsaiak raadhgftfg dvkstftghe icssstwlhs
 241 kllnigqsy hptaagqsgg ylpvmnsva

FIGURE 56

SEQ ID No. 46

1 ccaccgcccgg gtcggcggcg agtctcctgg cctcggctgc ggagagggtg gccgtgtagc
 61 gctcagcgc ggcgccgaac gctctctca ccgtgccgc gfactcgtg atcaggccct
 121 tgcctgtct cgacgcggcc tgaagccgg tgcctctt gagcgtgacg atgtagctgc
 181 cctgatcgc ggigggggg cggcggcga gcaccgtgc ctcggccggg gtggcctggg
 241 cgggcagtc ggtagatccg cccacgaggg cgcggctgc cacggcgtt atcgcggcga
 301 tccgatctt ctgctacgc agctgtcca tacgaggag tctctctg ggcagcggcg
 361 gcctggggg gggcgcacgg ctgtggggg tgcgcgctc atcacgcaca cggccctgga
 421 gcgtcgtgt ccgccctgg ttgagtaaag cctcggccat ctacgggggt ggctcaaggg
 481 agltgagacc ctgtcatgag tctgacatga gcacgcaatc aacggggccg tgagcaccct
 541 ggggcgacc cggaaagtgc cgagaagtct tggcatggac acttctctc aacacgcgta
 601 gctggtacga cggttacggc agagatcctg ctaaaggggg gttccatgag acgttcccga
 661 attagggcat acgtgacct actctctc gccgtcgtt gcgcctcac cggggcagcg
 721 acggcgcagg cgtcccagc cgcggcggcc acgggctatg tggccctcg cactctgac
 781 tctccgggt tggcgcggc cagctacct agctcagcg gcgactgca gcgcagttc
 841 aaggcctat cgtacctg gcaggcggc catcaccct cgtcgtcag ttcatggct
 901 tctcggggc ctgtacggg tgatgtctg gccaatcagc tcggcaccct gaactctcc
 961 accggcctg tctccctac catcggaggc aacgacggc gcttctcga cgtcatgacg
 1021 acctgtgtc tccagtcga cagcgcctgc ctctccgca tcaacacggc gaaggcgtac
 1081 gtcgactcca cctgcccgg ccaactcagc agcgtgtaca cggcagatcag cacgaaggcc
 1141 ccgtcggccc atgtggcctg gctggctac ccccgctct acaaactgg cggctcctg
 1201 ctgcggggc tctcggagc caagcggct gccatcaac acgcggcga ctatctaac
 1261 agcgcctat ccaagcgcgc cgcgacct gcctcacct tcggcgact caagagcacc
 1321 taccggcc atgagatct ctccagcagc acctggctgc acagctcga cctgtgaac
 1381 atcggccagt cctaccacc gaccgcggc ggcagtcg cgggctatct gccgtcatg
 1441 aacagcgtg cctgagctc caggcctga attttaagg cctgaattt taaggcgaag
 1501 gtaaccgga agcggaggcc cgtccgtc gggctcctg cgcacaggtc accgagaacg
 1561 gcacggaglt ggacgtctg cgcaccggg cgcgcacct gacggcgtc tctgtgaga
 1621 tcttccgt cgtgtctac gggtagca acacctgt ctgtgggtc ttccgcgc
 1681 tgcggggaa ggacagctc tccagccc gatccgggac ctgccttc ttggtaccc
 1741 agcgttact cactcagc ggcaccggc ccaccgtgaa ggtcggctg aacgtggcg
 1801 cctggcggg gggcggcgg caggcaccg agtagtcgt gtcacgcg gtagccgta
 1861 ccttcacgga ctggcggc ggggtctct taccgcgc gccaccgc cctccggag
 1921 tggagcccga gctgtgtc ccccgcct cggcgtgt gicctcggg gtttcaac

FIGURE 57

SEQ ID No. 47

1 mgsgraatr rfiigipal vivtaltvl avptgrethw mmwceatqdw clgvpvdsrg
61 qpæedgefii lspvqaatwg nyyalgdsys sgdgardyyp glavkggcwr sanaypelva
121 eaydfaghls flacsgqrgy amldaidevg sqldwnspht slvtigiggn dfgfstvikt
181 cmrvrvplds kactdqedai rkmakfett feelisevrt rapdarilv gyprifpeep
241 tgayytilas nqrwlneiq efnqqlaeav avhdeeiaas ggvgsvfevd vyhaldghei
301 gsdepwvngv qlrdlatgt vdrstfhpna aghravgerv iqietgpgr plyatfavva
361 gatvdtlage vg

FIGURE 58

SEQ ID No. 48

1 ctgcagacac ccgccccgcc ttctcccgga tegtcatgtt cggcgactcc ctacagcaca
61 ccggcaagat glactccaag atgcgcggct acctgccgtc ctccccgcc tactacgagg
121 gccgctctc gaacggcccc gictggctgg agcagctgac gaagcagttc cccggcctga
181 cgatcgcaa cgaggccgag gggggcgcga ccgcagtcgc ctacaacaag atctcctgga
241 acccgaagta ccaggtcalt aacaacctcg actacgaggt caccagttc ttgcagaagg
301 actcgttcaa gcccgacgac ctggtaacc tgtgggigg cgccaacgac tacctggcct
361 acggftgaa cacggagcag gacgccaagc gggfgcgcga cgccatctcg gacgcggcaa
421 accgatggt cctgaacggc gcgaagcaga tctgtctgt caacctgcc gacctgggcc
481 agaaccgctc cgcccgtcc cagaaggctg tcgaggccgt ctgcacgtg tccgctacc
541 acaacaagct gctctcaac ctgccccgc agctcgcgcc gacgggcatg gtaagctgt
601 tcgagatga caagcagttc gcggagatgc tgcgcgccc ccagaacttc ggctgagcg
661 acgtggagaa cccgtgctac gacggcggct acgtgtgaa gccgttcgcc acccggctcc
721 tctgaccga ccggcagctg tcggcctct cccccagga gcgctggcg atcgtggca
781 acccgtcct ggcaaggcg gtgcttcgc cgtggccc cgcctcggcc tcgccccta
841 actgcgagg caagatgtc tgggaccagg tccacccac caccgtggc cacgcccgc
901 tctggagcg ccgcccacc ttcatcgaga ccagtacga gttcctgcc cactagtcta
961 gaggatcc

Figure 59




Figure 60




Figure 61

- 1. L131
- 2. S. avermitilis
- 3. T. fusca
- 4. Consensus

```

1          1                               50
1 (1) -----MRLTRSLSAASVIVFALLLALLGISPAQAAG-----
2 (1) -----MRRSRITAYVTSLLLAVGCALTGAATAQASPA-----
3 (1) VGS GPRAATRRRLFLGIPALVLTALTLVLAVPTGRETLWRMWCEATQDW
4 (1)          MRRSRFLA  ALILLTLA  AL  GAA  ARAAP

1          51                               100
1 (32) -----P-AYVALGDSYSSGNGAGSYID
2 (33) -----AAATGYVALGDSYSSGVGAGSYLS
3 (51) CLGVPVDSRGPQPAEDGEFLLLSPVQAATWGNYYALGDSYSSGDGARDYYP
4 (51)          A A  YVALGDSYSSG  GAGSY

1          101                              150
1 (53) SSGD---CHRSNNAYPARWAAANAP---SSFTFAACSGAVTTDVIN---
2 (57) SSGD---CKRSSKAYPYLWQAAHSP---SSFSFMACSGARTGDVLA---
3 (101) GTAVKGGCWRSANAYPELVAEAYDFA--GHLSFLACSGQRGYAMLDAIDE
4 (101) SSGD  C RSTKAYPALWAAAHA      SSFSF  ACSGARTYDVLA

1          151                              200
1 (93) --NQLGALNAST--GLVSITIGGNDAGFADAMTTCVTS-----SDSTCL
2 (97) --NQLGTLNSST--GLVSLTIGGNDAGFSDVMTTCVLQ-----SDSACL
3 (149) VGSQLDWNSPHT--SLVTIIGGNDLGFSTVLKTCMVR-----VPLLDS
4 (151)  QL  LNS  T   LVSITIGGNDAGFAD  MTTCVL      SDSACL

1          201                              250
1 (133) NRLATATNYINTLLA-----RLDAVYSQIKARAPNARVVVLGYPERMY
2 (137) SRINTAKAYVDSTLPG-----QLDSVYTAISTKAPSAHVAVLGYPRFY
3 (191) KACTDQEDAIRKMAKF----ETTFEELISEVRTRAPDARILVVGYPRI
4 (201)  RIA  AK  YI  TLPA          RLDSVYSI  TRAP  ARVVVLGYPRIY

1          251                              300
1 (176) LASNPWYCLGLSNTKRAAINTTADTLNSVISSRATAH-----GF
2 (180) KLGGSCLAGLSETKRSAINDAADYLNSAIKRAADH-----GF
3 (237) PEEPTGAYYTLTASNORWLNETIQEFNOQLAEAVAVHDEEIAASGGVGSV
4 (251)  SG   LGLS  TKRAAINDAAD  LNSVIKRAADH      GF

1          301                              350
1 (215) RFGDVRPTFNNHELFFGNDWLHSLTLP-----VWESYH
2 (218) TFGDVKSTFTGHEICSSSTWLHSLDLLN-----IGQSYH
3 (287) EFDVYHALDGHEIGSDEPWVNGVQLRDLATG-----VTVDRSTFH
4 (301) TFGDV  TF  GHELCSA  PWLHSLTLP          V  SYH

1          351                              395
1 (248) PTSTGHQSGYLPVLNANSST-----
2 (252) PTAAGQSGGYLPVMNSVA-----
3 (328) PNAAGHRVGERVIEQIETGPRPLYATFAVVAGATVDTLAGEV
4 (351) PTA  GHAAGYLPVLNSI  T
    
```

PCT/GB2005/002823

A. CLASSIFICATION OF SUBJECT MATTER
 IPC 7 C11B3/00 C11C3/00 C07F9/10

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED
 Minimum documentation searched (classification system followed by classification symbols)
 IPC 7 C11B C11C C07F

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)
 EPO-Internal, WPI Data, PAJ, FSTA, BIOSIS, CHEM ABS Data, EMBL

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 2004/005399 A1 (CHAKRABARTI PRADOSH PRASAD ET AL) 8 January 2004 (2004-01-08)	1-4, 8-13, 27-37, 51-57
Y	the whole document	5-7, 14-26, 38-50
X	WO 03/100044 A (SCANDINAVIAN BIOTECHNOLOGY RESEARCH AB; DAHLQVIST, ANDERS; GHOSAL, AL) 4 December 2003 (2003-12-04) page 18, paragraph 3; claim 1 -/-	1-4, 8-13, 27-37, 55-57

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

- * Special categories of cited documents:
- *A* document defining the general state of the art which is not considered to be of particular relevance
 - *E* earlier document but published on or after the international filing date
 - *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
 - *O* document referring to an oral disclosure, use, exhibition or other means
 - *P* document published prior to the international filing date but later than the priority date claimed
 - *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
 - *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
 - *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
 - *Z* document member of the same patent family

Date of the actual completion of the international search
 24 October 2005

Date of mailing of the international search report
 16/11/2005

Name and mailing address of the ISA
 European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax. (+31-70) 340-3016

Authorized officer
 Rooney, K

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	KIM CLAUSEN: "New enzyme for degumming" OILS AND FATS INTERNATIONAL, vol. 17, no. 4, June 2001 (2001-06), pages 24-25, XP008054279 GB INTERNATIONAL TRADE PUBLICATIONS, REDHILL, the whole document	1-3, 8-13, 30-37, 55-57
X	KIM CLAUSEN: "Enzymatic oil-degumming by a novel microbial phospholipase" EUROPEAN JOURNAL OF LIPID SCIENCE AND TECHNOLOGY., vol. 103, 2001, pages 333-340, XP002350666 DEWILEY VCH VERLAG, WEINHEIM. the whole document	1-4,8, 10-13, 27-37, 51-53
X	DATABASE EMBL 'Online! EBI; 1 March 2001 (2001-03-01), LACHMANN, I., GUDMUNSDOTTIR, B., ATREYA, C.,: "Glycerophospholipid-cholesterol acyltransferase" XP002350670 retrieved from EBI Database accession no. Q9F7Y6 abstract	54
Y		5-7, 14-26, 38-50
A	WO 01/16308 A (MONSANTO COMPANY; LASSNER, MICHAEL; VAN EENENNAAM, ALISON; MONSANTO TE) 8 March 2001 (2001-03-08) page 11, paragraph 4 page 25, paragraph 2	1-57
P, A	MONJUR HOSSEN AND ERNESTO HERNANDEZ: "Phospholipase D-catalyzed synthesis of novel phospholipid-phytosterol conjugates" LIPIDS, vol. 39, August 2004 (2004-08), pages 777-782, XP008054148 USCHAMPAIGN, IL abstract	1-57
A	J. GRAILLE: "Possible applications of acyl-transferases in oleotechnology" LIPID TECHNOLOGY, vol. 5, no. 1, 1993, pages 11-16, XP008054101 GBBARKING ESSEX the whole document	1-57

Information on patent family members

PCT/GB2005/002823

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 2004005399 A1	08-01-2004	AU 2003250528 A1	19-12-2003
		CN 1659259 A	24-08-2005
		NO 03102118 A2	11-12-2003
		JP 2005527237 T	15-09-2005
WO 03100044 A	04-12-2003	AU 2003232714 A1	12-12-2003
		EP 1507854 A1	23-02-2005
WO 0116308 A	08-03-2001	AU 7092900 A	26-03-2001
		BR 0014154 A	07-05-2002
		CA 2381901 A1	08-03-2001
		CN 1372599 A	02-10-2002
		EP 1210417 A2	05-06-2002
		JP 2003508052 T	04-03-2003
		MX PA02002248 A	30-09-2002
		ZA 200201410 A	06-06-2003

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER: _____**

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.